# EDGAR Filing Document

**Accession Number:** 0001681622
**File Stem:** 0001681622-25-000108
**Filing Date:** 2025-11
**Character Count:** 515495
**Document Hash:** 270b73c212d69cf42a46c330ad33f1ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001681622-25-000108.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001681622-25-000108

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 143

**CONFORMED PERIOD OF REPORT**: 20251003

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Varex Imaging Corp
- **CENTRAL INDEX KEY:** 0001681622
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRONIC COMPONENTS, NEC [3679]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 813434516
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1003

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37860
- **FILM NUMBER:** 251494733

**BUSINESS ADDRESS:**
- **STREET 1:** 1678 S. PIONEER ROAD
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84104
- **BUSINESS PHONE:** 801-972-5000

**MAIL ADDRESS:**
- **STREET 1:** 1678 S. PIONEER ROAD
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84104

?xml version='1.0' encoding='ASCII'? var-20251003

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

____________________________________________________________

**FORM 10-K** 

____________________________________________________________

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the fiscal year ended October 3, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to**

**Commission File Number 001-37860** 

____________________________________________________________

![logoa37.jpg](var-20251003_g1.jpg)

**VAREX IMAGING CORPORATION** 

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **81-3434516** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| **1678 S. Pioneer Road, Salt Lake City, Utah** | **84104** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(801) 972-5000** 

**(Registrant's telephone number, including area code)**

____________________________________________________________

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | VREX | The Nasdaq Stock Market LLC |

---

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ◻No 🗷

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ◻ No 🗷

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes 🗷No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &nbsp;&nbsp;&nbsp;&nbsp;Yes 🗷 &nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

------

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐  | Accelerated filer | ☒ |
| Non-Accelerated filer | ☐  | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &nbsp;&nbsp;&nbsp;&nbsp;☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒

Indicate by check mark whether any of those corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 4, 2025, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of shares of the registrant's common stock held by non-affiliates of the registrant (based upon the closing sale price of such shares on the NASDAQ Global Select Market on April 4, 2025) was approximately $339.3 million.

As of November 11, 2025, there were 41.7 million shares of the registrant's common stock outstanding.

**Documents Incorporated by Reference**

Portions of registrant's proxy statement relating to registrant's 2026 annual meeting of stockholders are incorporated by reference in Part III of this annual report on Form 10-K.

------

**VAREX IMAGING CORPORATION**

**INDEX**

---

| | | |
|:---|:---|:---|
| **<u>[Part I.](#i8474629358084e7786308a95e9f157ba_1449)</u>** | | <u>[3](#i8474629358084e7786308a95e9f157ba_1449)</u> |
| <u>[Item 1.](#i8474629358084e7786308a95e9f157ba_1456)</u> | <u>[Business](#i8474629358084e7786308a95e9f157ba_1456)</u> | <u>[3](#i8474629358084e7786308a95e9f157ba_1456)</u> |
| <u>[Item 1A.](#i8474629358084e7786308a95e9f157ba_2042)</u> | <u>[Risk Factors](#i8474629358084e7786308a95e9f157ba_2042)</u> | <u>[13](#i8474629358084e7786308a95e9f157ba_2042)</u> |
| <u>[Item 1B.](#i8474629358084e7786308a95e9f157ba_2065)</u> | <u>[Unresolved Staff Comments](#i8474629358084e7786308a95e9f157ba_2065)</u> | <u>[27](#i8474629358084e7786308a95e9f157ba_2065)</u> |
| <u>[Item 1C.](#i8474629358084e7786308a95e9f157ba_2060)</u> | <u>[Cybersecurity](#i8474629358084e7786308a95e9f157ba_2060)</u> | <u>[27](#i8474629358084e7786308a95e9f157ba_2060)</u> |
| <u>[Item 2.](#i8474629358084e7786308a95e9f157ba_2055)</u> | <u>[Properties](#i8474629358084e7786308a95e9f157ba_2055)</u> | <u>[28](#i8474629358084e7786308a95e9f157ba_2055)</u> |
| <u>[Item 3.](#i8474629358084e7786308a95e9f157ba_133)</u> | <u>[Legal Proceedings](#i8474629358084e7786308a95e9f157ba_133)</u> | <u>[29](#i8474629358084e7786308a95e9f157ba_133)</u> |
| <u>[Item 4.](#i8474629358084e7786308a95e9f157ba_2075)</u> | <u>[Mine Safety Disclosures](#i8474629358084e7786308a95e9f157ba_2075)</u> | <u>[29](#i8474629358084e7786308a95e9f157ba_2075)</u> |
| **<u>[Part II.](#i8474629358084e7786308a95e9f157ba_2081)</u>** | | <u>[30](#i8474629358084e7786308a95e9f157ba_2081)</u> |
| <u>[Item 5.](#i8474629358084e7786308a95e9f157ba_3324)</u> | <u>[Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i8474629358084e7786308a95e9f157ba_3324)</u> | <u>[30](#i8474629358084e7786308a95e9f157ba_3324)</u> |
| <u>[Item 6.](#i8474629358084e7786308a95e9f157ba_3331)</u> | <u>[\[Reserved\]](#i8474629358084e7786308a95e9f157ba_3331)</u> | <u>[30](#i8474629358084e7786308a95e9f157ba_3331)</u> |
| <u>[Item 7.](#i8474629358084e7786308a95e9f157ba_3337)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i8474629358084e7786308a95e9f157ba_3337)</u> | <u>[30](#i8474629358084e7786308a95e9f157ba_3337)</u> |
| <u>Item 7A.</u> | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i8474629358084e7786308a95e9f157ba_124)</u> | <u>[39](#i8474629358084e7786308a95e9f157ba_124)</u> |
| <u>[Item 8.](#i8474629358084e7786308a95e9f157ba_3410)</u> | <u>[Financial Statements and Supplementary Data](#i8474629358084e7786308a95e9f157ba_3410)</u> | <u>[40](#i8474629358084e7786308a95e9f157ba_3410)</u> |
| <u>[Item 9.](#i8474629358084e7786308a95e9f157ba_3417)</u> | <u>[Changes in and Disagreements with Accountants on Accounting and Financial Disclosures](#i8474629358084e7786308a95e9f157ba_3417)</u> | <u>[40](#i8474629358084e7786308a95e9f157ba_3417)</u> |
| <u>[Item 9A.](#i8474629358084e7786308a95e9f157ba_3423)</u> | <u>[Controls and Procedures](#i8474629358084e7786308a95e9f157ba_3423)</u> | <u>[40](#i8474629358084e7786308a95e9f157ba_3423)</u> |
| <u>[Item 9B.](#i8474629358084e7786308a95e9f157ba_3440)</u> | <u>[Other Information](#i8474629358084e7786308a95e9f157ba_3440)</u> | <u>[43](#i8474629358084e7786308a95e9f157ba_3440)</u> |
| <u>[Item 9C.](#i8474629358084e7786308a95e9f157ba_3434)</u> | <u>[Disclosure](#i8474629358084e7786308a95e9f157ba_3434)[Regarding Foreign Jurisdictions that Prevent Inspections](#i8474629358084e7786308a95e9f157ba_3434)</u> | <u>[43](#i8474629358084e7786308a95e9f157ba_3434)</u> |
| **<u>[Part III.](#i8474629358084e7786308a95e9f157ba_3448)</u>** | | <u>[44](#i8474629358084e7786308a95e9f157ba_3448)</u> |
| <u>[Item 10.](#i8474629358084e7786308a95e9f157ba_3456)</u> | <u>[Directors, Executive Officers and Corporate Governance](#i8474629358084e7786308a95e9f157ba_3456)</u> | <u>[44](#i8474629358084e7786308a95e9f157ba_3456)</u> |
| <u>[Item 11.](#i8474629358084e7786308a95e9f157ba_3463)</u> | <u>[Executive Compensation](#i8474629358084e7786308a95e9f157ba_3463)</u> | <u>[44](#i8474629358084e7786308a95e9f157ba_3463)</u> |
| <u>[Item 12.](#i8474629358084e7786308a95e9f157ba_3469)</u> | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i8474629358084e7786308a95e9f157ba_3469)</u> | <u>[45](#i8474629358084e7786308a95e9f157ba_3469)</u> |
| <u>[Item 13.](#i8474629358084e7786308a95e9f157ba_3475)</u> | <u>[Certain Relationships and Related Transactions, and Director Independence](#i8474629358084e7786308a95e9f157ba_3475)</u> | <u>[45](#i8474629358084e7786308a95e9f157ba_3475)</u> |
| <u>[Item 14.](#i8474629358084e7786308a95e9f157ba_3481)</u> | <u>[Principal Accountant Fees and Services](#i8474629358084e7786308a95e9f157ba_3481)</u> | <u>[45](#i8474629358084e7786308a95e9f157ba_3481)</u> |
| **<u>[Part IV.](#i8474629358084e7786308a95e9f157ba_3487)</u>** | | <u>[46](#i8474629358084e7786308a95e9f157ba_3487)</u> |
| <u>[Item 15.](#i8474629358084e7786308a95e9f157ba_3494)</u> | <u>[Exhibits and Financial Statement Schedules](#i8474629358084e7786308a95e9f157ba_3494)</u> | <u>[46](#i8474629358084e7786308a95e9f157ba_3494)</u> |
| <u>[Item 16.](#i8474629358084e7786308a95e9f157ba_3507)</u> | <u>[Form 10-K Summary](#i8474629358084e7786308a95e9f157ba_3507)</u> | <u>[48](#i8474629358084e7786308a95e9f157ba_3507)</u> |
| | <u>[Signatures](#i8474629358084e7786308a95e9f157ba_3513)</u> | <u>[49](#i8474629358084e7786308a95e9f157ba_3513)</u> |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Forward-Looking Statements**

&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form 10-K (this "Annual Report"), including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" ("MD&A") contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a "safe harbor" for statements about future events, and financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of Varex Imaging Corporation ("we," "our," "us," the "Company," or "Varex,"). Actual results and the outcome or timing of certain events described in these forward-looking statements are subject to risk and uncertainties and may differ significantly from those described. Important factors that could cause our actual results and financial condition to differ significantly from those projections or expectations include, among other things, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reduction in or loss of business of one or more of our limited original equipment manufacturing ("OEM") customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations, and sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• loss of business to, and an inability to effectively compete with, competitors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pricing pressures and other factors that could result in margin erosion and loss of customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to meet customers' needs and demands;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruption of critical information systems or material breaches in the security of our systems or systems of third parties upon which we rely;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• inability to maintain or defend our intellectual property rights, and costs associated with protecting our intellectual property and defending such rights and defending against infringement claims;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• noncompliance with regulations applicable to marketing, manufacturing, labeling, and distributing our products and delays in obtaining regulatory clearances or approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limitations imposed by operating and financial restrictions of our debt financing agreements that could harm our long-term interests, limit our ability to make payments on our debt obligations, and impact our ability to maintain sufficient liquidity and/or to refinance our debt obligations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• and other factors cited in Risk Factors listed under Item 1A of this Annual Report, Business and MD&A and other factors described from time to time in our other filings with the U.S. Securities and Exchange Commission ("SEC"), or other reasons.

&nbsp;&nbsp;&nbsp;&nbsp;Statements concerning legislative, tariff, and trade wars and trade policy reforms, responsive retaliatory actions by affected countries, government investigations, and the uncertainty resulting therefrom; geopolitical tensions; supply chain and logistics challenges; cost increases and expense management; changes in U.S. and worldwide economic conditions, such as the impact of inflation, changes in interest rates, and fluctuations in foreign currency exchange rates; industry or business segment outlook; customer acceptance of or transition to new products or technologies such as advanced X-ray tube and digital flat panel detector products; growth drivers; future orders, revenues, market share, backlog, earnings or other financial results; and any statements using the terms "believe," "expect," "anticipate," "can," "should," "would," "could," "estimate," "may," "intend," "potential," and "possible" or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management's current expectations.

&nbsp;&nbsp;&nbsp;&nbsp;Any forward-looking statement made in this Annual Report (including in any exhibits or documents incorporated by reference) is based only on information currently available to Varex and its management and speaks only as of the date on which it is made. We have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**PART I**

**Item 1. Business**

**Overview**

&nbsp;&nbsp;&nbsp;&nbsp;Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, linear accelerators, image software processing solutions, and stand-alone X-ray based systems in select application areas. Our components are used in medical diagnostic imaging, security inspection systems, and industrial quality inspection systems, as well as for analysis and measurement applications in industrial manufacturing applications. Global OEMs incorporate our X-ray imaging components into their systems to detect, diagnose, protect, irradiate, and inspect. Varex has approximately 2,400 full-time equivalent employees, located at engineering, manufacturing, and service center sites in North America, Europe, and Asia.

&nbsp;&nbsp;&nbsp;&nbsp;Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.

&nbsp;&nbsp;&nbsp;&nbsp;Our success depends, among other things, on our ability to anticipate and respond to changes in our business, the direction of technological innovation, and the demand from our customers. We continually invest in research and development and employ approximately 400 individuals in product development related activities. Our focus on innovation and product performance along with strong and long-term customer relationships allows us to collaborate with our customers to deliver industry-leading X-ray imaging products. We continue to work to improve the life and quality of our imaging components and leverage our scale as one of the largest independent X-ray imaging component suppliers to provide cost-effective solutions for our customers.

***Operating Segments and Products***

&nbsp;&nbsp;&nbsp;&nbsp;We have two reportable operating segments: Medical and Industrial. The segments align our products and services offerings with customer use in medical and industrial imaging.

***Medical***

&nbsp;&nbsp;&nbsp;&nbsp;In our Medical segment, we design, manufacture, sell and service X-ray imaging components, including X-ray tubes, flat panel and photon counting detectors and accessories, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, automatic exposure control devices, generators, and coolers. These components are used in a range of medical imaging applications including computed tomography ("CT"), mammography, oncology, cardiac, surgery, dental, fluoroscopy, and other diagnostic radiography uses.

&nbsp;&nbsp;&nbsp;&nbsp;Our X-ray imaging components are primarily sold to OEM customers. These OEM customers then design-in our products to their X-ray imaging systems for a variety of medical modalities. A substantial majority of medical X-ray imaging OEMs globally are our customers, and many of these have been our customers for over 35 years. We believe one of the reasons for customer loyalty is that our hardware and software products are tightly integrated with our customers' systems. We work very closely with our customers to create custom built components for their systems based on technology platforms that we have developed. Because our products are often customized for our customers' specific equipment, it can be costly and complex for our customers to switch to another provider. Once our components are designed into our customers' equipment, our customers will typically continue to buy from us for any replacement components and for service and support for that equipment. Some of our products are also included in product registrations for our customers' equipment that require regulatory approval to change. In addition to sales to OEM customers, we sell our products to independent service companies and distributors as well as directly to end-users for replacement purposes.

&nbsp;&nbsp;&nbsp;&nbsp;We are one of the largest independent global manufacturers of X-ray imaging components, and each year, we produce over 27,000 X-ray tubes and 20,000 X-ray detectors. We estimate that our world-wide installed base of products includes more than 160,000 X-ray tubes, 170,000 X-ray detectors, 600,000 connect and control components, and 16,500 software instances. Replacement and service of our existing installed base makes up a significant portion of our revenue. Many of our components need to be replaced regularly, depending upon usage and other factors. For example, CT X-ray tubes generally need to be replaced every 2 to 6 years, in comparison to a general radiography tube which can last up to 10 years, depending on utilization. In China, the replacement cycle for CT X-ray tubes currently can be as frequent as every 10 to 20 months due to high utilization of imaging equipment. Other products such as X-ray detectors have a useful life of as much as 7 years or more but can require more frequent service and repairs during their useful life. In addition, our detector customers often elect to upgrade products to newer technology before the end of a current product's useful life. X-ray imaging software is a relatively small part of our business and includes maintenance revenue for software licenses.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;In China, the government has continued its efforts to broaden the availability of healthcare services. In the past 20 years, the number of medical institutions and diagnostic radiology equipment per million of population in China has increased substantially. We are developing CT X-ray tubes and related subsystems for Chinese OEMs as they introduce new systems in China. Over the long term, our objective is to become the partner of choice both for new systems and for replacement components in existing systems as CT systems continue to be more widely adopted throughout China.

***Industrial***

&nbsp;&nbsp;&nbsp;&nbsp;In our Industrial segment, we design, develop, manufacture, sell, and service X-ray imaging products for use in a number of applications, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other verticals. We also manufacture and sell our own X-ray imaging systems for industrial applications. Our Industrial products include Linatron® X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, flat panel and photon counting detectors, computed radiography scanners, high voltage connectors, and coolers. In addition, we license proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to our Industrial customers. Our Industrial business benefits from the research and development investment and manufacturing economies of scale on the Medical side of our business, as we continue to find new applications for our technology. Along with more favorable pricing dynamics, this allows us to generally achieve higher gross profit for Industrial products relative to our Medical business. In addition, our Industrial business benefits from our long-term service agreements for our Linatron® products.

&nbsp;&nbsp;&nbsp;&nbsp;Security applications primarily consist of cargo security for the screening of trucks, trains, and cargo containers at ports and borders as well as airport security for checked baggage and palletized cargo. The end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there can be significant variation in buying patterns. We have recently expanded our security offerings to include full systems that perform cargo and vehicle inspections. These systems are used for screening cargo at ports and borders.

&nbsp;&nbsp;&nbsp;&nbsp;Non-destructive testing and inspection verticals utilize X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including aerospace, automotive, electronics, oil and gas, food packaging, metal castings, and additive manufacturing. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging. We provide X-ray sources, digital detectors, high voltage connectors, and image processing software to OEM customers, system integrators, and manufacturers in a variety of these verticals. We believe that non-destructive testing represents a significant growth opportunity for our business, and we are actively pursuing new potential applications for our products.

**Customers**

&nbsp;&nbsp;&nbsp;&nbsp;Our customers are primarily large OEMs. Our top five customers, measured by revenue, are Canon Medical Systems Corporation ("Canon"), United Imaging Healthcare, General Electric Company, Siemens Healthineers AG ("Siemens"), and Rapiscan Systems, Inc., which collectively accounted for approximately 40% of total revenue in fiscal year 2025. Our largest customer, Canon, accounted for approximately 18%, 18%, and 17% of our total revenue for fiscal years 2025, 2024, and 2023, respectively, while our ten largest customers as a group accounted for approximately 52%, 53%, and 51% of our revenue for fiscal years 2025, 2024, and 2023, respectively.

**Competition**

&nbsp;&nbsp;&nbsp;&nbsp;The imaging components business is highly competitive. OEMs may choose to develop and manufacture X-ray imaging components in-house or they may choose to out-source to a supplier such as Varex or our competitors. Our success depends upon our ability to anticipate changes in the business environment, the direction of technological innovation and the demand from our customers. To remain competitive, we must continually invest in research and development focused on innovation, improve product performance and quality, and continue to reduce the cost of our imaging components. Significant capital investment is required to manufacture imaging components. We believe we have sufficient manufacturing scale to leverage our high volume to reduce overall costs by spreading fixed costs over more units.

*Medical*

&nbsp;&nbsp;&nbsp;&nbsp;We often compete with the in-house X-ray tube manufacturing operations of major diagnostic imaging systems companies, which are the primary OEM customers for our Medical products. To effectively compete with these in-house capabilities, we must have a competitive advantage in one or more significant areas, such as innovative technology and greater product performance, better product quality, better product availability, or lower product price. We sell a significant volume of our X-ray tubes to OEM customers that have in-house X-ray tube production capability. In addition, we compete with some OEM customers, such as Canon, Philips Healthcare and other companies who sell X-ray tubes to smaller OEMs and other manufacturers, as well as emerging X-ray tube

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

manufacturers. High capital costs and mastery of complex manufacturing processes that drive production yield and product life are significant characteristics of the X-ray tube business.

&nbsp;&nbsp;&nbsp;&nbsp;The digital detectors business is highly competitive. We sell our digital detectors to a number of OEM customers that incorporate our detectors into their medical diagnostic, oncology, 3D dental and veterinary imaging systems. Our amorphous silicon based digital detector technology, our photon counting technology, and our complementary metal-oxide-semiconductor technology compete with other detector technologies, such as amorphous selenium, charge-coupled devices, and variations of amorphous silicon scintillators. We believe that our products provide a competitive advantage due to product quality and performance and lower total cost of ownership over the product lifecycle. In our digital flat panel detector business, we primarily compete against Trixell S.A.S., Canon, Vieworks Co., Ltd., Hamamatsu Corporation, iRay Technology (Shanghai) Limited, and Jiangsu CareRay Medical Systems Co., Ltd.

*Industrial*

&nbsp;&nbsp;&nbsp;&nbsp;In the low-energy sector of our Industrial segment, we compete with other OEM suppliers, such as iRay, Teledyne, and Comet AG, as well as those described above for Medical digital detectors. While there are other manufacturers of low-energy X-ray tubes and digital detectors for specialized and niche industrial applications, our products are designed for a broad range of applications in inspection, analysis, and non-destructive testing. In the high-energy sector, we compete against technologies from Nuctech Company Limited, Siemens, ETM Electromatic Inc., and PMB Alcen, whose X-ray sources are used in applications that include cargo and container scanning, border security, aerospace applications, castings, and pressure vessel inspections. Like medical, we sell our high energy products to OEMs and may also compete with those OEMs for cargo system sales. The companies we both sell to and compete with are Rapiscan, Smiths, Leidos, and Astrophysics.

**Customer Services and Support**

&nbsp;&nbsp;&nbsp;&nbsp;We generally warrant our products for 12 to 27 months. In certain cases, the warranty is specified by usage metrics such as number of scans. We provide technical advice and consultation to major OEM customers from our offices in the United States, Europe, Asia, and India. Our application specialists and engineers make recommendations to meet the customer's technical requirements within the customer's budgetary constraints. We often develop specifications for a unique product that will be designed and manufactured to meet a specific customer's requirements.

**Manufacturing and Supplies**

&nbsp;&nbsp;&nbsp;&nbsp;We manufacture our products at facilities in the United States, the United Kingdom, the Netherlands, Germany, Finland, the Philippines, China, and India. These facilities employ state-of-the-art manufacturing techniques, and several have been recognized by the press, governments, and trade organizations for their commitment to quality improvement. Each of these manufacturing facilities are certified by the International Standards Organization ("ISO") under ISO 9001 (for industrial products) or ISO 13485 (for medical devices). In addition, we have a regional service center in Germany.

&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing processes at our various facilities include machining, fabrication, subassembly, system assembly, and final testing. We have invested in various automated and semi-automated equipment for the fabrication and machining of the parts and assemblies that we incorporate into our products. We may, from time to time, invest further in such equipment. Our quality assurance program includes various quality control measures from inspection of raw materials, purchased parts, and assemblies through in-line inspection. In some cases, we outsource the manufacturing of sub-assemblies while still performing system design, final assembly, and testing in-house. In such cases, we believe outsourcing enables us to reduce or maintain fixed costs and capital expenditures, while also providing the flexibility to increase production capacity. We purchase material and components from various suppliers that are either standard products or customized to our specifications. Some of the components included in our products may be sourced from a limited group of suppliers or from a single source supplier, such as transistor arrays and cesium iodide coatings for digital detectors and specialized integrated circuits, X-ray tube targets, housings, bearings, and various other components. We require certain raw materials, such as copper, nickel, silver, gold, lead, tungsten, iridium, rhenium, molybdenum, rhodium, niobium, zirconium, beryllium, and various high grades of steel alloy for X-ray tubes and industrial products. Worldwide demand, availability and pricing of these raw materials have been volatile, and we expect that availability and pricing will continue to fluctuate in the future.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Research and Development**

&nbsp;&nbsp;&nbsp;&nbsp;Innovation and developing products, systems, and services based on advanced technology is essential to our ability to compete effectively in the marketplace. We maintain a research and development and engineering staff responsible for product design and engineering.

&nbsp;&nbsp;&nbsp;&nbsp;Research and development are primarily conducted at our facilities in the United States and Europe. Our research and development activities are primarily focused on developing and improving imaging component technology. Current X-ray source development areas include smaller footprint linear accelerators, improvements to tube life and tube stability, reductions of tube noise, and tube designs that will enable OEMs to continue to reduce dose delivered and improve image resolution, cost effectively. Research in digital detector imaging technology is aimed at developing new panel technologies (such as photon counting) with better dose utilization, improved image quality and materials discrimination, lower product costs, and new image processing tools for advanced applications.

&nbsp;&nbsp;&nbsp;&nbsp;One of our competitive advantages is that some of the foundational technologies and software components developed for medical applications may also be applicable in industrial components, and vice versa. In addition to these product development synergies, we are also able to realize sourcing, production, service center, and logistics synergies across the different products and business lines.

**Product and Other Liabilities**

&nbsp;&nbsp;&nbsp;&nbsp;Our business exposes us to potential product liability claims that are inherent in the manufacture, sale, installation, servicing and support of X-ray imaging devices, related software and other devices that contain hazardous material or deliver radiation. Because our products are involved in the intentional delivery of radiation to the human body and other situations where people may come in contact with radiation (for example, when our Industrial products are being used to scan cargo) as well as the detection, planning, and treatment of medical problems, the possibility for significant injury or death exists if our products fail to work or are not used properly. We may face substantial liability to patients, our customers and others for damages resulting from the faulty, or allegedly faulty, design, manufacture, installation, servicing, support, testing, or interoperability of our products and our customers' products, or their misuse or failure. We may also be subject to claims for property damages or economic loss related to or resulting from any errors or defects in our products, or the installation, servicing, and support of our products. Any accident or mistreatment could subject us to legal costs, litigation, adverse publicity, and damage to our reputation, whether or not our products or services were a factor. In addition, if a product we design or manufacture were defective (whether due to design, labeling or manufacturing defects, improper use of the product, or other reasons), or found to be so by a regulatory authority, we may be required to correct or recall the product and notify other regulatory authorities. We maintain limited product liability, professional liability, and omissions liability insurance coverage.

**Government Regulation**

*U.S. Regulations*

&nbsp;&nbsp;&nbsp;&nbsp;*Laws governing marketing of medical devices*. In the United States, as a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, we and some of our suppliers and distributors are subject to extensive regulation by federal governmental authorities, such as the U.S. Food and Drug Administration (the "FDA"), the Nuclear Regulatory Commission ("NRC"), and state and local regulatory agencies, to ensure the devices are safe and effective and comply with laws governing products that emit, produce, or control radiation. Similar international regulations apply overseas. These regulations, which include the U.S. Food, Drug and Cosmetic Act (the "FDC Act") and regulations promulgated by the FDA, govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale and marketing, and disposal of medical devices, post market surveillance, and reporting of serious injuries and death, repairs, replacements, recalls, and other matters relating to medical devices, radiation emitting devices, and devices utilizing radioactive by-product material. State regulations are extensive and vary from state to state. Our X-ray tube products, imaging workstations, and flat panel detectors are considered medical devices. Under the FDC Act, each medical device manufacturer must comply with quality system regulations that are strictly enforced by the FDA.

&nbsp;&nbsp;&nbsp;&nbsp;Unless an exception applies, the FDA requires that the manufacturer of a new medical device or a new indication for use of, or other significant change in, an existing currently marketed medical device obtain 510(k) pre-market notification clearance before it can market or sell those products in the United States. The 510(k) clearance process can be time consuming, costly, and uncertain, and in the case of modification to an existing device, may require the manufacturer to cease marketing and recall the product until 510(k) clearance is obtained. Most of our products are non-classified or Class I medical devices, which do not require 510(k) clearance.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;*Quality systems*. Our manufacturing operations for medical devices, and those of our third-party manufacturers, are required to comply with the FDA's Quality System Regulation ("QSR"), which addresses a company's responsibility for product design, testing, and manufacturing quality assurance, and the maintenance of records and documentation. The QSR requires that each manufacturer establish a quality systems program by which the manufacturer monitors the manufacturing process and maintains records that show compliance with FDA regulations and the manufacturer's written specifications and procedures relating to the devices. QSR compliance is necessary to receive and maintain FDA clearance or approval to market new and existing products. The FDA makes announced and unannounced periodic and ongoing inspections of medical device manufacturers to determine compliance with the QSR. If in connection with these inspections the FDA believes the manufacturer has failed to comply with applicable regulations and/or procedures, it may issue observations that would necessitate prompt corrective action. If FDA inspection observations are not addressed and/or corrective action is not taken in a timely manner and to the FDA's satisfaction, the FDA may issue a warning letter (which would similarly necessitate prompt corrective action) and/or proceed directly to other forms of enforcement action. Failure to respond timely to FDA inspection observations, a warning letter, or other notice of noncompliance and to promptly come into compliance could result in the FDA bringing enforcement action against us, which could include the total shutdown of our production facilities, denial of importation rights to the United States for products manufactured in overseas locations, and denial of export rights for U.S. products and criminal and civil fines.

&nbsp;&nbsp;&nbsp;&nbsp;The FDA and the Federal Trade Commission (the "FTC") regulate advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that we have adequate and reasonable scientific data to substantiate our claims and that our promotional labeling and advertising is neither false nor misleading. We may not promote or advertise our products for uses not within the scope of our intended use statement in our clearances or approvals or make unsupported safety and effectiveness claims.

&nbsp;&nbsp;&nbsp;&nbsp;It is also important that our products comply with electrical safety and environmental standards, such as those of Underwriters Laboratories ("UL"), the Canadian Standards Association ("CSA"), and the International Electrotechnical Commission ("IEC"). In addition, the manufacture and distribution of medical devices utilizing radioactive material requires a specific radioactive material license. For the United States, manufacture and distribution of these radioactive sources and devices also must be in accordance with a model-specific certificate issued by either the NRC or by an Agreement State. In essentially every country and state, installation and service of these products must be in accordance with a specific radioactive materials license issued by the applicable radiation control agency. Service of these products must be in accordance with a specific radioactive materials license. We are also subject to a variety of additional environmental laws regulating our manufacturing operations and the handling, storage, transport and disposal of hazardous substances, and which impose liability for the cleanup of any contamination from these substances.

&nbsp;&nbsp;&nbsp;&nbsp;*Other applicable U.S. regulations*. As a participant in the healthcare industry, we are also subject to extensive laws and regulations protecting the privacy and integrity of patient medical information that we receive, including the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), new state privacy laws, "fraud and abuse" laws and regulations, including physician self-referral prohibitions, and false claims laws. From time to time, these laws and regulations may be revised or interpreted in ways that could make it more difficult for our customers to conduct their businesses, such as recent proposed revisions to the laws prohibiting physician self-referrals, and such revisions could have an adverse effect on the demand for our products, and therefore our business and results of operations. We also must comply with numerous federal, state and local laws of more general applicability relating to such matters as environmental protection, safe working conditions, manufacturing practices, fire hazard control and other matters.

&nbsp;&nbsp;&nbsp;&nbsp;The laws and regulations and their enforcement are constantly undergoing change, and we cannot predict what effect, if any, changes to these laws and regulations may have on our business.

*Medicare and Medicaid Reimbursement*

&nbsp;&nbsp;&nbsp;&nbsp;The federal and state governments of the United States establish guidelines and pay reimbursements to hospitals and free-standing clinics for diagnostic examinations and therapeutic procedures under Medicare at the federal level and Medicaid at the state level. Private insurers often establish payment levels and policies based on reimbursement rates and guidelines established by the government.

&nbsp;&nbsp;&nbsp;&nbsp;The federal government and Congress review and adjust rates annually, and from time to time consider various Medicare and other healthcare reform proposals that could significantly affect both private and public reimbursement for healthcare services in hospitals and free-standing clinics. In the past, we have seen demand for our customers' systems (in which our products are incorporated) negatively impacted by the uncertainties surrounding reimbursement rates in the United States. State government reimbursement for services is determined pursuant to each state's Medicaid plan, which is established by state law and regulations, subject to requirements of federal law and regulations.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The sale of medical devices, the referral of patients for diagnostic examinations and treatments utilizing such devices, and the submission of claims to third-party payors (including Medicare and Medicaid) seeking reimbursement for such services, are subject to various federal and state laws pertaining to anti-kickbacks and healthcare "fraud and abuse."

*Foreign Regulations*

&nbsp;&nbsp;&nbsp;&nbsp;Our operations, sales and service of our products outside the United States are subject to regulatory requirements that vary from country to country and may differ significantly from those in the United States. In general, our products are regulated outside the United States as medical devices by foreign governmental agencies similar to the FDA.

&nbsp;&nbsp;&nbsp;&nbsp;*Marketing a medical device internationally*. For us to market our products internationally, we must obtain clearances or approvals for products and product modifications. We are required to affix the CE mark to our products to sell them in member countries of the European Union ("EU"). The CE mark is an international symbol of adherence to certain essential principles of safety and effectiveness, which once affixed enables a product to be sold in member countries of the European Economic Area ("EEA"). The CE mark is also recognized in many countries outside the EU and can assist in the clearance process. To receive permission to affix the CE mark to our medical device products, we must obtain approvals and Quality System certification, e.g., ISO 13485, through an accredited Notified Body and must otherwise have a quality management system that complies with the EU Medical Device Directive, which was superseded by the EU MDR-Medical Device Regulations in May 2021. The ISO promulgates standards for certification of quality assurance operations. We are certified as complying with the ISO 9001 for our security and inspection products and ISO 13485 for our medical devices. Several Asian countries, including Japan and China, have adopted regulatory schemes that are comparable, and in some cases more stringent, than the EU scheme. To import medical devices into Japan, the requirements of the Japanese Pharmaceutical and Medical Device Act must be met and an approval to sell medical products in Japan, must be obtained. Similarly, a registration certification issued by the National Medical Products Administration and a China Compulsory Certification mark for certain products are required to sell medical devices in China. Obtaining such certifications on our products can be time-consuming and can cause us to delay marketing or sales of certain products in such countries. Similarly, prior to selling a device in Canada, manufacturers of Class II devices must obtain a medical device license from Health Canada. Additionally, many countries have laws and regulations relating to radiation and radiation safety that apply to our products. In most countries, radiological regulatory agencies require some form of licensing or registration by the facility prior to acquisition and operation of an X-ray generating device or a radiation source. The handling, transportation and recycling of radioactive metals and source materials are also highly regulated.

&nbsp;&nbsp;&nbsp;&nbsp;A number of countries, including the members of the EU, have implemented or are implementing regulations that would require manufacturers to dispose, or bear certain disposal costs, of products at the end of a product's useful life and restrict the use of some hazardous substances in certain products sold in those countries. These regulations could impose future costs on the Company.

&nbsp;&nbsp;&nbsp;&nbsp;*Manufacturing and selling a device internationally*. We are subject to laws and regulations outside the United States applicable to manufacturers of radiation-producing devices and products utilizing radioactive materials, and laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices and other matters, in each case that are often comparable to, if not more stringent than, regulations in the United States. In addition, our sales of products in foreign countries are subject to regulation of matters such as product standards, packaging requirements, labeling requirements, import restrictions, environmental and product recycling requirements, tariff regulations, and duties and tax requirements. In some countries, we rely on our foreign distributors and agents to assist us in complying with foreign regulatory requirements.

&nbsp;&nbsp;&nbsp;&nbsp;*Other applicable international regulations*. In addition to the U.S. laws regarding the privacy and integrity of patient medical information, we are subject to similar or stricter laws and regulations in foreign countries covering data privacy and other protection of health and employee information. Particularly within Europe, data protection legislation is comprehensive and complex and there has been a recent trend toward more stringent enforcement of requirements regarding protection and confidentiality of personal data, as well as enactment of stricter legislation. We are also subject to international "fraud and abuse" laws and regulations, as well as false claims and misleading advertisement laws. We also must comply with numerous international laws of more general applicability relating to such matters as environmental protection, safe working conditions, manufacturing practices, fire hazard control and other matters.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

*Anti-Corruption Laws and Regulations*

&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws in foreign countries, such as the U.K. Bribery Act of 2010 and the law "On the Fundamentals of Health Protection in the Russian Federation". In general, there is a worldwide trend to strengthen anti-corruption laws and their enforcement, and the healthcare industry and medical equipment manufacturers have been particular targets of these investigation and enforcement efforts. Any violation of these laws by us or our agents or distributors could create substantial liability for us, subject our officers and directors to personal liability and also cause a loss of reputation.

&nbsp;&nbsp;&nbsp;&nbsp;In 2023, China launched a national anti-corruption campaign directed at the healthcare industry, designed to rectify unethical practices related to services and procurement in the Chinese healthcare industry. The anti-corruption campaign had a broad-based impact on the healthcare industry in China and contributed to lower sales in our Medical business during fiscal year 2024. During fiscal year 2025, we had stronger sales in our Medical business in China.

&nbsp;&nbsp;&nbsp;&nbsp;Transparency International's 2024 Corruption Perceptions Index measured the degree to which public sector corruption is perceived to exist in 180 countries/territories around the world and found that over two-thirds of the countries in the index, including many that we consider to be high-growth areas for our products, such as China and India, scored below 50, which strongly indicates they have significant corruption issues. We currently operate in many countries where the public sector is perceived as being more or highly corrupt and our strategic business plans include expanding our business in regions and countries that are rated as higher risk for corruption activity by Transparency International.

&nbsp;&nbsp;&nbsp;&nbsp;Increased business in higher-risk countries could subject us and our officers and directors to increased scrutiny and increased liability. In addition, becoming familiar with and implementing the infrastructure necessary to comply with laws, rules and regulations applicable to new business activities and mitigating and protecting against corruption risks could be quite costly. Failure by us or our agents or distributors to comply with these laws, rules and regulations could delay our expansion into high-growth business areas and could materially and adversely affect our business.

*Competition and Trade Compliance Laws*

&nbsp;&nbsp;&nbsp;&nbsp;We are subject to various competition and trade compliance laws in the jurisdictions where we operate. Regulatory or government authorities where we operate may have enforcement powers that can subject us to sanctions and can impose changes or conditions in the way we conduct our business. For example, local authorities may disagree with how we classify our products, and we may be required to change our classifications, which could increase our operating costs or subject us to increased taxes or fines and penalties. In addition, an increasing number of jurisdictions also provide private rights of action for competitors or consumers to seek damages asserting claims of anti-competitive conduct. Increased government scrutiny of our actions or enforcement or private rights of action could materially and adversely affect our business or damage our reputation. In addition, we may conduct, or we may be required to conduct, internal investigations or face audits or investigations by one or more domestic or foreign governments or regulatory agencies, which could be costly and time-consuming, and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to increased costs, fines or criminal or other penalties, which could materially and adversely affect our business and financial results. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that we may desire to undertake.

&nbsp;&nbsp;&nbsp;&nbsp;International sales of certain of our Linatron® X-ray accelerators are subject to U.S. export licenses that are issued at the discretion of the U.S. government. Orders and revenues for our security and inspection products have been and may continue to be unpredictable as governmental agencies may place large orders with us or with our customers over a short period of time and then may not place additional orders until complete deployment and installation of previously ordered products. Furthermore, tender awards in this business may be subject to challenge by third parties, as we have previously encountered, which can make the conversion of orders to revenues unpredictable for some security and inspection products. We experienced strong sales of our Linatron® X-ray accelerators for border protection applications in fiscal year 2025. While we anticipate some contraction, we expect demand to remain solid in fiscal year 2026.

&nbsp;&nbsp;&nbsp;&nbsp;In recent years, our business, particularly in China, has been impacted by the United States-China trade war in the following ways, among others: (1) importing raw materials from China to the United States has become more expensive, (2) importing raw materials and sub-assemblies from the United States to China has become more expensive, (3) importing finished United States manufactured products into China has become more difficult and expensive, and (4) increasing competitive pressures domestically and globally versus our Asian- and European-based competitors who may not have been as impacted by the trade war. While the governments of both the United States and China have, in the past, granted tariff exclusions that temporarily eliminate certain duties payable for specific commodities, providing partial relief, these exclusions are temporary and/or must be solicited and approved on a shipment-by-shipment basis. There is no guarantee that such exclusions will be granted or extended by either government, and the U.S. tariff exclusions are set to expire on November 10, 2026, unless extended. In order to mitigate the impact of tariffs on materials

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

imported from China, we have implemented changes to secure more non-China sources of materials used to manufacture our X-ray imaging products. To help mitigate the impact of tariffs on materials imported to China, and to be closer to our global customer base, we continue to expand manufacturing capabilities at our facilities in China, Germany, the Netherlands, the Philippines and India. We have also implemented local sourcing strategies to offer local content. This local-for-local strategy has been well received by both our local customers as well as global OEMs, and acts as a natural hedge against trade wars and other potential supply chain disruptions. In addition, while we have been working to implement other tariff mitigation measures, such as free trade zones, bonded mechanisms, and drawback programs, we cannot provide any guarantee that we will be able to effectively implement such measures.

**Intellectual Property**

&nbsp;&nbsp;&nbsp;&nbsp;We place considerable importance on obtaining and maintaining patent, copyright and trade secret protection for significant new technologies, products and processes, because of the length of time and expense associated with bringing new products through the development process and to the marketplace.

&nbsp;&nbsp;&nbsp;&nbsp;We generally rely on a combination of patents, copyrights, trademarks, trade secret and other laws, and contractual restrictions on disclosure, copying and transferring title, including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants and other third parties, to protect our proprietary rights in the developments, improvements and inventions that we have originated and which are incorporated in our products or that fall within our fields of interest. As of October 3, 2025, we own approximately 240 patents issued in the United States, approximately 420 patents issued throughout the rest of the world and have approximately 210 patent applications pending with various patent agencies worldwide. The patents issued expire between 2025 and 2044. We intend to file additional patent applications as appropriate. We have trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for our products in the marketplace. We also have agreements with third parties that provide for licensing of patented or proprietary technology, including royalty-bearing licenses and technology cross-licenses. These licenses generally can only be terminated for breach. See Item 1A. "Risk Factors - *Risks Relating to our Information Systems and Intellectual Property*."

&nbsp;&nbsp;&nbsp;&nbsp;In conjunction with the January 2017 separation from Varian Medical Systems, Inc. ("Varian"), we entered into an Intellectual Property Matters Agreement with Varian, pursuant to which, among other things, we each granted the other licenses to use certain intellectual property. Varian was subsequently acquired by Siemens in April 2021.

**Environmental Matters**

&nbsp;&nbsp;&nbsp;&nbsp;Our operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, we are obligated to indemnify Varian for 20% of the cleanup liabilities related to prior corporate restructuring activities while a division of Varian and fully indemnify Varian for other liabilities arising from the operations of the business transferred to it as part of those activities. Those include facilities sold as part of Varian's electron devices business in 1995 and thin film systems business in 1997. The U.S. Environmental Protection Agency ("EPA") or third parties have named Varian as a potentially responsible party under the amended Comprehensive Environmental Response Compensation and Liability Act of 1980 ("CERCLA"), at sites to which Varian or the facilities of the businesses sold in 1995 and 1997 were alleged to have shipped waste for recycling or disposal (the "CERCLA sites"). We anticipate that we will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these CERCLA sites (after adjusting for any insurance proceeds). As of October 3, 2025, we had an existing environmental liability of approximately $3.2 million, net of expected insurance proceeds, related to the CERCLA sites.

**Working Capital**

&nbsp;&nbsp;&nbsp;&nbsp;Our working capital needs and our credit practices are comparable to those of other companies manufacturing and selling similar products to similar customers. We endeavor to carry sufficient levels of inventory to meet the product delivery needs of our customers. We also provide payment terms to customers in the normal course of business. The product warranty obligations contained in our standard terms and conditions typically range from 12 to 27 months, depending on the product.

**Human Capital Resources**

*Talent Management*

&nbsp;&nbsp;&nbsp;&nbsp;To remain a leading innovator, designer, and manufacturer of critical components of X-ray based diagnostic equipment, it is crucial that we continue to attract and retain exceptional talent. Our business results depend on our ability to successfully manage our human capital resources, including attracting, identifying, and retaining key talent. Factors that may affect our ability to attract and

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

retain qualified employees include employee morale, our reputation, competition from other employers, wage inflation, and availability of qualified individuals.

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, we had approximately 2,400 full-time equivalent employees worldwide. None of our employees based in the United States are unionized or subject to collective bargaining agreements. Employees based in some foreign countries may, from time to time, be represented by works councils or unions or subject to collective bargaining agreements. We consider our relations with our employees to be good.

&nbsp;&nbsp;&nbsp;&nbsp;As part of our people management strategy, we monitor employee morale and our reputation. To better understand how to measure the effectiveness of our people management strategy, and to establish a baseline understanding of employee loyalty and retention, we solicit feedback from our employees through employee satisfaction and other surveys. The results of these surveys are analyzed, and we hold meetings with employees to share and discuss areas of improvement. We believe this is a useful process to inform how future decisions are made in order to improve employee morale and engagement.

*Total Rewards*

&nbsp;&nbsp;&nbsp;&nbsp;We invest in our workforce by offering a competitive total rewards package that includes a combination of salaries and wages, health and wellness benefits, equity incentives, retirement benefits, and educational benefits. We strive to offer a total rewards package that is responsive to local markets. In the United States, where our largest employee base resides, our benefits for eligible employees have included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Health insurance coverage available to full-time employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Tuition reimbursement up to a specified dollar amount on an annual basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Matching contributions to a tax-qualified defined contribution savings ("401(k)") plan, on a dollar-for-dollar basis up to four percent of the employee's base compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An employee assistance program; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Training and development programs designed to help employees improve workplace performance.

&nbsp;&nbsp;&nbsp;&nbsp;Approximately 90% of our eligible employees participate in our 401(k) plan. In addition, in an effort to further align the interests of eligible employees with our stockholders, we have an equity-based incentive plan that provides for the grant of nonqualified stock options, restricted stock units, performance units and other equity-based awards to directors, officers and other eligible employees. Additionally, to create performance incentives and to encourage share ownership by our employees, we have an employee stock purchase plan, which enables eligible employees to purchase our common stock at a discount through payroll contributions.

*Safety and Wellness*

&nbsp;&nbsp;&nbsp;&nbsp;The health and safety of our workforce is fundamental to the success of our business. We provide our employees upfront and ongoing safety training to ensure that safety policies and procedures are effectively communicated and implemented. Personal protective equipment is provided to those employees where needed for the employee to safely perform their job function. We have experienced personnel on site at each of our manufacturing locations that are tasked with environmental, health and personal safety education and compliance and, in Salt Lake City, we have an onsite nurse practitioner available to our employees for medical needs.

*Equity and Inclusion*

&nbsp;&nbsp;&nbsp;&nbsp;As one of our values states, "we embrace equality," and we are committed to an inclusive workplace that is respectful to all. Some of our initiatives include establishing a global employee resource group to drive advocacy and inclusion; providing internships with a focus on building science, technology, engineering, and mathematics ("STEM") programs; and regularly analyzing pay equity. We expect our teams to conduct themselves ethically at all times in accordance with Varex's Code of Conduct.

**Information Available to Investors**

&nbsp;&nbsp;&nbsp;&nbsp;The SEC maintains an internet site, www.sec.gov, that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. As soon as reasonably practicable after filing with or furnishing to the SEC, we also make the following reports and information available free of charge on the Investors page of our website www.vareximaging.com:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our annual reports on Form 10-K;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• quarterly reports on Form 10-Q;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• current reports on Form 8-K (including any amendments to those reports);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• proxy statements; and

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Section 16 ownership reports.

&nbsp;&nbsp;&nbsp;&nbsp;Additionally, our Code of Conduct, Corporate Governance Guidelines, Human Rights Policy, and the charters of the Audit Committee, Compensation and Human Capital Management Committee, and Nominating and Corporate Governance Committee are also available on the Investors page of our website. Investors and others should note that we announce material financial and operational information to our investors using our investor relations website (https://www.vareximaging.com/investor-relations/), press releases, SEC filings and public conference calls and webcasts. Please note that information on, or that can be accessed through, our website is not deemed "filed" with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act").

**Information about our Executive Officers**

&nbsp;&nbsp;&nbsp;&nbsp;The biographical summaries of our executive officers are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;*Sunny S. Sanyal, 61*, has served as President, Chief Executive Officer, and Director since January 2017. Prior to the separation of Varex from Varian, Sunny served as senior vice president and president of Varian's Imaging Components business for Varian since February 2014. Prior to joining Varian in 2014, Sunny was chief executive officer of T-System, a privately held company providing information technology solutions and services to hospitals and urgent care facilities. He also served as president of McKesson Provider Technologies, where he led the company to significant business expansion with its clinical software, medical imaging technology, and services solutions. Sunny has held executive positions at GE Healthcare, Accenture, and IDX Systems. He received a Master of Business Administration ("MBA") from Harvard Business School, a Master of Science in industrial engineering from Louisiana State University, and a Bachelor of Engineering in electrical engineering from the University of Bombay.

&nbsp;&nbsp;&nbsp;&nbsp;*Shubham Maheshwari, 54*, has served as Chief Financial Officer ("CFO") since July 2020. Shubham (Sam) joined Varex from SiFive, Inc., a leading provider of hardware and software solutions for developing RISC-V based processors and semiconductor chips, where he served as CFO. Before SiFive, Sam served for six years as CFO, and later as CFO and COO, of Veeco Instruments Inc. (Nasdaq: VECO), a manufacturer of semiconductor process equipment. Previous notable positions include Senior Vice President, Finance for semiconductor company Spansion, Inc., where he helped lead the company through its restructuring and IPO in 2010, and more than 10 years in various senior positions, including Vice President of M&A and Corporate Controller, at KLA-Tencor Corp., a global semiconductor equipment company. Sam holds an MBA in Finance from Wharton, and a bachelor's degree in chemical engineering from the Indian Institute of Technology, Delhi.

&nbsp;&nbsp;&nbsp;&nbsp;*Matthew Martinez, 44*, has served as Chief Legal Officer and Corporate Secretary since October 2025. Prior to rejoining Varex, Matt served as general counsel of Energy Exemplar, a global provider of energy market simulation software. He originally joined Varex in September 2017 as senior corporate counsel and served as assistant general counsel and assistant corporate secretary from October 2020 until his departure for Energy Exemplar in April 2022. Matt has significant international experience, having previously served as senior legal counsel for Apache Corporation in Argentina and Canada. In addition to his in-house experience, Matt practiced at the law firms of Akin Gump Strauss Hauer and Feld LLP and Stoel Rives LLP where he focused on securities compliance, mergers and acquisitions, and other transactional matters. Matt holds a juris doctor from Vanderbilt University of Law School and a bachelor's degree in political science from Brigham Young University.

&nbsp;&nbsp;&nbsp;&nbsp;*Karen Aranki*, *51*, has served as Chief Human Resources Officer since March 2023. Prior to joining the Company, Karen was the Global VP of HR and Communications at Honeywell Aerospace, where she worked for 16 years, including 8 years in senior human resources positions. Karen has over 22 years of experience in global human resources management, with notable expertise in the semiconductor and transportation industries driving program management, and employee engagement, through voice of employee actions and communications, community outreach, and management capability development. She is Six Sigma Green Belt certified in the use of lean tools and methodologies to improve processes, solve quality problems, and lead projects. Karen earned a Masters Degree in Labor Relations and Human Resources Management, and a Bachelor of Art degree in International Relations, both from Michigan State University.

&nbsp;&nbsp;&nbsp;&nbsp;*Andrew Hartmann, 63*, has served as Senior Vice President and General Manager - Detectors since April 2023 and previously as Senior Vice President, Medical Sales & Marketing since July 2018. Prior to joining Varex he worked for a number of leading OEMs in various leadership roles, most recently as General Manager of the X-ray and Ultrasound Business for Carestream Health, Inc., a worldwide provider of X-ray imaging systems, from April 2012 to June 2018. Prior to Carestream, Andrew worked for Siemens Medical Solutions USA, Inc. (Siemens Healthineers), a leading medical technology company, in sales and marketing roles both domestically in the United States and internationally for Siemens' ultrasound business. Prior to Siemens, he held leadership roles at Acuson Corp. (subsequently acquired by Siemens), including General Manager for Acuson's Australia and New Zealand business. Andrew received a Master of Business Administration ("EMBA") from Ashridge Business School in London, United Kingdom, and received a diploma in electronics from Sydney Technical College in Australia.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;*Mark S. Jonaitis, 64,* has served as Senior Vice President and General Manager - X-Ray Sources since January 2017. Prior to the separation of Varex from Varian, Mark served in various management positions at Varian, including most recently as vice president and general manager, X-ray Tube Products and global manufacturing. Mark joined Varian's predecessor, Varian Associates, in 1983, where he served in various product and engineering positions. Mark received his Bachelor of Science in physics from the University of Utah.

**Item 1A. Risk Factors**

&nbsp;&nbsp;&nbsp;&nbsp;Investing in Varex Imaging Corporation common stock involves risks and the following risk factors and other information included in this Annual Report on Form 10-K under Item 1 "Business", Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Item 7A "Quantitative and Qualitative Disclosures about Market Risk" should be carefully considered. Although the risk factors described below are the ones management deems significant, additional risks and uncertainties not presently known to us or that are presently known to us that we presently deem not material may also adversely affect our business operations.

**Risks Relating to Our Business**

***Our business has in the past been, is currently being, and in the future may be, negatively impacted by changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto.***

&nbsp;&nbsp;&nbsp;&nbsp;We are both a global importer of raw materials that are used in our finished products and an exporter of finished goods to our customers worldwide. Our products are integrated into the systems and products of our OEM customers, as well as into our own industrial systems. Tariffs, trade wars, import restrictions, boycotts, embargoes, government investigations, trade policies and compliance matters have in the past limited, are currently limiting, and in the future could limit our ability and our customers' ability to compete, which could cause our long-term prospects in such countries to suffer. Tariffs on imported materials have increased our costs and prices and lowered gross margins on some of our products, thereby having a direct adverse impact on our business and results of operations. Retaliatory tariffs have increased our customers' costs for products exported from the United States, which has caused us to make, and may in the future require us to make, price and other concessions on some products and has caused, and may in the future cause, some customers to stop purchasing our products.

&nbsp;&nbsp;&nbsp;&nbsp;For example, during the calendar year 2025, the United States Administration has announced and imposed a variety of new tariffs on imports from other countries. In response, a number of those impacted or potentially impacted countries have announced and/or imposed retaliatory tariffs on United States imports. These actions impacted our results of operations and profitability in fiscal year 2025, particularly the bilateral United States and Chinese tariffs. Absent a de-escalation of the current tariff environment, particularly between the United States and China, the tariffs have and are expected to continue to negatively impact our business, results of operation, and financial condition, including by increasing our costs and prices, lowering gross margins, adversely impacting revenue, and making our products less competitive with similar products not imported from the United States, which could have a material adverse impact on our business. Additional new tariffs, trade restrictions or other retaliatory actions aimed at specific industries, such as X-ray imaging products, could also materially impact our business.

&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, if international customers' negative perceptions of the actions of the United States Administration influence their buying decisions, our business and results of operations could be negatively impacted.

&nbsp;&nbsp;&nbsp;&nbsp;In the past, both the governments of the United States and China have granted tariff exclusions that temporarily eliminate certain duties payable for specific commodities, providing partial relief from such tariffs, but with certain exceptions, they must be solicited and approved. There is no guarantee that exclusions will be granted or that existing exclusions will be extended by either government. In addition, we cannot provide any guarantee that we will be able to effectively implement other tariff mitigation measures, such as free trade zones, bonded mechanisms, or drawback programs.

&nbsp;&nbsp;&nbsp;&nbsp;In addition to tariffs, China's stated policy of reducing its dependence on foreign manufacturers and technology companies may result in reduced demand for our products and our customers' products in China, which could have a material adverse impact on our business, results of operations and financial position. There are risks that the Chinese government may, among other things, require the use of local suppliers, compel companies that do business in China to partner with local companies to conduct business, or provide incentives to government-backed local customers to buy from local suppliers rather than companies like ours, all of which could adversely impact our business, results of operations and financial position. As an example, in April 2025 the China Ministry of Commerce ("MOFCOM") initiated two investigations related to medical products imported into China (the "MOFCOM Investigations"). One investigation relates to the impact of imports of X-ray tubes on the domestic industry and its competitiveness, and another relates to imports into China of certain medical CT X-ray tubes and tube inserts for CT devices (collectively "CT Tubes and Inserts") originating from the United States and India. We produce CT Tubes and Inserts in the United States and export them to

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

China, but do not produce CT Tubes and Inserts in India. Total sales of medical X-ray tubes we imported into China represented approximately 10% of our total revenue in fiscal year 2025.

&nbsp;&nbsp;&nbsp;&nbsp;MOFCOM temporarily suspended both of the MOFCOM Investigations in May 2025 and again in August 2025. In November 2025, the MOFCOM Investigations were suspended indefinitely. If recommenced, we anticipate that the MOFCOM Investigations may take approximately one year from commencement to resolve. If, as a result of the outcome of the MOFCOM Investigations, we are required to increase our prices or tariffs are imposed on the CT Tubes and Inserts we export to China, our prices may not be competitive with local and other manufacturers, which could negatively impact our ability to compete in China and negatively impact our business, results of operations and financial condition.

&nbsp;&nbsp;&nbsp;&nbsp;Any of the foregoing factors could require us to reconsider our current operating model, including whether we can continue to operate in specifically impacted locations, or if we need to relocate or otherwise restructure existing operations. Such changes may require us to invest significant additional capital we had anticipated using for other purposes such as expanding existing operations, entering new markets, or paying down debt. Diversion of these funds from their anticipated uses could adversely impact our business, results of operations, financial position, and our ability to pay down or restructure our existing debt.

&nbsp;&nbsp;&nbsp;&nbsp;Increasing tensions between countries, such as China and Taiwan, as well as local conflicts including the Ukraine-Russia war and Middle East conflicts, may lead the United States and/or other countries to impose new tariffs and sanctions or expand existing tariffs and sanctions, enact boycotts and embargoes, and otherwise seek to limit or stop the flow of goods to or from involved countries. In the past, such actions both in China and Russia, have caused, are causing, and could in the future cause, significant disruptions in the regions and industries we serve and in our supply chain, as well as decrease demand from customers for the ultimate products using our solutions and materially harm our business, financial condition, and results of operations.

***We sell our products and services to a limited number of OEM customers, many of which are also our competitors, and a delay in an order to a future period, as well as a reduction in or loss of business of one or more of these customers has in the past and may in the future materially reduce our sales.***

&nbsp;&nbsp;&nbsp;&nbsp;We had one customer during fiscal year 2025 that accounted for 18.0% of our revenue, all of which was in our Medical segment. Our ten largest customers as a group accounted for approximately 52%, 53% and 51% of our revenue for fiscal years 2025, 2024 and 2023, respectively. Because we often take significant time to replace lost business, in the past our operating results have been, and in the future it is likely that our operating results would be, materially and adversely affected if one or more of our major OEM customers were to cancel, delay, or reduce orders.

&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, we generate significant accounts receivables from the sale of our products and the provision of services directly to these customers. One customer accounted for 14.0% of our accounts receivables as of October 3, 2025. If one or more of these customers were to cancel a product order or service contract, become insolvent, or otherwise be unable or fail to pay for our products and/or services in a timely manner, our operating results and financial condition could be materially and adversely affected.

***Customer-driven changes in order forecasts is a frequent occurrence that has created and continues to create challenges for us in accurately predicting the demand or delivery schedules for our products.***

&nbsp;&nbsp;&nbsp;&nbsp;End-user product demand, economic uncertainties, the impact of pandemic diseases, natural disasters, armed conflicts, geopolitical tensions, a prolonged United States government shutdown, legislative, tariff, and trade policy reforms, including, for example, the tariffs announced by the United States during the calendar year 2025 and the retaliatory actions announced by a number of countries in response, potential social unrest and uncertainty resulting therefrom, government investigations, including, for example, the MOFCOM Investigations that have been suspended indefinitely, and before that, the Chinese government initiated anti-corruption investigations related to China's healthcare industry, and other matters beyond our control, make it difficult for our customers to accurately forecast and plan future business activities, which makes it difficult for us to accurately predict demand or delivery schedules for our products. Because the manufacture of our products requires some lead-time, changes in customer purchasing forecasts have previously resulted in excess inventory and slowdowns in sales, which are likely to occur again in the future. Changes to customer forecasts can occur on short notice, as our customers face inherent competitive issues, new product introduction delays, and regulatory risks. Our agreements for imaging components contain purchasing estimates that are typically based on our customers' forward-looking forecasts rather than firm commitments, and actual purchasing volumes under the agreements may vary significantly from these estimates. The variation from forecasted purchasing volume may be due, in part, to the increasing life of X-ray tubes, which can result in reduced demand for replacement X-ray tubes in ways we may not be able to accurately forecast. Reductions in purchasing patterns have in the past, and may in the future, materially and adversely affect our operating results.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***We compete in highly competitive industries, and we are subject to pricing pressures and other factors that have in the past and may in the future result in margin erosion and loss of customers.***

&nbsp;&nbsp;&nbsp;&nbsp;We compete in industries characterized by rapidly evolving technology, intense competition and pricing pressure. We often compete with companies that have greater financial, marketing and other resources than us. Some of the major diagnostic imaging systems companies, which are the primary OEM customers for our X-ray imaging components, also manufacture X-ray imaging components, including X-ray tubes and flat panel detectors, for use in their own imaging systems products. We have experienced, and may in the future experience, decreased sales of our products to these customers if they manufacture a greater percentage of their components in-house or purchase components from external sources other than us, which has had and may in the future have an adverse effect on our business and results of operations. We have in the past made price and other concessions to maintain existing customers and attract new customers, and may have to make additional price and other concessions in the future.

&nbsp;&nbsp;&nbsp;&nbsp;In addition, we compete against other stand-alone, independent X-ray tube manufacturers for both the OEM business of major diagnostic imaging equipment manufacturers and the independent servicing business for X-ray tubes. The flat panel detectors industry is also very competitive, and we face intense competition from over a dozen smaller competitors. In our Industrial business, we also compete with other OEM suppliers primarily outside of the United States. Some of our competitors outside of the United States may have resources and support from their governments that we do not, such as preferences for local manufacturers, and may not be subject to the same tariffs, trade policies, trade compliance regulations and government investigations as us.

&nbsp;&nbsp;&nbsp;&nbsp;Our competitors are not all subject to the same standards, regulatory and/or other legal requirements to which we are subject and, therefore, they could have a competitive advantage in developing, manufacturing, and marketing products and services. Any inability to develop, gain regulatory approval for, and supply commercial quantities of competitive products to existing and potential customers as quickly and effectively as our competitors could limit acceptance of our products and negatively and materially affect our pricing, sales, revenues, market share, and gross margins and our ability to maintain or increase our operating margins.

***Our success depends on meeting our customers' needs and demands.***

&nbsp;&nbsp;&nbsp;&nbsp;To be successful, we must anticipate our customers' needs and demands, as well as potential shifts in preferences. If we are unable to anticipate these needs and demands, or the mix of products requested by our customers changes from what we expect, our revenue, margins, and financial results could be adversely affected. When the U.S. Dollar is strong compared to the operating currencies of our international customers, our ability to meet such customers' pricing expectations is particularly challenging and may result in erosion of revenues, product margin, and/or market share or other concessions on business terms.

&nbsp;&nbsp;&nbsp;&nbsp;In addition, certain costs, including installation and warranty costs, associated with new products have been, and may in the future be proportionately greater than the costs associated with existing products and have or may therefore disproportionately, materially, and adversely affect our gross and operating margins. We may also experience lower margins due to increased commodities prices, higher tariffs, and inadequate transfer pricing favoring sales to third parties over internal sales. If we are unable to lower these costs over time, our operating results could be materially and adversely affected. Some of the electronic components and integrated circuits used in our flat panel detectors are susceptible to discontinuance and obsolescence risks, which may force us to incorporate newer generations of these components, resulting in unplanned additional R&D expenses, delays in the launch of new products, supply disruptions, or inventory write-downs. Further, using aging production equipment might hamper our capacity to innovate to meet customers' needs and demands and stay competitive. Failure to develop and adopt artificial intelligence ("AI") technology could also hinder our competitiveness and growth potential. We may also experience challenges in developing and implementing effective product and sales strategies, leading to missed opportunities and customer dissatisfaction.

***Our success depends on the successful development, introduction, and commercialization of new generations of products and enhancements to or simplifications of existing product lines.***

&nbsp;&nbsp;&nbsp;&nbsp;We operate in business segments characterized by rapid change and technological innovation. Our customers use our products in their medical diagnostic, security, and industrial imaging systems, and we must continually introduce new products at competitive prices while also improving existing products with higher quality, lower costs, and increased features. We and our joint ventures have in the past spent, and in the future may need to spend, more time and money than we expect to develop, market, and introduce new products, product enhancements, and technologies. Even if we succeed in introducing new products, enhancements, or technologies as soon as expected, potential customers may not accept or purchase these new products, enhancements, or technologies, and we may not be able to recover all or a meaningful part of our investment. Once introduced, new products may materially and adversely impact sales of our existing products or make them less desirable or even obsolete, which could materially and adversely impact our revenues and operating results.

&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, we may not be able to successfully develop, manufacture, or introduce new products or enhancements to existing products, the roll-out of which involves compliance with complex quality assurance processes, including the Quality System Regulation ("QSR") of the U.S. Food and Drug Administration ("FDA"). Failure to complete these processes timely and efficiently

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

could result in delays that could affect our ability to attract and retain customers or cause customers to delay or cancel orders, which would materially and adversely affect our revenues and operating results.

***More than half of our revenue is currently generated from customers located outside the United States, and is subject to global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars and other risks associated with international manufacturing, operations, and sales.***

&nbsp;&nbsp;&nbsp;&nbsp;Revenues generated from customers located outside the United States accounted for approximately 70%, 68%, and 69% of our total revenues during fiscal years 2025, 2024, and 2023, respectively. We intend to continue to expand our presence internationally and expect to expend significant resources in doing so. Our results have in the past, are currently, and could in the future be impacted by a variety of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• governmental imposition of additional taxes, tariffs, global economic sanctions programs, or other restrictions on foreign trade, and responsive retaliatory actions from impacted countries, including, for example, the current trade war between the United States and China, and the MOFCOM Investigations that have been suspended indefinitely;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• political and economic instability, including the possibility of civil unrest, terrorism, mass violence, armed conflict, or pandemic diseases, which may among other things, impact our operations and business access;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• currency fluctuations, and in particular the relative strength of the U.S. Dollar, which is our functional and reporting currency;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in staffing and managing employee relations in foreign operations, including in foreign joint ventures, particularly in attracting and retaining personnel qualified to design, test, sell and support our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in coordinating our operations globally and in maintaining uniform standards, controls, procedures, and policies across our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the longer payment cycles associated with many customers located outside the United States;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in interpreting or enforcing agreements and collecting receivables through many foreign countries' legal systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• imposition of burdensome governmental regulations, including changing data privacy laws and regulations ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• compliance with import/export laws and requirements.

&nbsp;&nbsp;&nbsp;&nbsp;Some of our locations expose us to higher security risks, which could result in both harm to our employees and contractors or substantial costs. Some of our services are performed in or adjacent to high-risk locations where the country or location and surrounding area experience political, social, or economic turmoil, war or civil unrest, or high levels of criminal or terrorist activities. In those locations where we have employees or operations, we may incur substantial costs to maintain the safety of our personnel, and we may suffer the loss of employees and contractors, which could harm our business, reputation, and operating results.

***We may be unable to complete future acquisitions or joint ventures or realize expected benefits from acquisitions of or investments in new businesses and joint ventures, products, or technologies, which could harm our business.***

&nbsp;&nbsp;&nbsp;&nbsp;Our ability to identify and take advantage of attractive acquisitions or other business development opportunities (including through joint ventures) is an important component in implementing our overall business strategy. Such transactions involve a number of risks, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may not be able to identify suitable candidates or successfully complete or finance identified acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may incur substantial costs, including advisory fees and diversion of management attention, in evaluating a potential transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may be unable to achieve the anticipated benefits from the transaction, including a return on our investment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may have difficulty integrating organizations, products, technologies, or employees of an acquired business into our operations and may have difficulty retaining the key personnel of the acquired business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquisitions, investments, and joint ventures could result in increased risks, including from potential litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may find that we need to restructure or divest acquired businesses or assets of the acquired business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if we fail to achieve the anticipated growth from an acquisition or joint venture, or if we decide to sell assets or a business, we may be required to dispose of a business at a lower price or on less advantageous terms, or to recognize an impairment loss on the write-down of our assets and goodwill.

&nbsp;&nbsp;&nbsp;&nbsp;We participate in joint ventures and other investments in privately held and publicly traded companies. For example, we hold a 40% ownership interest in dpiX Holding Company LLC, the parent company of the major supplier of our amorphous silicon-based thin film transistor arrays for flat panels used in our digital image detectors, a 50% interest in VEC Imaging GmbH & Co. KG ("VEC"), a joint venture formed to develop technology for use in X-ray imaging components, a 75% interest in Varex Imaging Arabia LLC, a joint venture in Saudi Arabia and a minority interest in another X-ray imaging components technology company. These and other investments are subject to risk of loss of investment capital as well as losses associated with contributed or jointly developed intellectual property, or intellectual property developed at or about the same time as these investments. These types of investments are

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

inherently risky, in some instances because customer demand and sales for the technologies or products under development may never materialize, may develop more slowly than expected, or may underperform relative to our expectations. If these companies do not succeed, we could lose or be required to write down some or all of our investment in these companies. As discussed in the risk factor "*Legal proceedings may materially and adversely affect our business, results of operations, or cash flows,"* we may incur significant time, management resources, and costs to enforce our rights, protect our intellectual property and other assets, address disputes or legal claims that have arisen, are ongoing, or may arise in the future, and/or unwind, dispose of or terminate our arrangements with respect to these joint ventures and/or investments. There is no guarantee that the time and money invested by us in developing these projects, intellectual property, or product or product enhancements, will yield the expected returns on the anticipated timeline or at all.

***Legal proceedings may materially and adversely affect our business, results of operations, or cash flows.***

&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we are a party to or otherwise involved in legal proceedings, claims, government inspections, audits or investigations, and other legal matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. Such proceedings are often lengthy, subject to significant uncertainty and may be expensive, time consuming, and disruptive to our operations. For these and other reasons, we may choose to settle legal proceedings and claims, regardless of their actual merit. If a legal proceeding were to be ultimately resolved against us, we may be required to pay damages or fines, some of which may be in excess of our insurance coverage, or may require us to change our business practices, which could materially and adversely impact our business, results of operations, or cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;Our subsidiary Varex Imaging Deutschland AG ("Varex Germany") holds a 50% interest in VEC. In August 2023, February 2024, and August 2024, the partners to the VEC joint venture filed judicial proceedings in Germany against one another disputing the validity of shareholder resolutions passed in January 2023, January 2024, and August 2024, respectively. Each party was, in effect, seeking to have the other party's managing director(s) removed and to exclude the other party from the joint venture. On October 31, 2025, the court in Germany ruled that neither party had been validly excluded and that each remain parties to the joint venture. Each party has 30 days to appeal the court's decision. If either party were to successfully appeal, the prevailing party would be required to purchase the non-prevailing party's interest in the joint venture for an amount equal to 75% of the fair market value thereof, which amount is in dispute. In addition, in June 2024, Varex Germany filed an action in Germany for a negative declaratory judgment and an injunction against business damaging statements made by certain third parties, and in August 2024, October 2024 and subsequently, Varex Germany and Varex Imaging Corporation filed additional lawsuits in Germany and the United States relating to intellectual property matters, breach of contracts and other matters. The October 2024 lawsuit was subsequently voluntarily dismissed while the parties try to negotiate a settlement. These disputes, including any determinations not in Varex Germany's favor, have diverted, are diverting, and could in the future divert management's attention, increase our costs, and otherwise adversely impact our business, results of operations, or cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;Our subsidiary Varex Imaging International AG holds a 75% interest in Varex Imaging Arabia LLC. We currently have ongoing disputes with our joint venture partner relative to the operation of the joint venture. These disputes could divert management's time and attention, increase our costs, and otherwise adversely impact our business, results of operations, or cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;As discussed in the risk factor "*Our business has in the past been, is currently being, and in the future may be, negatively impacted by changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto,*" MOFCOM initiated, then temporarily suspended, and then recently indefinitely suspended two investigations relating to medical products imported into China that include products we import to China. If recommenced, the outcome of these investigations has the potential to negatively impact our business, results of operations and financial condition.

***Product defects or misuse may result in material product or other liability or professional errors and omissions claims, litigation, investigation by regulatory authorities, or product recalls.***

&nbsp;&nbsp;&nbsp;&nbsp;Our business exposes us to potential product and other liability claims that are inherent in the manufacture, sale, installation, servicing, and support of components that are used in medical devices and other devices that deliver radiation. Because our products are involved in the intentional delivery of radiation to the human body and other situations where people may come into contact with radiation, the possibility for significant personal injury or loss of life exists. Furthermore, if our x-ray inspection systems fail to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, this may lead to personal injury, loss of life, and extensive property damage. We may also be subject to warranty and damage claims for property damage, personal injury, or economic loss related to or resulting from any errors or defects in our products or the installation, servicing, or support of our products. Any accident or mistreatment could subject us to legal costs, litigation, adverse publicity, and damage to our reputation, whether or not our products or services were a factor. We are currently a party to certain products liability litigation which, if adversely determined, could have an adverse material impact on our financial results. If a product we design or manufacture were defective, we may be required to correct or recall the product and notify regulatory authorities.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;We may choose to settle product liability claims against us regardless of their actual merit. A product liability action determined against us could result in adverse publicity or significant damages, including the possibility of punitive damages, and our financial position, results of operations, or cash flows could be materially and adversely affected.

&nbsp;&nbsp;&nbsp;&nbsp;We maintain limited product liability insurance coverage. Our product liability insurance policies are expensive and have high deductible amounts and self-insured retentions. Our insurance coverage may prove to be inadequate, and future policies may not be available on acceptable terms or in sufficient amounts, if at all. If a material claim is not insured or is in excess of our insurance coverage, we may have to pay substantial damages, which could have a material and adverse effect on our financial position and/or results of operations.

**Risks Relating to the Manufacture of our Products**

***Supply chain disruptions, including the loss of a supplier, and any inability to obtain raw materials or supplies of important components due to inflation have impacted our ability to manufacture products, have caused delays in our ability to deliver products, and have increased our costs and may continue to do so.***

&nbsp;&nbsp;&nbsp;&nbsp;Inflation and supply chain disruptions have had, and could in the future have, an impact on our ability to manufacture certain products. Any rise in future inflation has the potential to increase our overall cost structure, and sustained inflation has resulted in, and may continue to result in, higher interest rates and capital costs, increased shipping costs, supply shortages, increased costs of labor, weakening exchange rates, and other similar effects.

&nbsp;&nbsp;&nbsp;&nbsp;Material shortages and delays due to inflation and other constraints have caused, and could in the future cause, us to temporarily stop production of certain products or miss opportunities to pursue additional sales of some products. We require certain raw materials, such as copper, nickel, silver, gold, lead, tungsten, iridium, rhenium, molybdenum, rhodium, niobium, zirconium, beryllium, and various high grades of steel alloy for X-ray tubes and industrial products. Worldwide demand, availability, and pricing of these raw materials have been volatile. If we are unable to obtain the materials necessary to make certain products without unreasonable cost or delay, our customers may seek alternative suppliers who are less impacted by the current tariff environment, or decide to in-source certain products or if we must pay more for certain materials, it could reduce our profit margin or otherwise have a material adverse effect on our business and financial results. Further, our competitors with greater financial resources may be better able to restructure their manufacturing and supply chains in response to geopolitical and economic trends and thereby have a competitive advantage over us.

&nbsp;&nbsp;&nbsp;&nbsp;We obtain some of the components included in our products, such as transistor arrays, cesium iodide coatings and specialized integrated circuits for flat panel detectors, X-ray tube targets and windows, housings, glass frames, high-voltage cable, bearings, and various other components, from a limited group of suppliers or from sole-source suppliers. If our suppliers cease producing these or other components, prioritize other customers, fail to provide products on our delivery timelines, are in countries subject to significant tariffs, or become unable to continue operations, we may be unable to obtain the components from other suppliers on reasonable terms or at all, and this could materially and adversely affect our business and financial results.

&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, we may be required to obtain and qualify one or more replacement suppliers or to manufacture the components internally. Such an event could (1) require us to redesign or modify our products to incorporate new parts and/or further require us to obtain clearance, qualification, or certification of these products, including by the FDA, or obtain other applicable regulatory approvals in other countries, (2) significantly increase costs for the affected products, (3) cause material delays in the delivery of affected and other related products, or (4) prevent us from meeting our delivery obligations to our customers.

***Our operations are vulnerable to interruption or loss due to natural or other disasters, the adverse effects of climate change, power loss, strikes, and other events beyond our control.***

&nbsp;&nbsp;&nbsp;&nbsp;We conduct some of our activities, including manufacturing, research and development, administration, and data processing at facilities located in areas that have in the past experienced or may in the future experience natural disasters. Natural disasters (such as a major fire, hurricane, earthquake, flood, tsunami, or volcanic eruption), severe weather conditions, adverse climate change-related events, war or terrorism, and disruption in utilities and other services affecting our facilities, or those of our suppliers, could significantly disrupt our operations and delay or prevent product manufacture and shipment during the time required to repair, rebuild, or replace our or our suppliers' damaged manufacturing facilities. These delays could be lengthy and costly. If any of our customers' facilities are adversely affected by such a disaster or event, shipments of our products could be delayed. Additionally, customers may delay purchases of our products until our or their operations return to normal. Even if our suppliers or customers are able to quickly respond to such a disaster or event, the ongoing effects could create some uncertainty in the operations of our business. In addition, concerns about terrorism, the effects of a terrorist attack, political turmoil, or an outbreak of epidemic diseases have in the past had, and could in the future have, a negative effect on our business operations, those of our suppliers and customers, and the ability to travel, resulting in adverse consequences on our revenues and financial performance.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***If we are not able to match our manufacturing capacity with demand for our products, our financial results may suffer.***

&nbsp;&nbsp;&nbsp;&nbsp;Many of our products have a long production cycle, and we must anticipate demand for our products to ensure adequate manufacturing and testing capacity. If we are unable to anticipate demand, and our manufacturing or testing capacity does not keep pace with product demand, we will be unable to fulfill orders in a timely manner, which may negatively impact our financial results and overall business. Conversely, if demand for our products decreases, the fixed costs associated with excess manufacturing capacity may harm our financial results, including by decreasing gross margins and increasing research and development costs as a percentage of revenue.

***Demand for our security, industrial, and inspection products tend to be unpredictable, leading to volatility in our revenues and earnings.***

&nbsp;&nbsp;&nbsp;&nbsp;The demand for our security and inspection products is heavily influenced by United States and foreign governmental policies on national and homeland security, border protection, and customs activities, which depend upon levels of government employment, government debt, and government budgets and appropriations that are subject to economic conditions, political changes, and oil prices. Even when government budgets and appropriations levels, economic and political conditions, and oil prices are favorable it is difficult to predict when governments may issue requests for bids, complete their bid process and award tenders, which tends to lead to volatility in our revenues and earnings.

**Risks Relating to our Information Systems and Intellectual Property**

***Disruption of critical information systems or material breaches in the security of our systems may materially and adversely affect our business and customer relations.***

&nbsp;&nbsp;&nbsp;&nbsp;Information technology (including technology from third-party providers) helps us operate efficiently, interface with and support our customers, maintain financial accuracy and efficiency, and produce our financial statements. In the ordinary course of our business, we collect, process, and store sensitive data, including intellectual property, proprietary business information, and information of customers, suppliers, business partners, and third parties accessing our website, patient data, and personally identifiable information of customers and employees, in our data centers and on our networks, as well as in third-party off-site data centers. We have been, and expect to be, subject to cyberattacks, and may be subject to ransomware and distributed denial-of-service attacks, spearfishing attacks and other attempted intrusions on our networks and systems by a wide range of actors. We expect our third-party vendors to be subject to similar cyberattacks and other attempted intrusions. Despite security measures, there is an increasing threat of information security breaches and attacks, including from computer viruses or other malicious codes, unauthorized access attempts, employee misuse, human error, and cyber-attacks that pose risks to companies, including us. Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, have become increasingly sophisticated, and generally are not recognized until launched against a target, we may be unable to anticipate or immediately detect these techniques, or the vulnerabilities they have caused or other potential vulnerabilities or security defects, or to implement adequate preventative measures, which could result in data leaks or otherwise compromise our confidential or proprietary information and materially disrupt our operations. Such security breaches could expose us to a risk of loss of information and intellectual property, litigation, and possible liability to employees, customers, shareholders, and/or regulatory authorities. If our data management or other systems do not effectively collect, secure, store, process, or report relevant data for the operation of our business, whether due to equipment malfunction or constraints, service interruptions, software deficiencies, or human error, our ability to effectively plan, forecast, and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows, and the timeliness with which we report our operating results internally and externally.

&nbsp;&nbsp;&nbsp;&nbsp;We use certain cloud-based software. A security breach, whether of our products, of our customers' network security and systems, or of third-party hosting services could disrupt access to our customers' stored information and could lead to the loss of, damage to, or public disclosure of our customers' stored information, including patient health information. Such an event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced demand for our solutions, an unwillingness of our customers to use our solutions, harm to our reputation and brand, and time-consuming and expensive litigation, any of which could have a material and adverse effect on our financial results.

***Our competitive position would be harmed if we are not able to maintain or defend our intellectual property rights, and protecting our intellectual property and defending against infringement claims can be costly.***

&nbsp;&nbsp;&nbsp;&nbsp;We file applications as appropriate for patents covering new products and manufacturing processes. We cannot provide assurance, however, that patents will be issued from any of our pending or future patent applications or that our current patents, the claims allowed under our current patents, or patents for technologies licensed to us will be sufficiently broad to protect our technology

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

position against competitors. We also jointly develop intellectual property with third parties and seek to protect our rights to such intellectual property through licenses and other contractual arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;We also rely on a combination of copyright, trade secret, and other laws, and contractual restrictions on disclosure, copying and transferring title (including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants, and other third parties), to protect our proprietary, and other confidential rights. Our trade secrets may become known to or be independently developed by others, including as a result of misappropriation by unauthorized access to our technology systems, and our business and financial results could be materially and adversely impacted. We have trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for our products in the marketplace, but unauthorized parties may still use them. We also license certain patented or proprietary technologies from others. In some cases, products with substantial revenues may depend on these license rights. If we were to lose the rights to license these technologies, or our costs to license these technologies were to materially increase, our business would suffer.

&nbsp;&nbsp;&nbsp;&nbsp;There is a substantial amount of litigation over patent and other intellectual property rights in the industries in which we compete. Our competitors, like companies in many high technology businesses, continually review other companies' activities for possible conflicts with their own intellectual property rights. In addition, non-practicing entities may review our activities for conflicts with their patent rights. From time to time, we have received notices from parties asserting infringement, and we have been subject to lawsuits alleging infringement of patent or other intellectual property rights. In addition, from time to time we have entered, and in the future we may enter, into agreements that require us to indemnify our customers for intellectual property infringement, which agreements could subject us to liability. Legal disputes relating to intellectual property have occurred, are occurring, and may occur in the future. Any dispute regarding patents or other intellectual property, including with respect to breaches of licensing agreements or other contractual arrangements, could be costly and time consuming and could divert our management and key personnel from our business operations. We may not prevail in a dispute. We do not maintain insurance for intellectual property infringement, so costs of defense, whether or not we are successful in defending an infringement claim, will be borne by us and could be significant. If we are unsuccessful in defending or appealing an infringement claim or claims alleging other contractual breaches, we may be subject to significant damages, and our combined financial position, results of operations, or cash flows could be materially and adversely affected. We may also be subject to injunctions against development and sale of our products, the effect of which could be a material reduction of our revenues. Additionally, as we expand our manufacturing capabilities outside of the United States, more of our intellectual property may be held in jurisdictions that lack robust intellectual property protections, which may make it harder for us to adequately protect our intellectual property.

**Risks Relating to Our Legal and Regulatory Environment**

***Compliance with United States laws and regulations applicable to the marketing, manufacturing, and distribution of our products may be costly, and failure or delays in obtaining regulatory clearances or approvals, or failure to comply with applicable laws and regulations could harm our business.***

&nbsp;&nbsp;&nbsp;&nbsp;If we or any of our suppliers, distributors, agents, or customers fail to comply with FDA, Federal Trade Commission, or other applicable United States regulatory requirements or are perceived to have failed to comply with regulations, we may face:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse publicity affecting both us and our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased pressures from competitors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• investigations by governmental authorities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fines, injunctions, civil penalties, and criminal prosecution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• partial suspension or total shutdown of production facilities or the imposition of operating restrictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased difficulty in obtaining required clearances or approvals or losses of clearances or approvals already granted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• seizures or recalls of our products or those of our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• delays in purchasing decisions by customers or cancellation of existing orders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the inability to sell our products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulty in obtaining product liability or operating insurance at a reasonable cost, or at all.

&nbsp;&nbsp;&nbsp;&nbsp;Generally, our manufacturing operations for medical devices, and those of our third-party manufacturers, are required to comply with the QSR of the FDA, as well as other federal and state regulations for medical devices and radiation-emitting products. Failure to respond in a timely manner to a warning letter or any other notice of noncompliance with applicable regulations and/or procedures and to promptly come into compliance could result in the FDA bringing an enforcement action, which could include the total shutdown of our production facilities, denial of importation rights to the United States for products manufactured in overseas locations, adverse publicity, and criminal and civil fines. The expense and costs of any corrective actions that we may take, which may include product recalls, product correction, removal of products from customer sites, or changes to our product manufacturing and quality systems, could materially and adversely impact our financial results and may also divert management resources, attention, and

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

time. Additionally, if a warning letter were issued, customers could delay purchasing decisions or cancel orders, and we could face increased pressure from our competitors, who could use the warning letter against us in competitive sales situations, either of which could materially and adversely affect our reputation, business, and stock price.

&nbsp;&nbsp;&nbsp;&nbsp;We produce some products that are classified as "Class II" devices subject to 510(k) pre-market notification clearance. A new medical device or a new indication for use of, or other significant change in, any such products, or the development of a new Class II device would require us to obtain a new 510(k) clearance before we could market or sell those products in the United States. We cannot ensure that the FDA will agree with our decisions not to seek additional approvals or clearances for particular modifications to our products or that we will be successful in obtaining new 510(k) clearances for new products or for modifications to existing products. Obtaining clearances or approvals is time consuming, expensive, and uncertain. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses of the product, which may limit the potential customers for the product. If we are unable to obtain required FDA clearance or approval for a product or are unduly delayed in doing so, or the uses of that product were limited, our business could suffer.

&nbsp;&nbsp;&nbsp;&nbsp;We are required to timely file various reports with the FDA, including reports required by the medical device reporting regulations ("MDRs"), that require we report to regulatory authorities if our devices may have caused or contributed to a death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If we initiate a correction or removal of a device to reduce a risk to health posed by the device, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall, which could lead to increased scrutiny by the FDA, other international regulatory agencies, and our customers regarding the quality and safety of our devices. If these MDRs or correction and removal reports are not filed on a timely basis, regulators may impose sanctions, sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.

&nbsp;&nbsp;&nbsp;&nbsp;Government regulation may also cause significant delays or prevent the marketing and full commercialization of future products or services that we may develop and/or may impose costly requirements on our business. As we enter new businesses or pursue new business opportunities, we will become subject to additional laws, rules, and regulations, including FDA and foreign rules and regulations and compliance can be costly. Failure to comply with these laws, rules and regulations could delay the introduction of new products and could materially and adversely affect our business.

&nbsp;&nbsp;&nbsp;&nbsp;We are also subject to federal and state laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices, and other matters. Insurance coverage is not commercially available for violations of law, including the fines, penalties, or investigatory costs that we may incur as the consequence of regulatory violations. Consequently, we do not have insurance that would cover this type of liability.

***Compliance with foreign laws and regulations applicable to the marketing, manufacturing, and distribution of our products may be costly, and failure to comply may result in unfavorable legal proceedings, in significant penalties and other harm to our business.***

&nbsp;&nbsp;&nbsp;&nbsp;Outside the United States, some of our products are regulated as medical devices by foreign governmental agencies similar to the FDA. For us to market our products internationally, we must obtain clearances or approvals for products and product modifications, which can be time consuming, expensive, uncertain, and which can delay our ability to market products. Delays in the receipt of or failure to receive regulatory approvals, the inclusion of significant limitations on the indicated uses of a product, the loss of previously obtained approvals or failure to comply with existing or future regulatory requirements could restrict or prevent us from doing business in a country or subject us to a variety of enforcement actions and civil or criminal penalties, which would materially and adversely affect our business. In addition, compliance with changing regulatory schemes may add additional complexity, cost, and delays in marketing, or selling our products.

&nbsp;&nbsp;&nbsp;&nbsp;Within the European Union ("EU") and the European Economic Area ("EEA"), we must obtain, and in turn affix, a CE mark certification, that indicates that a product meets the essential requirements of the EU's Medical Device Directive ("MDD") and the EU Medical Device Regulations. By affixing the CE mark to our product, we are certifying that our products comply with the laws and regulations required by the EU/EEA countries, thereby allowing the free movement of our products within these countries and others that accept CE mark standards. If we cannot support our performance claims and demonstrate compliance with the applicable European laws and the MDD, we would lose our right to affix the CE mark to our products, which would prevent us from selling our products within the EU/EEA/Switzerland territory and in other countries that recognize the CE mark.

&nbsp;&nbsp;&nbsp;&nbsp;We are subject to international laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, and manufacturing practices, as well as others. These are often comparable to, or more stringent than, equivalent regulations in the United States. Sales overseas are also affected by regulation of matters such as product standards, packaging, labeling, environmental and product recycling requirements, import and export restrictions, tariffs, duties, and taxes.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;In addition, we are required to timely file various reports with international regulatory authorities similar to the reports we are required to timely file with United States regulatory authorities, including reports required by international adverse event reporting regulations. If these reports are not timely filed, regulators may impose sanctions, including temporarily suspending our market authorizations or CE mark, and sales of our products may suffer as a result.

&nbsp;&nbsp;&nbsp;&nbsp;As we enter new businesses or pursue new business opportunities internationally, or as regulatory schemes change, we may become subject to additional laws, rules, and regulations, and compliance can be costly. The failure by us or our agents to comply with these laws, rules, and regulations could delay the introduction of new products, cause reputational harm, or result in investigations, fines, injunctions, civil penalties, criminal prosecution, or an inability to sell our products in or to import our products into certain countries, which could materially and adversely affect our business.

***We are subject to federal, state, and foreign laws governing our business practices which, if violated, could result in substantial penalties. Additionally, challenges to or investigations into our practices could cause adverse publicity and be costly to respond to and thus could harm our business.***

&nbsp;&nbsp;&nbsp;&nbsp;*Anti-corruption laws and regulations*. We are subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws in foreign countries, such as the U.K. Bribery Act. Any violation of these laws by us or our agents or distributors could create substantial liability for us, subject our officers and directors to personal liability, and cause a loss of reputation. We operate in many countries, including India and China, where the public sector is perceived as being corrupt. Our strategic business plans include expanding our business in regions and countries that are rated as higher risk for corruption activity by Transparency International e.V., an international non-profit that publishes an annual corruption perception index, which could subject us and our officers and directors to increased scrutiny and increased liability from our business operations. Becoming familiar with and implementing the infrastructure necessary to comply with laws, rules, and regulations applicable to new business activities and mitigating and protecting against corruption risks could be costly. Failure by us or our agents or distributors to comply with these laws, rules, and regulations could delay our expansion into high-growth areas and materially and adversely affect our business.

&nbsp;&nbsp;&nbsp;&nbsp;*Competition and trade compliance laws*. We are subject to various competition and trade compliance laws in the jurisdictions where we operate throughout the world. Regulatory authorities in those jurisdictions may have the power to subject us to sanctions, tariffs, and duties and may impose changes or conditions in the way we conduct our business. An increasing number of jurisdictions provide private rights of action for competitors or consumers to assert claims of anti-competitive conduct and seek damages. Increased government scrutiny of our actions or enforcement or private rights of action could materially and adversely affect our business or damage our reputation. We may be required to conduct internal investigations or face audits or investigations by one or more domestic or foreign government agencies, which could be costly and time consuming and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to fines and criminal or other penalties, which could materially and adversely affect our business and financial results. The currently indefinitely suspended MOFCOM Investigations are an example of the type of investigations or audits we are currently, and could in the future, face. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that we may desire to undertake.

&nbsp;&nbsp;&nbsp;&nbsp;*Laws and ethical rules governing interactions with healthcare providers*. We may occasionally sell our products to healthcare providers through distributors or otherwise engage healthcare providers to provide services. The U.S. Medicare and Medicaid "anti-kickback" laws, and similar state laws, prohibit payments or other remuneration that is intended to induce hospitals, physicians, or others either to refer patients or to purchase, lease, or order, or to arrange for or recommend the purchase, lease, or order of healthcare products or services for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. These laws affect our sales, marketing, and other promotional activities by limiting the kinds of financial arrangements we may have with hospitals, physicians, or other potential purchasers of our products. They particularly impact how we structure our sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants, and other fee-for-service arrangements. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances.

&nbsp;&nbsp;&nbsp;&nbsp;Federal and state "false claims" laws generally prohibit knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government payors that are false or fraudulent, or for items or services that were not provided as claimed. Although we do not submit claims directly to payors, manufacturers can be, and have been, held liable under these laws if they are deemed to "cause" the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers or through certain other activities, including promoting products for uses not approved or cleared by the FDA, which is called off-label promotion. Violating "anti-kickback" and "false claims" laws can result in civil and criminal penalties, which can be substantial, as well as potential mandatory or discretionary exclusion from healthcare programs for noncompliance. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to defend and thus could harm our business and results of operations. Additionally, several recently-enacted state and federal laws, including laws in Massachusetts and Vermont, and the federal Physician Payment Sunshine Act, now require, among other things, extensive tracking and maintenance

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

of databases regarding the disclosure of equity ownership and payments to physicians, healthcare providers, and hospitals. These laws may require us to implement the necessary and costly infrastructure to track and report certain payments to healthcare providers. Failure to comply with these tracking and reporting laws could subject us to significant civil monetary penalties.

&nbsp;&nbsp;&nbsp;&nbsp;*Other laws.* We are subject to other laws in foreign countries where we conduct business. For example, within the EU, the control of unlawful marketing activities is a matter of national law in each of the member states. The member states of the EU closely monitor perceived unlawful marketing activities. We could face civil, criminal, and administrative sanctions if any member state determines that we have breached such state's national laws. Industry associations also closely monitor the activities of member companies. If these organizations or authorities name us as having breached our obligations under their regulations, rules, or standards, our reputation would suffer, and our business and financial condition could be materially and adversely affected.

***A change in the percentage of our total earnings from international sales, changes in our international activities, or additional changes in tax laws could increase our effective tax rate.***

&nbsp;&nbsp;&nbsp;&nbsp;Earnings from our international subsidiaries are generally taxed at rates that differ from United States rates. A change in the percentage of our total earnings from our international subsidiaries, a change in the mix of particular tax jurisdictions between our international subsidiaries, a change in currency exchange rates, or a shift in where we perform manufacturing, research and development, and other activities internally could cause our effective tax rate to increase. Furthermore, while United States tax reform imposed a current tax on cumulative undistributed earnings, these earnings could also become subject to incremental foreign withholding or United States state taxes should they actually be remitted to the United States, in which case our financial results could be materially and adversely affected.

&nbsp;&nbsp;&nbsp;&nbsp;Statutory changes included in proposed United States legislation, if passed, including interpretive guidance, could materially impact our income tax expense, effective tax rate, or the value of deferred tax assets and liabilities. Changes in the valuation of our deferred tax assets or liabilities, changes in tax laws or rates, changes in the interpretation of tax laws in other jurisdictions, or other changes beyond our control could materially and adversely affect our financial position and results of operations. For example, a change in tax law, which became effective for us in 2023 and requires capitalization of research and experimental expenditures, significantly increased our cash tax expense in the United States in fiscal year 2024. We expect this increase in cash tax expense to continue until normalizing in fiscal year 2027.

&nbsp;&nbsp;&nbsp;&nbsp;We have entities in certain jurisdictions with cumulative net operating losses for which no income tax benefit can be recorded due to full valuation allowance positions. There could be additional future losses in these and other jurisdictions that would negatively impact our effective tax rate.

***We sell certain X-ray tube products as replacements which are subject to medical device certification and product registration laws and regulations that vary by country and are subject to change, and we may be unable to receive registration approval or renewal of existing registrations.***

&nbsp;&nbsp;&nbsp;&nbsp;We market and distribute certain X-ray tubes through distributors and third-party/multi-vendor service organizations that are used as equivalent replacements for specific OEM tubes. We are subject to medical device certification and product registration laws that vary by country and are subject to periodic reviews and changes by regulatory authorities in those countries. Certain of these local laws and regulations have the effect of serving as a barrier to trade and can be difficult to navigate predictably. In addition, certain countries where we sell our products require products to undergo re-registration if the product is altered in any significant way. These registration processes can be costly and time consuming, and customers may decide to purchase products from our competitors that do not have to be involved in a re-registration process. In addition, our inability to receive or renew product registrations may prevent us from marketing and/or distributing those particular products for replacement applications in the specific country.

***Existing and future healthcare reforms and changes to reimbursement rates may indirectly have a material adverse effect on our business and results of operations.***

&nbsp;&nbsp;&nbsp;&nbsp;Sales of our products to OEMs in the medical sector indirectly depend on whether adequate reimbursement is available for our customers' products from a variety of sources, such as government healthcare insurance programs, including U.S. Medicare and Medicaid programs, foreign government programs, private insurance plans, health maintenance organizations, and preferred provider organizations. Without adequate reimbursement, the demand for our customers' products, and therefore indirectly our products, may be limited, which could harm our business, results of operations, financial condition, and prospects.

&nbsp;&nbsp;&nbsp;&nbsp;Healthcare reform proposals and medical cost containment measures in the United States and in many foreign countries could limit the use of both ours and our customers' products, reduce reimbursement available for such use, further tax the sale or use of our products, and further increase the administrative and financial burden of compliance. Any changes that lower reimbursements for us or our customers' products and/or procedures using these products, including, for example, existing reimbursement incentives to convert

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

from analog to digital X-ray systems, or changes that reduce medical procedure volumes or increase cost containment pressures on us or others in the healthcare sector could materially and adversely affect our business and results of operations.

***Certain of our products are subject to regulations relating to use of radioactive material, compliance with which may be costly, and a failure to comply with these regulations may materially and adversely affect our business.***

&nbsp;&nbsp;&nbsp;&nbsp;As a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, we and some of our suppliers and distributors are subject to extensive regulation by United States governmental authorities, such as the FDA, the Nuclear Regulatory Commission ("NRC"), and state and local regulatory agencies, which is intended to ensure the devices are safe and effective and comply with laws governing products which emit, produce, or control radiation. These regulations govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale, marketing, and disposal of our products. We are also subject to international laws and regulations that apply to manufacturers of radiation-emitting devices and products utilizing radioactive materials. These are often comparable to, if not more stringent than, the equivalent regulations in the United States.

&nbsp;&nbsp;&nbsp;&nbsp;Our industrial and medical devices utilizing radioactive material are subject to NRC clearance and approval requirements, and the manufacture and sale of these products are subject to extensive federal and state regulation that varies from state to state and among regions. Our manufacture, distribution, installation, service, and removal of industrial devices utilizing radioactive material or emitting radiation also requires us to obtain a number of licenses and certifications for these devices and materials. Service of these products must also be performed in accordance with specific radioactive materials licenses. Obtaining licenses and certifications may be time consuming, expensive, and uncertain.

&nbsp;&nbsp;&nbsp;&nbsp;The handling and disposal of radioactive materials resulting from the manufacture, use, or disposal of our products may impose significant costs and requirements. Disposal sites for the lawful disposal of materials generated by the manufacture, use, or decommissioning of our products may no longer accept these substances in the future or may accept them on unfavorable terms.

***Environmental laws impose compliance costs on our business and may also result in liability.***

&nbsp;&nbsp;&nbsp;&nbsp;Environmental laws regulate many aspects of our operations, including our handling, storage, transport, and disposal of hazardous substances, such as the chemicals and materials that we use in the course of our manufacturing operations. For example, pursuant to a remediation plan related to certain hazardous volatile organic compounds present at our Salt Lake City property, we and Varian Medical Systems, Inc. ("Varian") entered into an environmental covenant with the Director of the Utah Division of Waste Management and Radiation Control on behalf of the Utah Department of Environmental Quality requiring certain remediation measures and imposing certain limitations relating to the property and the groundwater in the aquifer underlying the property, including use of the property for commercial and industrial uses only and not allowing groundwater to be used for culinary and other domestic purposes, among other limitations. Our compliance with environmental laws can also impose cleanup liabilities, including with respect to discontinued operations. Like other businesses, we may mishandle or inadequately manage hazardous substances used in our manufacturing operations and can never completely eliminate the risk of contamination or injury from certain materials that we use in our business and, therefore, we cannot completely eliminate the prospect of resulting claims and damage payments. We may also be assessed fines and/or other penalties for failure to comply with environmental laws and regulations. Insurance has provided coverage for portions of cleanup costs resulting from historical occurrences, but we do not expect to maintain insurance coverage for costs or claims that might result from any future contamination.

&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Separation and Distribution Agreement we entered into with Varian when we spun off from Varian, we are obligated to indemnify Varian for 20% of the cleanup liabilities related to prior corporate restructuring activities undertaken while we were a division of Varian. This includes facilities sold as part of Varian's electron devices business in 1995 and thin film systems business in 1997. The U.S. Environmental Protection Agency ("EPA") or third parties have named Varian as a potentially responsible party under the amended Comprehensive Environmental Response Compensation and Liability Act of 1980 ("CERCLA"), at sites to which Varian or the facilities of the businesses sold in 1995 and 1997 were alleged to have shipped waste for recycling or disposal (the "CERCLA sites"). We anticipate that we will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these CERCLA sites (after adjusting for any insurance proceeds or tax benefits received by Varian). We assess this indemnification obligation quarterly with Varian and make accruals accordingly. These accruals have historically been small, but can sometimes fluctuate significantly from period to period.

&nbsp;&nbsp;&nbsp;&nbsp;Future changes in environmental laws could also increase our costs of doing business, perhaps significantly. Several countries, including some in the EU, now require medical equipment manufacturers to bear certain disposal costs of products at the end of the product's useful life, thereby increasing its costs. The EU has also adopted directives that may lead to restrictions on the use of certain hazardous substances or other regulated substances in some of our products sold there. These directives, along with another that requires substance information to be provided upon request, could increase our operating costs by increasing the cost of

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

maintaining our access to certain customers. All of these costs, and any future violations or liabilities under environmental laws or regulations, could have a material adverse effect on our business.

**Risks Relating to Our Indebtedness**

***The Credit Agreement and the indenture governing our Senior Secured Notes impose significant operating and financial restrictions that may limit our current and future operating flexibility, particularly our ability to respond to changes in the economy or our industry or to take certain actions, which could harm our long-term interests and may limit our ability to make payments on the notes.***

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, our total combined indebtedness was approximately $369.9 million of principal, which consisted almost entirely of our 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes"). For more information regarding our borrowings, see Note 6, *Borrowings* of the Notes to the Consolidated Financial Statements of this report.

&nbsp;&nbsp;&nbsp;&nbsp;The Credit Agreement providing for the Revolving Credit Facility and the indenture governing our Senior Secured Notes impose significant operational and financial restrictions on us that include, but are not limited to our ability to:

&nbsp;&nbsp;&nbsp;&nbsp;• incur, assume, or permit to exist additional indebtedness (including guarantees thereof);

&nbsp;&nbsp;&nbsp;&nbsp;• pay dividends or certain other distributions on our capital stock or repurchase our capital stock or prepay subordinated indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;• prepay, redeem, or repurchase certain debt;

&nbsp;&nbsp;&nbsp;&nbsp;• issue certain preferred stock or similar equity securities;

&nbsp;&nbsp;&nbsp;&nbsp;• incur liens on assets;

&nbsp;&nbsp;&nbsp;&nbsp;• make certain loans, investments, or other restricted payments;

&nbsp;&nbsp;&nbsp;&nbsp;• allow to exist certain restrictions on the ability of our restricted subsidiaries to pay dividends or make other payments to us;

&nbsp;&nbsp;&nbsp;&nbsp;• engage in transactions with affiliates;

&nbsp;&nbsp;&nbsp;&nbsp;• alter the business that we conduct; and

&nbsp;&nbsp;&nbsp;&nbsp;• sell certain assets or merge or consolidate with or into other companies.

&nbsp;&nbsp;&nbsp;&nbsp;As a result of these restrictions, we may be:

&nbsp;&nbsp;&nbsp;&nbsp;• limited in how we conduct our business;

&nbsp;&nbsp;&nbsp;&nbsp;• unable to raise additional debt or equity financing on acceptable terms or at all, to operate during general economic or business downturns;

&nbsp;&nbsp;&nbsp;&nbsp;• limited in our ability to borrow additional funds as needed or increasing the cost of such borrowing;

&nbsp;&nbsp;&nbsp;&nbsp;• challenged in satisfying our obligations, including our debt obligations;

&nbsp;&nbsp;&nbsp;&nbsp;• vulnerable to adverse economic and general industry conditions, including interest rate fluctuations, because a portion of our borrowings are and will continue to be at variable rates of interest;

&nbsp;&nbsp;&nbsp;&nbsp;• required to dedicate a substantial portion of our cash flow from operations to payments on our debt, which would reduce the availability of our cash flow from operations to fund working capital, capital expenditures, or other general corporate purposes;

&nbsp;&nbsp;&nbsp;&nbsp;• disadvantaged compared to competitors that may have proportionately less debt; or

&nbsp;&nbsp;&nbsp;&nbsp;• unable to compete effectively or to take advantage of new business opportunities.

&nbsp;&nbsp;&nbsp;&nbsp;A breach of the covenants under the indenture governing our Senior Secured Notes or the Credit Agreement could result in an event of default under the applicable indebtedness. Such a default, if not cured or waived, may allow the creditors to accelerate the related debt, may result in the acceleration of any other debt that is subject to an applicable cross-acceleration or cross-default provision, and would permit the lenders under the Revolving Credit Facility to terminate all commitments to extend further credit under the credit facility. Furthermore, if we were unable to repay the amounts due and payable under the Revolving Credit Facility, the lenders could proceed against the collateral securing such indebtedness. In the event our lenders or holders of the notes accelerate the repayment of our borrowings, we and our subsidiaries may not have sufficient assets to repay that indebtedness.

&nbsp;&nbsp;&nbsp;&nbsp;If our cash requirements in the future are greater than expected or our cash flow from operations is less than expected, our cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and we may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance our debt. Any future refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants which could further restrict our business operations. Additionally, the indenture relating to our Senior Secured Notes limits the use of the proceeds from any disposition of our assets. As a result, the indenture may prevent us from using the proceeds from such dispositions to satisfy our debt service obligations.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Our ability to continue to have the necessary liquidity to operate our business may be adversely impacted by a number of factors, and a deterioration of our results of operations and cash flow resulting from decreases in customer spending, could, among other things, impact our ability to comply with the consolidated fixed charge coverage ratio and the consolidated total net leverage ratio contained in our Revolving Credit Facility.***

&nbsp;&nbsp;&nbsp;&nbsp;Our historical sources of liquidity to fund ongoing cash requirements include cash flows from operations, cash and cash equivalents, borrowings through credit facilities, and debt offerings. The sufficiency and availability of credit may be adversely affected by a variety of factors, including, without limitation, the tightening of the credit markets, including lending by financial institutions who are sources of credit for our borrowing and liquidity; an increase in the cost of capital; the reduced availability of credit; our ability to execute our strategy; the level of our cash flows, which will be impacted by customer demand for our products; compliance with a fixed charge coverage ratio that is included in our Revolving Credit Facility; and interest rate fluctuations. We cannot predict the future level of interest rates or the effect of any change in interest rates on the availability or aggregate cost of our borrowings. We cannot be certain that any additional required financing, whether debt or equity, will be available in amounts needed or on terms acceptable to us, if at all.

&nbsp;&nbsp;&nbsp;&nbsp;The Credit Agreement providing for our Revolving Credit Facility contains a minimum consolidated fixed charge coverage ratio of 1.25 to 1.00 and a maximum consolidated total net leverage ratio (the "CTNL Ratio"). For the period from September 26, 2025 to June 26, 2026, the CTNL Ratio for any fiscal quarter may not exceed 3.75:1.00, and thereafter, the CTNL Ratio for any fiscal quarter may not exceed 3.50:1.00. Each ratio is tested on the last day of each fiscal quarter. Adverse developments in the economy in the past have led and in the future could lead to reduced spending by our customers and end-users which could adversely impact our net sales and cash flow and our ability to comply with one or both of these ratios.

**General Risks**

***Failure to maintain effective internal controls and procedures and changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters, could negatively impact us.***

&nbsp;&nbsp;&nbsp;&nbsp;In the past, we have not always been successful in maintaining effective internal controls and procedures. Internal control over financial reporting is complex and may be revised over time to adapt to changes in our business or changes in applicable accounting rules. We cannot assure that our internal control over financial reporting will be effective in the future or that material weaknesses will not be discovered with respect to a prior period for which we had previously believed that internal controls were effective. If our internal controls and procedures are not effective, our financial statements may not accurately reflect the results of our business and operations. In addition, there could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements, which could affect our stock price.

&nbsp;&nbsp;&nbsp;&nbsp;GAAP and related accounting pronouncements, implementation guidelines and interpretations with regard to a wide range of matters that are relevant to our business, such as revenue recognition, impairment of intangible assets, fair value determinations, lease obligations, vendor allowances, tax matters and litigation, are complex and involve many subjective assumptions, estimates and judgments by our management. Changes in accounting standards or their interpretation or changes in underlying assumptions, estimates or judgments by our management could change our reported or expected financial performance or financial condition or have an impact on our consolidated financial statements. As described in Note 1 to our Consolidated Financial Statements under "*Revision of Prior Period Financial Statements"* during the three months ended July 4, 2025, we identified an error related to deferred tax assets and liabilities and income tax expense in prior periods. The effect of the error was not material, individually or in aggregate in prior periods, but correcting the effect of the error as an out-of-period adjustment for the quarter ended July 4, 2025 would have been material.

***We have incurred, and may in the future incur, impairment charges related to our goodwill, which could have an adverse effect on our financial condition and results of operations.***

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, our goodwill was $198.4 million. We are required to test intangible assets with indefinite lives, including goodwill, annually or, in certain instances, more frequently, and may be required to record impairment charges, which would reduce any earnings or increase any loss for the period in which the impairment was determined to have occurred. For example, during the three months ended July 4, 2025, changes in facts and circumstances related to sustained decreases in our stock price, a decrease in our market capitalization, and downward revisions in our longer-term forecast received during the quarter, which include the impact of tariffs and the MOFCOM Investigations announcements, resulted in our determination that the carrying amount of our Medical reporting unit exceeded its fair value. Accordingly, we recorded a $93.9 million goodwill impairment charge to our Medical reporting unit. Our goodwill impairment analysis is sensitive to changes in key assumptions used in our analysis. If the assumptions used in our analysis are not realized, it is possible that a further impairment charge may need to be recorded in the future. We cannot accurately predict the amount and timing of any impairment of goodwill or other intangible assets. However, any such impairment could have an adverse effect on our results of operations.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***If we are unable to retain, attract, expand, integrate, and train our management team and other key personnel, we may not be able to maintain or expand our business.***

&nbsp;&nbsp;&nbsp;&nbsp;Our future success depends on our ability to retain, attract, expand, integrate, and train our management team and other key personnel, such as qualified engineering, service, sales, marketing, manufacturing, and other staff. We compete for key personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions. We have observed a competitive labor market over the past several years, particularly in Utah, where unemployment rates are relatively low. As a result, compensation-related costs have increased and could continue to increase. Additionally, our United States-based employees, including our senior management team, work for us on an at-will basis, and there is no assurance that any such employees will remain with us. Replacing key employees may take an extended period of time, and to the extent we hire employees from competitors, we also may be subject to allegations that they have been improperly solicited or divulged proprietary or other confidential information. Freezing new positions or terminating existing ones could hinder our ability to execute our strategic plan and achieve growth targets, resulting in long-term sacrifices for short-term gains. If we are unable to retain or hire and train qualified personnel, we may not be able to maintain or expand our business. Similarly, if we fail to adequately invest in leadership training and career development resources this could limit employee growth, lead to shortages of skilled personnel, hinder effective management and decision making, and hamper overall organizational success.

***Our business is subject to evolving matters relating to environmental, social and governance and/or our reporting of such matters that could expose us to numerous risks.***

&nbsp;&nbsp;&nbsp;&nbsp;We are subject to evolving, and sometimes conflicting, laws, regulations, policies, and investor and other stakeholder expectations concerning environmental, social, and governance matters, such as environmental sustainability and climate change, both in the United States and internationally. Any initiatives, goals, or commitments we disclose in this regard involve risks and uncertainties and could be difficult to achieve and costly to implement. In addition, in a climate where there are changing and increasingly divergent views on where our focus should be on these matters, our initiatives, goals, or commitments, or any revisions to them, are often criticized and the accuracy, adequacy, or completeness of such disclosures challenged. Our actual or perceived failure to achieve our initiatives, goals, or commitments, or otherwise successfully manage investor or other stakeholder expectations on these matters, could negatively impact our reputation or otherwise harm our business.

&nbsp;&nbsp;&nbsp;&nbsp;In addition, a number of our customers have adopted, and may continue to adopt, procurement policies that require us to comply with social and environmental provisions. An increasing number of investors have adopted, and may continue to adopt, environmental, social, and governance policies for their portfolio companies, and various voluntary sustainability initiatives and organizations have promulgated different social and environmental and sustainability guidelines. These practices, policies, provisions, and initiatives are under active development, subject to change, can be unpredictable and conflicting, and may prove difficult and expensive for us to comply with and could negatively affect our reputation, business, or financial condition.

**Item 1B. Unresolved Staff Comments**

&nbsp;&nbsp;&nbsp;&nbsp;None.

**Item 1C. Cybersecurity**

**Cybersecurity Risk Management and Strategy**

&nbsp;&nbsp;&nbsp;&nbsp;We depend on information systems and technology in many aspects of our business, including running our manufacturing operations and communicating among our employees, suppliers and customers. Such uses of information systems and technology give rise to cybersecurity risks, including risk of system disruption, security breach, ransomware, theft, and inadvertent release of information. We have a risk-based cybersecurity program and a dedicated team of cybersecurity professionals focused on protecting our data and information systems. These cybersecurity threats and related risks make it necessary for us to stay apprised of developments in the information security field, and dedicate resources to cybersecurity. With Board of Directors and Audit Committee oversight, as part of our annual enterprise-wide risk management process, we assess and manage the material risks associated with cybersecurity.

&nbsp;&nbsp;&nbsp;&nbsp;To identify, assess, and manage material cybersecurity risks, our team uses a cybersecurity risk assessment process aligned with leading frameworks such as the Cyber Security Framework of the National Institute of Standards and Technology ("NIST") and the Center for Internet Security ("CIS") Critical Security Controls. Our cybersecurity risk assessment program provides the underlying basis for the activities of our team to identify and mitigate risks from, as well as develop risk management and response strategies for, evolving and emerging cybersecurity threats.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;Our cybersecurity program includes a variety of processes to assess, identify and manage risks from cybersecurity threats arising from our own and third-party provided systems, including information security policies and procedures, simulation exercises, network and endpoint monitoring and detection tools, vulnerability management processes, risk assessments, third-party penetration testing and security requirements for our suppliers, vendors, and service providers. We have also engaged third parties to enhance and strengthen our cybersecurity program, to provide additional capabilities and support, and to provide periodic independent assessments and evaluations of our cybersecurity program, including through table top exercises to simulate responses to cybersecurity incidents, and other professional services.

&nbsp;&nbsp;&nbsp;&nbsp;We also monitor and test our safeguards and train our employees on cybersecurity safeguards related to our information technology systems. Our employees are required to take periodic training on cybersecurity and data privacy, and we conduct regular phishing email simulations to enhance awareness and responsiveness to such possible threats. We carry information security risk insurance that provides protection against certain defined potential losses arising from a cybersecurity incident.

&nbsp;&nbsp;&nbsp;&nbsp;In the event of a suspected incident, our incident response plan outlines the steps to be followed from incident detection to mitigation, recovery and notification, including notifying the head of our Information Technology department ("Head of IT") and functional areas (e.g., legal and human resources) as appropriate. This includes processes for assessing such incidents for materiality, making required notifications, disclosures or communications and determining, among other things, whether any prohibition on the trading of our common stock by insiders should be imposed prior to the disclosure of information about a material cybersecurity event.

&nbsp;&nbsp;&nbsp;&nbsp;We describe whether and how risks from identified cybersecurity threats have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under Item 1A, "Risk Factors" in this Annual Report, which disclosures are incorporated by reference herein. In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none.

**Cybersecurity Governance**

&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors, both directly and through the delegation of responsibilities to the Audit Committee, is responsible for the oversight of risks from cybersecurity threats. At least annually, the Audit Committee receives an overview from management of our cybersecurity strategy, programs, and risk mitigation activities, as well as other developments and action items related to cybersecurity. In its meetings, the Audit Committee has the opportunity to discuss these matters with the head of our Information Technology department and other members of executive management. Members of the Board are also encouraged to engage in ad hoc conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs.

&nbsp;&nbsp;&nbsp;&nbsp;Our cybersecurity risk management and strategy processes are managed by the head of our Information Technology department, and our Information Technology team is responsible for enterprise-wide informational technology, coordinating with various functions and business groups to ensure they are following best practices.

&nbsp;&nbsp;&nbsp;&nbsp;The head of our Information Technology department, along with our cybersecurity program manager, are principally responsible for overseeing the risks related to cybersecurity. They are responsible for cybersecurity incident preparedness, approving cybersecurity processes, reviewing security assessments and other security-related reports, and providing senior leadership with regular updates on cybersecurity-related matters. These team members combined have more than 40 years of experience in technology and information security risk management across a number of organizations, have multiple relevant technical and governance certifications, and are active in a number of cybersecurity related boards and organizations.

**Item 2. Properties**

&nbsp;&nbsp;&nbsp;&nbsp;Our corporate headquarters is located in Salt Lake City, Utah, at an owned site used for manufacturing, administrative functions, and research and development for both our Medical and Industrial segments. We also own or lease 30 other facilities throughout North America, Europe, Asia, and India that comprise manufacturing facilities, warehouses, sales and service, research and development, and office space, which are used for our Medical and/or Industrial segments, depending on the location.

&nbsp;&nbsp;&nbsp;&nbsp;In addition to our location in Salt Lake City, Utah, our other primary owned facilities are located in Nevada, Illinois, the Netherlands, and India. Our primary leased facilities in the Philippines, China, Germany, India, and California, are used for manufacturing, research and development, or administrative functions for our Medical and Industrial segments.

&nbsp;&nbsp;&nbsp;&nbsp;We believe our current facilities are well-maintained and adequate to meet our current and reasonably anticipated future needs. We believe we will be able to renew leases, as needed, on acceptable terms or that we will be able to find suitable alternatives.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Item 3. Legal Proceedings**

&nbsp;&nbsp;&nbsp;&nbsp;We are subject to various claims, complaints, and legal actions in the normal course of business from time to time. The resolution of such claims, complaints, and legal actions is subject to significant uncertainty and may be expensive, time consuming and disruptive to our operations. At the present time, we do not believe we have any current or pending litigation for which the outcome could have a material adverse effect on our operations or financial position. See, also, Note 16, *Commitments and Contingencies*, included in the accompanying Notes to the Consolidated Financial Statements.

**Item 4. Mine Safety Disclosures**

&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**PART II**

**Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

&nbsp;&nbsp;&nbsp;&nbsp;Varex's common stock is traded on the Nasdaq Global Select Market (the "NASDAQ") under the symbol "VREX."

&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have not paid any cash dividends and have no current plan to pay cash dividends on Varex common stock. As of November 11, 2025, there were approximately 1,178 holders of record of Varex common stock. This number does not include beneficial owners holding shares in "nominee" or "street" name.

&nbsp;&nbsp;&nbsp;&nbsp;The following graph shows the total return on VREX common stock for the five years ended October 3, 2025, with comparative total returns for the Russell 2000 Index ("RUT") and the Dow Jones Medical Equipment Index ("DJUSAM"). The graph below assumes that $100.00 was invested on October 2, 2020 in our common stock and the companies listed in the RUT and the DJUSAM, as well as a reinvestment of dividends paid on such investments throughout the period.

![549755814844](var-20251003_g2.jpg)

**Item 6. [Reserved]**

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**

&nbsp;&nbsp;&nbsp;&nbsp;The following discussion and analysis contains forward-looking statements relating to future events or our future financial or operating performance that involve risks and uncertainties, as set forth above under "Forward-Looking Statements." Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors described in this Annual Report on Form 10-K.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Our Business**

&nbsp;&nbsp;&nbsp;&nbsp;Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, linear accelerators, and image software processing solutions, which are critical components of a variety of X-ray based imaging equipment, and stand-alone X-ray based systems in select application areas. Our success depends, among other things, on our ability to anticipate and respond to changes in our business, the direction of technological innovation, and the demand from our customers. For additional information on our business, see Item 1 "Business".

**Impact of Current Economic and Trade Environment**

&nbsp;&nbsp;&nbsp;&nbsp;The current economic and trade environment remains dynamic and unpredictable. The uncertain outcome and effect of tariffs and reciprocal actions between the United States and other countries and its impact on the economic and geopolitical environment, supply chain and logistic challenges, and geopolitical tensions and local conflicts have contributed to, and may continue to contribute to, delayed customer purchasing decisions, increased tariff costs, higher inflation, fluctuations in interest rates and capital costs, supply chain disruption, increased costs of labor and materials, exchange rate volatility, increased shipping costs, and other similar effects. Additionally, a sustained United States government shutdown could negatively impact the global economy and in turn our financial condition and results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;During the calendar year 2025, the United States Administration has announced and/or imposed a variety of new tariffs on imports from other countries. In response, a number of those impacted or potentially impacted countries have announced and/or

imposed retaliatory tariffs on United States imports. These actions impacted our results of operations and profitability in fiscal year 2025, particularly the bilateral United States and Chinese tariffs. Absent a de-escalation in the current trade wars, particularly the trade war between the United States and China, these tariffs have and are expected to make our products less competitive with similar product not imported from the United States, which has had and in the future is expected to negatively impact our business and financial results. Additional new tariffs, trade restrictions or other retaliatory actions aimed at specific industries, such as X-ray imaging products, could also materially impact our business. We remain committed to working with our customers to minimize the effects of the tariffs. In this regard, we are actively working to implement a number of options that could reduce the impact, including pursuing commonly utilized mitigation practices and localizing more manufacturing in the region. At this time, however, we do not anticipate these efforts will allow us to fully offset the additional costs or other negative impacts resulting from such tariffs. Considering the mitigation efforts we have in flight at this point, we are not currently planning to do any restructuring in China.

&nbsp;&nbsp;&nbsp;&nbsp;We continue to monitor potential changes in customer procurement decisions resulting from the current trade climate, along with other tariff-related actions, investigations and other activities that might negatively affect our costs or otherwise impact our business and results of operations. Furthermore, if international customers' negative perceptions of the actions of the United States Administration influence their buying decisions, our business and results of operations could be negatively impacted.

&nbsp;&nbsp;&nbsp;&nbsp;In April 2025, the China Ministry of Commerce initiated two investigations related to medical products imported into China. One investigation relates to the impact of imports of X-ray tubes on the domestic industry and its competitiveness, and another relates to imports into China of certain medical CT X-ray tubes and tube inserts for CT devices (collectively "CT Tubes and Inserts") originating from the United States and India. We produce CT Tubes and Inserts in the United States and export them to China, but we do not produce CT Tubes and Inserts in India. Total sales of medical X-ray tubes we import into China represented approximately 10% of our total revenue in fiscal year 2025. Both investigations were temporarily suspended in May 2025 and again in August 2025, and then both were indefinitely suspended in November 2025. If recommenced, we anticipate that the MOFCOM Investigations may take approximately one year to resolve. We are committed to complying with all applicable regulations.

&nbsp;&nbsp;&nbsp;&nbsp;In the past, we have experienced supply chain, manufacturing, and logistics challenges but these challenges have largely subsided. However, given the current tariff environment and uncertainty around how it may impact customer purchasing decisions and the timing of those decisions, supply chain and logistics challenges could re-emerge.

&nbsp;&nbsp;&nbsp;&nbsp;For additional information on risks related to tariffs and trade wars, supply chain and logistics challenges, cost increases, changes in U.S. and worldwide economic conditions, geopolitical tensions, and other risks that could impact our results, see Item 1A "*Risk Factors*".

***Fiscal Year***

&nbsp;&nbsp;&nbsp;&nbsp;Our fiscal year is the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2025 was the 53-week period that ended October 3, 2025, fiscal year 2024 was the 52-week period that ended September 27, 2024, and fiscal year 2023 was the 52-week period that ended September 29, 2023.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Results of Operations** 

&nbsp;&nbsp;&nbsp;&nbsp;For a discussion and analysis of our year-over-year changes, financial condition, and results of operations for the fiscal years ended September 27, 2024 and September 29, 2023 refer to Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our annual report on Form 10-K for the fiscal year ended September 27, 2024, filed with the SEC on November 19, 2024. Our year-over-year changes, financial condition, and results of operations for the fiscal years ended October 3, 2025 and September 27, 2024 are set forth below.

**Comparison of Results of Operations for Fiscal Years 2025 and 2024**

***Revenues, net***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **2025** | **% Change** | **2024** | **% Change** | **2023** |
| Medical | $592.6 | 2% | $581.7 | (14)% | $673.3 |
| Industrial | 252.0 | 10% | 229.3 | 4% | 220.1 |
| &nbsp;&nbsp;Total revenues, net | $844.6 | 4% | $811.0 | (9)% | $893.4 |
| *Medical as a percentage of total revenues* | *70.2 %* |  | *71.7 %* |  | *75.4 %* |
| *Industrial as a percentage of total revenues* | *29.8 %* |  | *28.3 %* |  | *24.6 %* |

---

&nbsp;&nbsp;&nbsp;&nbsp;Medical revenues increased $10.9 million in fiscal year 2025 compared to fiscal year 2024, primarily due to increased sales of CT, oncology, and mammography of $24.6 million, partially offset by decreased sales in radiography, veterinary, and dental modalities of $13.7 million.

&nbsp;&nbsp;&nbsp;&nbsp;Industrial revenues increased $22.7 million in fiscal year 2025 compared to fiscal year 2024, primarily due to increased sales of security inspection products and X-ray tubes of $15.3 million, digital detectors of $6.0 million and other components of $1.4 million.

***Revenues, net by Region***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **2025** | **% Change** | **2024** | **% Change** | **2023** |
| Americas | $276.5 | 4% | $266.5 | (5)% | $281.8 |
| EMEA | 284.8 | 2% | 280.3 | (4)% | 290.7 |
| APAC | 283.3 | 7% | 264.2 | (18)% | 320.9 |
| &nbsp;&nbsp;Total revenues, net | $844.6 | 4% | $811.0 | (9)% | $893.4 |
| *Americas as a percentage of total revenues* | *32.7 %* |  | *32.9 %* |  | *31.5 %* |
| *EMEA as a percentage of total revenues* | *33.7 %* |  | *34.6 %* |  | *32.5 %* |
| *APAC as a percentage of total revenues* | *33.5 %* |  | *32.6 %* |  | *35.9 %* |

---

&nbsp;&nbsp;&nbsp;&nbsp;Overall revenue during fiscal year 2025 increased as compared to fiscal year 2024. During fiscal year 2025, Americas revenues increased $10.0 million due to increased security inspection products sales of $13.3 million, increased X-ray tubes sales of $4.7 million, increased other product sales of $0.7 million, partially offset by decreased veterinary sales of $4.7 million, digital detector sales of $2.2 million, and software sales of $1.8 million. EMEA revenues increased $4.5 million primarily due to increased digital detector sales of $4.3 million, other product sales of $2.4 million, and security inspection product sales of $0.9 million, partially offset by decreased veterinary sales of $1.8 million, software sales of $0.7 million, and X-ray tubes sales of $0.5 million. APAC revenues increased $19.1 million primarily due to increased X-ray tubes sales of $14.7 million, security inspection products sales of $3.2 million, digital detector sales of $1.8 million, and software sales of $0.6 million, partially offset by decreased other product sales of $1.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;See Note 2, *Revenue*, of the Notes to the Consolidated Financial Statements for information regarding disaggregated revenue by country.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Gross Profit***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **2025** | **% Change** | **2024** | **% Change** | **2023** |
| &nbsp;&nbsp;&nbsp;Medical | $200.1 | 13% | $176.7 | (14)% | $205.5 |
| &nbsp;&nbsp;&nbsp;Industrial | 90.4 | 13% | 80.2 | (5)% | 84.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $290.5 | 13% | $256.9 | (12)% | $290.3 |
| &nbsp;&nbsp;&nbsp;*Medical gross margin* | *33.8 %* |  | *30.4 %* |  | *30.5 %* |
| &nbsp;&nbsp;&nbsp;*Industrial gross margin* | *35.9 %* |  | *35.0 %* |  | *38.5 %* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Total gross margin* | *34.4 %* |  | *31.7 %* |  | *32.5 %* |

---

&nbsp;&nbsp;&nbsp;&nbsp;Medical segment gross profit increased $23.4 million in fiscal year 2025 compared to fiscal year 2024 primarily due to increased sales volume, increased favorable product mix, and lower material costs of $13.3 million and improved productivity of $10.1 million.

&nbsp;&nbsp;&nbsp;&nbsp;Industrial segment gross profit increased $10.2 million in fiscal year 2025 compared to fiscal year 2024, primarily due to improved sales volume and favorable product mix of $20.1 million, partially offset by decreased productivity and increased material costs of $9.9 million.

***Operating Expenses***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **2025** | **% Change** | **2024** | **% Change** | **2023** |
| Research and development | $91.1 | 5% | $87.0 | 3% | $84.8 |
| &nbsp;&nbsp;&nbsp;*As a percentage of total revenues* | *10.8 %* |  | *10.7 %* |  | *9.5 %* |
| Selling, general and administrative | $133.3 | (3)% | $137.8 | 7% | $128.4 |
| &nbsp;&nbsp;&nbsp;*As a percentage of total revenues* | *15.8 %* |  | *17.0 %* |  | *14.4 %* |
| Impairment of goodwill | $93.9 | 100% | $— | —% | $— |
| &nbsp;&nbsp;&nbsp;*As a percentage of total revenues* | *11.1 %* |  | *— %* |  | *— %* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating expenses | $318.3 | 42% | $224.8 | 5% | $213.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*As a percentage of total revenues* | *37.7 %* |  | *27.7 %* |  | *23.9 %* |

---

*Research and Development*

&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs for fiscal year 2025 remained relatively unchanged at 10.8% of total revenue when compared to fiscal year 2024.

*Selling, General, and Administrative*

&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative expenses for fiscal year 2025 decreased primarily due to a decrease in fixed cost commitments to a supplier of $3.5 million and amortization of intangibles of $3.0 million, partially offset by an increase in depreciation costs of $1.2 million.

*Impairment of Goodwill*

&nbsp;&nbsp;&nbsp;&nbsp;During the third quarter of fiscal year 2025, we recognized a goodwill impairment charge of $93.9 million, following a determination that the fair value of the Medical reporting unit was below its carrying value. See Note 5, *Goodwill and Intangible Assets,* of the Notes to the Consolidated Financial Statements of this report for further details.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Interest and Other Expense, Net***

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's interest and other expense, net:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **2025** | **% Change** | **2024** | **% Change** | **2023** |
| Interest income | $8.5 | 16% | $7.3 | 97% | $3.7 |
| Interest expense | (35.5) | 18% | (30.2) | 3% | (29.3) |
| Other expense, net | (4.4) | 5% | (4.2) | (79)% | (20.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and other expenses, net | $(31.4) | 16% | $(27.1) | (41)% | $(45.8) |

---

&nbsp;&nbsp;&nbsp;&nbsp;Interest income increased primarily due to an increase in the average cash and cash equivalents balance being held in interest bearing deposit accounts during fiscal year 2025 as compared to fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;Interest expense increased primarily due to higher interest costs in connection with the additional Senior Secured Notes issued during the first quarter of fiscal year 2025 to partially refinance our convertible senior unsecured notes that matured in June 2025 and the Revolving Credit Facility established during the final week of the second quarter of fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;Other expense, net remained relatively unchanged during fiscal year 2025 as compared to fiscal year 2024.

***Taxes on Income (Loss)***

---

| | | |
|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** |
| Effective tax rate | (18.1)% | 1066.0% |

---

&nbsp;&nbsp;&nbsp;&nbsp;We had an income tax expense of $10.7 million and an income tax expense of $53.3 million, resulting in effective rates of (18.1)% and 1,066.0%, for fiscal years 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2025, our effective tax rate varied from the U.S. federal statutory rate of 21% primarily due to the goodwill impairment that took place in the third quarter of fiscal year 2025, the unfavorable impact of U.S. deferred tax attributes and losses in certain foreign jurisdictions for which a valuation allowance is provided as well as profit in foreign jurisdictions with statutory tax rates greater than 21%. These unfavorable items were partially offset by the favorable impact of U.S. tax reform regarding international provisions, R&D credits, and return to provision adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2024, our effective tax rate varied from the U.S. federal statutory rate of 21% primarily due to the unfavorable impact of U.S. deferred tax attributes and losses in certain foreign jurisdictions for which a valuation allowance is provided as well as profit in foreign jurisdictions with statutory tax rates greater than 21%. These unfavorable items were partially offset by the favorable impact of U.S. tax reform regarding international provisions, R&D credits, and return to provision adjustments.

***Liquidity and Capital Resources***

&nbsp;&nbsp;&nbsp;&nbsp;We assess our liquidity in terms of our ability to generate cash to fund our operations, including working capital and investing activities. We believe that our operating cash flow, cash on our balance sheet, availability under our Revolving Credit Facility, and our ability to access the credit and capital markets are sufficient to meet our anticipated operating activities and cash commitments for at least the next 12 months and will be sufficient to allow us to continue to invest in our existing businesses, consummate strategic acquisitions, and manage our capital structure on a short-term and long-term basis. We are currently not aware of any trends or demands, commitments, events, or uncertainties that will result in or that are reasonably likely to result in a material change to our liquidity needs during the next 12 months. Beyond the next 12 months, our Senior Secured Notes mature in October 2027. As of October 3, 2025, the availability under our Revolving Credit Facility was $154.8 million, and we had total debt of $367.5 million, net of deferred issuance costs of $2.4 million.

***Cash and Cash Equivalents, Certificates of Deposit, and Marketable Debt Securities***

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our cash and cash equivalents, certificates of deposit, and marketable debt securities:

---

| | | | |
|:---|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** | **$ Change** |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $145.0 | $168.7 | $(23.7) |
| &nbsp;&nbsp;&nbsp;Certificates of deposit not included in cash and cash equivalents |  | 3.4 | (3.4) |
| &nbsp;&nbsp;&nbsp;Marketable debt securities not included in cash and cash equivalents | 10.1 | 40.8 | (30.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $155.1 | $212.9 | $(57.8) |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Borrowings***

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the changes in our debt outstanding:

---

| | | | |
|:---|:---|:---|:---|
| | **October 3, 2025** | **September 27, 2024** | |
| **(In millions, except for percentages)** | **Amount** | **Amount** | **$ Change** |
| **Current maturities of long-term debt:** | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible Senior Unsecured Notes | $— | $45.0 | $(45.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other debt | 1.5 | 1.5 |  |
| **Total current maturities of long-term debt** | $1.5 | $46.5 | $(45.0) |
| **Non-current maturities of long-term debt:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible Senior Unsecured Notes<sup>(1)</sup> | $— | $155.0 | $(155.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior Secured Notes | 368.0 | 243.0 | 125.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other debt | 0.4 | 2.1 | (1.7) |
| **Total non-current maturities of long-term debt** | $368.4 | $400.1 | $(31.7) |
| **Unamortized issuance costs and debt discounts:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs - Convertible Notes | $— | $(1.0) | $1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs, net of debt premium - Senior Secured Notes | (2.4) | (2.2) | (0.2) |
| **Total unamortized issuance costs and debt discounts** | (2.4) | (3.2) | 0.8 |
| **Total debt outstanding, net** | $367.5 | $443.4 | $(75.9) |

---

<sup>(1)</sup> This amount was excluded from current liabilities as it was supported by the Revolving Credit Facility and restricted cash from the proceeds of the Senior Secured Notes Add On (as defined in Note 6, *Borrowings*), which were expected to, and did, remain outstanding for an uninterrupted period extending beyond one year from the balance sheet date.

***Cash Flows***

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| &nbsp;&nbsp;&nbsp;Net cash flow provided by (used in) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $41.7 | $47.3 | $108.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | 10.3 | (27.5) | (44.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (75.9) | (3.3) | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effects of exchange rate changes on cash and cash equivalents and restricted cash | 0.6 | (0.1) | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (decrease) increase in cash and cash equivalents and restricted cash | $(23.3) | $16.4 | $63.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;*Net cash provided by operating activities.* Cash provided by operating activities was $41.7 million and $47.3 million for fiscal years 2025 and 2024, respectively. Net cash provided by operating activities decreased $5.6 million for fiscal year 2025 compared to fiscal year 2024. Significant changes in operating assets and liabilities affecting cash flows during these periods included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $69.9 million for fiscal year 2025 compared to a net loss of $48.3 million for fiscal year 2024. The increase in net loss was primarily due to a goodwill impairment charge of $93.9 million in fiscal year 2025 and $5.3 million of higher interest expense in fiscal year 2025 compared to fiscal year 2024, partially offset by $33.6 million of higher sales compared to fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-cash adjustments to reconcile net loss to net cash provided by operating activities increased $49.4 million in fiscal year 2025 compared to fiscal year 2024. The increase was primarily due to the add back related to the goodwill impairment charge of $93.9 million, partially offset by a $38.6 million reduction in deferred taxes add back in fiscal year 2025, compared to fiscal year 2024 as a result of the increase in a valuation allowance during the fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash used for inventories was $46.5 million higher in fiscal year 2025, compared to the fiscal year 2024, primarily due to an increase in quantity of inventory for anticipated future demand.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash provided by accrued liabilities and other current and other long-term liabilities increased by $9.2 million in fiscal year 2025, compared to fiscal year 2024, primarily due to an increase of $16.2 million related to the timing of and estimation of certain compensation costs, partially offset by $5.5 million related to the reduction of warranty accruals.

&nbsp;&nbsp;&nbsp;&nbsp;*Net cash provided by (used in) investing activities.* Cash provided by (used in) investing activities was $10.3 million and $(27.5) million for fiscal years 2025 and 2024, respectively. The increase in cash provided by investing activities was primarily due to the implementation of an investment strategy to increase the Company's cash balance to pay down the outstanding Convertible Notes that matured and were repaid in full during the third quarter of fiscal year 2025. This strategy resulted in lower purchases of short-term marketable securities and CDs of $30.4 million, increased proceeds from maturities and sales of marketable debt securities of $4.8 million, and lower purchases of property, plant, and equipment of $4.0 million.

&nbsp;&nbsp;&nbsp;&nbsp;*Net cash used in financing activities.* Net cash used in financing activities was $75.9 million and $3.3 million for fiscal years 2025 and 2024, respectively. The increase in cash used in financing activities was primarily due to the repayment in full of the Convertible Notes of $200.0 million, partially offset by the issuance of the Senior Secured Notes Add On of $126.9 million during the first quarter of fiscal year 2025.

***Days Sales Outstanding***

&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable days sales outstanding ("DSO") was 62 days and 70 days at October 3, 2025 and September 27, 2024, respectively. Our accounts receivable and DSO are impacted by a number of factors, including the timing of product shipments, collections performance, payment terms, the mix of revenues from different regions and the effects of economic instability.

***Material Contractual Obligations***

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes, as of October 3, 2025, the total amount of future payments due in various future periods:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** |
| **(In millions)** | **Total** | **Fiscal Year 2026** | **Fiscal Years 2027-2028** | **Fiscal Years 2029-2030** | **Beyond** |
| Lease obligations | $46.2 | $6.9 | $11.3 | $8.5 | $19.5 |
| Principal payments on borrowings | 369.9 | 1.5 | 368.4 |  |  |
| dpiX fixed cost commitment | 3.4 | 3.4 |  |  |  |
| Dividends to MeVis noncontrolling interest | 2.5 | 0.5 | 1.0 | 1.0 |  |
| Non-cancellable supplier purchase obligations | 3.0 | 3.0 |  |  |  |
| Total | $425.0 | $15.3 | $380.7 | $9.5 | $19.5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;We lease office space under non-cancelable operating leases. For further information on our operating leases, see Note 8, *Leases*, included in the accompanying Notes to the Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;For further discussion regarding our borrowings, see Note 6, *Borrowings,* included in the accompanying Notes to the Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;In October 2013, we entered into an amended agreement with dpiX and other parties that, among other things, provides us with the right to 50% of dpiX's total manufacturing capacity produced after January 1, 2014. The amended agreement requires us to pay for 50% of the fixed costs (as defined in the amended agreement), as determined and approved by the dpiX board of directors at the beginning of each calendar year. In January 2025, the Company's fixed cost commitment was determined to be $13.7 million for calendar year 2025. For the remainder of calendar year 2025, we estimate that we have fixed cost commitments of $3.4 million related to this amended agreement. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).

&nbsp;&nbsp;&nbsp;&nbsp;In August 2015, pursuant to a Domination and Profit and Loss Transfer Agreement (the "DPLTA"), we committed to pay the noncontrolling shareholders of MeVis Medical an annual recurring net compensation of €0.95 per MeVis Medical share. The annual net payment will continue for the life of the DPLTA, which we anticipate will continue for as long as we remain as the controlling shareholder of MeVis Medical. As of October 3, 2025, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.

&nbsp;&nbsp;&nbsp;&nbsp;The Company enters into purchase agreements with its suppliers in the ordinary course of its business for the purchase of goods and services. Some of these purchase agreements are non-cancellable and thus contractually obligate us to future cash payments. As of October 3, 2025, our non-cancellable supplier purchase obligations totaled $3.0 million.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;Our operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, we are obligated to indemnify Varian for the cleanup liabilities related to prior corporate restructuring activities. As of October 3, 2025, our estimated environmental liability for these sites is $3.2 million, net of expected insurance proceeds. For further discussion regarding our environmental obligation, see Note 1, *Summary of Significant Accounting Policies,* included in the accompanying Notes to the Consolidated Financial Statements.

***Contingencies***

&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we are a party to or otherwise involved in legal proceedings, government inspections, investigations, customs and duty audits, and other claims and contingency matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. We accrue amounts for probable losses, to the extent they can be reasonably estimated, that we believe are adequate to address any liabilities related to legal proceedings as well as other loss contingencies that we believe will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. We did not have any material contingent liabilities as of October 3, 2025 and September 27, 2024. Legal expenses are expensed as incurred.

&nbsp;&nbsp;&nbsp;&nbsp;See Item 3 "*Legal Proceedings*" of this Annual Report for additional information regarding legal proceedings and Note 16, *Commitments and Contingencies,* in the Notes to the Consolidated Financial Statements for further information regarding certain of our contractual obligations and contingencies, which discussion is incorporated herein by reference.

***Critical Accounting Estimates***

&nbsp;&nbsp;&nbsp;&nbsp;The preparation of our consolidated financial statements and related disclosures in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies that are affected by accounting estimates require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates.

&nbsp;&nbsp;&nbsp;&nbsp;We periodically review our accounting policies, estimates, and assumptions and make adjustments when facts and circumstances dictate. Such accounting policies require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. Our critical accounting policies that are affected by accounting estimates include valuation of inventories, assessment of recoverability of goodwill and intangible assets, and income taxes. Note 1, *Summary of Significant Accounting Policies,* of the Notes to the Consolidated Financial Statements, Item 8. "*Financial Statements and Supplementary Data*" describe the significant accounting policies and methods used in the preparation of the Company's consolidated financial statements. For a discussion of how these estimates and other factors may affect our business, see Item 1A. "*Risk Factors*."

*Inventories, net*

&nbsp;&nbsp;&nbsp;&nbsp;Inventory is valued at the lower of cost or net realizable value. Costs include materials, labor, external service and manufacturing overhead and is computed using standard cost, which approximates actual cost, on a first-in-first-out basis. We review inventory quantities on hand and record provisions for estimated excess, slow moving, and obsolete inventory. The evaluation of the carrying value of our inventories takes into consideration such factors as historical and anticipated future sales compared to quantities on hand and the prices we expect to obtain for products in our various businesses. We adjust excess and obsolete inventories to net realizable value, and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues. See Note 1, *Summary of Significant Accounting Policies*, "Inventories, net" for further details.

*Goodwill and Intangible Assets*

&nbsp;&nbsp;&nbsp;&nbsp;Goodwill is initially recorded when the purchase price paid for a business acquisition exceeds the estimated fair value of the net identified tangible and intangible assets acquired. Our future operating performance will be impacted by the future amortization of these acquired intangible assets and potential impairment charges related to these intangibles or to goodwill if indicators of impairment exist. The allocation of the purchase price from business acquisitions to goodwill and intangible assets could have a material impact on our future operating results. In addition, the allocation of the purchase price of the acquired businesses to goodwill and intangible assets requires us to make significant estimates and assumptions, including estimates of future cash flows expected to be generated by the acquired assets and the appropriate discount rate for those cash flows. Should conditions differ from management's estimates at the

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

time of the acquisition, material write-downs of intangible assets and/or goodwill may be required, which would adversely affect our operating results.

&nbsp;&nbsp;&nbsp;&nbsp;We evaluate goodwill for impairment at least annually or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The evaluation includes consideration of qualitative factors including industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. If we determine that a quantitative analysis is necessary, we perform a quantitative analysis that consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit.

&nbsp;&nbsp;&nbsp;&nbsp;In fiscal years 2024 and 2023, we performed the annual goodwill qualitative impairment test for our two reporting units and determined that, at those times, it was not more likely than not that the fair values of the reporting units were less than their carrying amounts and accordingly recorded no impairment. We performed the annual goodwill analysis as of the first day of the fourth quarter of each fiscal year (using balances as of the end of the third quarter of that fiscal year).

&nbsp;&nbsp;&nbsp;&nbsp;In fiscal year 2025, changes in facts and circumstances related to a sustained decrease in our stock price, a decrease in our market capitalization, and downward revisions in our longer term forecast, which included the impact of tariffs and the MOFCOM initiating two investigations related to medical products imported into China resulted in our management determining that an indicator of possible impairment existed within our reporting units. Accordingly, we performed a quantitative impairment analysis to determine the fair values of those reporting units, using both an income approach utilizing the discounted cash flow method and a market approach utilizing the public company market multiple method. Based on the output of the analysis, we determined that the carrying amount of our Medical reporting unit exceeded its fair value. Accordingly, we recorded a $93.9 million impairment charge to our Medical reporting unit within impairment of goodwill in the Consolidated Statements of Operations during the fiscal quarter ended July 4, 2025. Refer to Note 5, *Goodwill and Intangible Assets,* of our Consolidated Financial Statements for additional information. Significant changes in our projections of our operating results or other factors could cause us to make interim assessments of impairment in any quarter that could result in some or all of the goodwill being impaired. A future impairment charge for goodwill could have a material effect on the Company's consolidated financial position and results of operations.

*Taxes on Income*

&nbsp;&nbsp;&nbsp;&nbsp;We calculate income taxes based on the tax statutes, regulations, and case law of the various jurisdictions in which we operate. Significant judgment is required in determining the timing and amounts of deductible and creditable items. The benefits of uncertain tax positions are recorded in our financial statements only after determining it is more likely than not that the uncertain tax positions would withstand challenge by taxing authorities. We periodically reassess our positions and record any changes in the financial statements as appropriate. Gross uncertain tax positions, exclusive of interest and penalties, were $1.3 million and $1.6 million as of October 3, 2025, and September 27, 2024, respectively. We believe the resolution of these matters will not materially affect our consolidated financial statements. Income taxes are described further in Note 12, *Taxes on Income (Loss),* in our Notes to the Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;The assessment regarding whether a valuation allowance is required or should be adjusted is based on an evaluation of possible sources of taxable income and also considers all available positive and negative evidence factors. Our accounting for the valuation of deferred tax assets represents our best estimate of future events. Changes in our current estimates, due to unanticipated business conditions, governmental legislative actions or events, could have a material effect on our ability to utilize deferred tax assets. The valuation allowance balances were $79.4 million and $74.7 million as of October 3, 2025 and September 27, 2024, respectively. Refer to Note 12, *Taxes on Income (Loss),* of our Consolidated Financial Statements for additional information on the composition of valuation allowances.

***Compensation Recovery Analysis***

&nbsp;&nbsp;&nbsp;&nbsp;As disclosed in more detail in "Revision to Prior Period Financial Statements" in Note 1, *Summary of Significant Accounting Policies*, of the accompanying Notes to the Consolidated Financial Statements, the Consolidated Financial Statements include the correction of an error to previously issued financial statements that required a recovery analysis of incentive-based compensation received by our executive officers under the Varex Imaging Corporation Compensation Recovery Policy filed as Exhibit 97 to this Annual Report. We have determined that no recovery of incentive-based compensation is required as the correction resulted in no changes to the performance metrics used to determine incentive-based compensation for executive officers during any of the applicable completed fiscal years.

***Recent Accounting Standards or Updates Not Yet Effective***

&nbsp;&nbsp;&nbsp;&nbsp;See Note 1, *Summary of Significant Accounting Policies*, of the accompanying Notes to the Consolidated Financial Statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Backlog***

&nbsp;&nbsp;&nbsp;&nbsp;Backlog is the accumulation of all orders for which revenues have not been recognized and are still considered valid. Backlog also includes a small portion of billed service contracts that are included in deferred revenue. Our estimated total backlog at October 3, 2025 was approximately $262 million.

&nbsp;&nbsp;&nbsp;&nbsp;Orders may be revised or canceled, either according to their terms or as customers' needs change. Consequently, it is difficult to predict with certainty the amount of backlog that will result in revenues. We perform a quarterly review to verify that outstanding orders in the backlog remain valid. Aged orders that are not expected to be converted to revenues are deemed dormant and are reflected as a reduction in the backlog amounts in the period identified.

&nbsp;&nbsp;&nbsp;&nbsp;In addition to orders for which revenues have not been recognized and are still considered valid, we have pricing agreements with many of our established customers that span multi-year periods. These pricing agreements include volume ranges under which orders are placed.

**Item 7A. Quantitative and Qualitative Disclosures about Market Risk**

&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to four primary types of market risks: foreign currency exchange rate risk, credit and counterparty risk, interest rate risk, and commodity price risk.

***Foreign Currency Exchange Rate Risk***

&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of our customers are outside the United States, while our financial statements are denominated, and our products are generally priced in U.S. Dollars. A strong U.S. Dollar may result in pricing pressure for our customers that are located outside the United States and that conduct their businesses in currencies other than the U.S. Dollar. Such pricing pressure has caused, and could continue to cause, some of our customers to ask for discounted prices, delay purchasing decisions, or consider moving to in-sourcing supply of components or migrating to lower cost alternatives. In addition, because our business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact our revenues and expenses and/or the profitability in U.S. Dollars of products and services that we provide or purchase in foreign markets.

&nbsp;&nbsp;&nbsp;&nbsp;We may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, net investments in foreign subsidiaries, and forecast purchases denominated in foreign currencies. We may hedge portions of forecasted foreign currency exposure, typically for one to three months. In addition, we hold cross-currency swaps between the Euro and U.S. Dollar as a net investment hedge of our acquisition of Direct Conversion. Depending on the spot rate between the Euro and U.S. Dollar at the time of settlement and whether we have sufficient Euros available, we may have to borrow incrementally in U.S. Dollars to settle this obligation. Additionally, we may choose not to hedge certain foreign exchange exposures for a variety of reasons including, but not limited to, accounting considerations, the prohibitive economic cost of hedging particular exposures, or due to natural offsets among the different exposures. See Note 9, *Financial Derivatives and Hedging Activities,* of the Notes to the Consolidated Financial Statements for further information.

***Credit and Counterparty Risk***

&nbsp;&nbsp;&nbsp;&nbsp;We use a centralized approach to manage substantially all of our cash and to finance our operations. Our cash and cash equivalents and marketable securities may be exposed to a concentration of credit risk, and we may also be exposed to credit risk and interest rate risk to the extent that we enter into credit facilities.

&nbsp;&nbsp;&nbsp;&nbsp;We perform ongoing credit evaluations of our customers, and we maintain what we believe to be strong credit controls in evaluating and granting customer credit, including performing ongoing evaluations of our customers' financial condition and creditworthiness and often using letters of credit or requiring certain customers to provide a down payment.

***Interest Rate Risk***

&nbsp;&nbsp;&nbsp;&nbsp;Borrowings under our Revolving Credit Facility bear interest at floating interest rates. As of October 3, 2025, we had no borrowings subject to floating interest rates. See Note 6, *Borrowings,* of the Notes to the Consolidated Financial Statements for further information.

&nbsp;&nbsp;&nbsp;&nbsp;Our exposure to interest rate risk also relates to our interest-bearing assets, primarily our cash and cash equivalents and marketable securities. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fluctuate due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Commodity Price Risk***

&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risks related to volatility in the prices of raw materials used in our products. The prices of these raw materials fluctuate in response to changes in supply and demand fundamentals and our product margins and level of profitability tend to fluctuate with changes in these raw materials prices. We try to protect against such volatility through various business strategies. During fiscal year 2025, we did not have any commodity derivative instruments in place to manage our exposure to price changes.

**Sensitivity Analysis**

&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the potential loss in future earnings, fair value, or cash flows resulting from hypothetical changes in relevant market rates or prices as of October 3, 2025. The actual impact of the respective underlying rates and price changes on the financial instruments may differ significantly from those shown in the sensitivity analysis.

---

| | | | |
|:---|:---|:---|:---|
| **Market Risk Category** | **Hypothetical Change** | **Estimated Annual Impact<br>(In millions)** | **Impact Category** |
| Foreign Currency - Revenue | 10% decrease in foreign exchange rates | $14.6 | Earnings |
| Interest Rate - Marketable Securities | 100 basis point decrease in interest rate of underlying investments | 0.9 | Earnings |
| Commodity Price | 10% increase in commodity prices | $3.1 | Earnings |

---

**Item 8. Financial Statements and Supplementary Data.**

&nbsp;&nbsp;&nbsp;&nbsp;The Consolidated Financial Statements and Schedules listed in the Index to Consolidated Financial Statements, Schedules and Exhibits on page F-1 are filed as part of this Annual Report and incorporated in this Item 8 by reference.

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

&nbsp;&nbsp;&nbsp;&nbsp;None.

**Item 9A. Controls and Procedures.**

***Evaluation of Disclosure Controls and Procedures***

&nbsp;&nbsp;&nbsp;&nbsp;Our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are designed to provide reasonable assurance that information required to be disclosed in our periodic reports that we file or submit under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed, and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have concluded that our disclosure controls and procedures were effective as of October 3, 2025.

***Management's Annual Report on Internal Control Over Financial Reporting***

&nbsp;&nbsp;&nbsp;&nbsp;Management, under the supervision of our CEO and CFO, is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our management evaluated the design and operating effectiveness of our internal control over financial reporting based on the criteria established in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO framework" (2013)). All internal control systems, no matter how well designed, have inherent limitations. Accordingly, even effective internal controls and procedures can provide only reasonable assurance with respect to financial statement preparation and presentation.

&nbsp;&nbsp;&nbsp;&nbsp;Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of October 3, 2025. Based on this evaluation, our management concluded that we maintained effective internal control over financial reporting as of October 3, 2025.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The effectiveness of our internal control over financial reporting as of October 3, 2025 has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their attestation report, which appears below in this Item 9A.

***Changes in Internal Control Over Financial Reporting***

&nbsp;&nbsp;&nbsp;&nbsp;There were no changes to our internal control over financial reporting during the quarter ended October 3, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

To the Stockholders and the Board of Directors of Varex Imaging Corporation

**Opinion on Internal Control over Financial Reporting**

We have audited the internal control over financial reporting of Varex Imaging Corporation and subsidiaries (the "Company") as of October 3, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of October 3, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended October 3, 2025, of the Company and our report dated November 18, 2025, expressed an unqualified opinion on those financial statements.

**Basis for Opinion** 

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

**Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Salt Lake City, Utah

November 18, 2025

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Item 9B. Other Information**

*Revision of Prior Period Financial Statements*

&nbsp;&nbsp;&nbsp;&nbsp;As disclosed in more detail in "Revision to Prior Period Financial Statements" in Note 1 to the Consolidated Financial Statements included in this Annual Report on Form 10-K, the financial statements include the correction of an error to previously issued financial statements that required a recovery analysis of incentive-based compensation received by our executive officers under the Varex Imaging Corporation Compensation Recovery Policy filed as Exhibit 97 to this Annual Report. We have determined that no recovery of incentive-based compensation is required as the correction resulted in no changes to the performance metrics used to determine incentive-based compensation for executive officers during any of the applicable completed fiscal years.

*Insider Trading Arrangements*

&nbsp;&nbsp;&nbsp;&nbsp;During the three months ended October 3, 2025, none of our directors or officers informed us of the adoption, modification or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.**

&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**PART III**

&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise disclosed below, the information required by Items 10, 11, 12, 13 and 14 is incorporated by reference from our definitive proxy statement for the 2026 Annual Meeting of Stockholders. Our definitive proxy statement for the 2026 Annual Meeting of Stockholders ("Proxy Statement") will be filed with the SEC no later than 120 days after October 3, 2025.

**Item 10. Directors, Executive Officers and Corporate Governance.**

**Directors and Executive Officers**

&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item 10 with respect to our executive officers is set forth in Item 1 "*Business*" of this Annual Report on Form 10-K and information relating to the availability of our code of conduct for executive officers and directors is set out below.

**Code of Conduct**

&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Conduct that applies to all our executive officers and directors. The Code of Conduct is available on our website at http://www.vareximaging.com.

&nbsp;&nbsp;&nbsp;&nbsp;In the event of an amendment to, or waiver from, a provision of the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or persons performing similar functions, we intend to comply with the disclosure requirements of Item 5.05(c) of Form 8-k by posting such information on our website, specified above.

&nbsp;&nbsp;&nbsp;&nbsp;We will provide disclosure of delinquent Section 16(a) reports, if any, in our Proxy Statement, and such disclosure, if any, is incorporated herein by reference.

**Insider Trading Policy**

&nbsp;&nbsp;&nbsp;&nbsp;We have an Insider Trading Policy applicable to our directors, officers, employees and certain persons and entities that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing standards applicable to our Company. The foregoing summary of our Insider Trading Policy is not complete and is qualified in its entirety by reference to the full text of our Insider Trading Policy, which is filed as Exhibit 19.1 to this Annual Report on Form 10-K.

**Item 11. Executive Compensation**

&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item 11 is incorporated by reference from our Proxy Statement under the caption "Executive Compensation."

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.**

***Equity Compensation Plan Information***

&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of October 3, 2025 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.

---

| | | | |
|:---|:---|:---|:---|
| **Plan Category (amounts in thousands except per share data)** | **Number of securities to be issued upon exercise of outstanding options, warrants and rights** <sup>(1)</sup> **(a)** | **Weighted average exercise price of outstanding options, warrants, and rights** <sup>(2)</sup> **(b)** | **Number of securities remaining available for future issuance under equity compensation plans** <sup>(3)</sup> **(excluding securities reflected in columns (a) and (b))** |
| Equity compensation plans approved by security holders | 3775 | $25.61 | 5279 |

---

<sup>(1)</sup> Consists of stock options, restricted stock units ("RSUs"), performance stock units ("PSUs") and deferred stock units ("DSUs") granted under the Varex Imaging Corporation 2017 Omnibus Stock Plan and the 2020 Omnibus Stock Plan, as Amended and Restated (the "2020 Stock Plan"). Excludes purchase rights under the ESPP.

<sup>(2)</sup> The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding RSUs, PSUs, and DSUs, which have no exercise price.

<sup>(3)</sup> Includes 4,456 thousand shares available for future issuance under the 2020 Stock Plan, and also includes 823 thousand shares available for future issuance under the ESPP. Shares available for issuance under the ESPP, including shares subject to purchase during the current purchase period, which commenced on September 2, 2025 (the exact number of which will not be known until the purchase date on February 27, 2026). Subject to the number of shares remaining in the share reserve, the maximum number of shares purchasable by any participant on any one purchase date for any purchase period, including the current purchase period, may not exceed 2,000 shares.

&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item 12 with respect to the security ownership of certain beneficial owners and the security ownership of directors and executive officers is incorporated by reference from our Proxy Statement under the caption "Stock Ownership—Beneficial Ownership of Certain Stockholders, Directors and Executive Officers."

**Item 13. Certain Relationships and Related Transactions and Director Independence.**

&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item 13 with respect to certain relationships and related transactions is incorporated by reference from our Proxy Statement under the caption "Certain Relationships and Related Transactions." The information required by this item with respect to director and committee member independence is incorporated by reference from our Proxy Statement under the caption "Proposal - Election of Directors."

**Item 14. Principal Accountant Fees and Services.**

&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item 14 is incorporated by reference from our Proxy Statement under the caption "Proposal - Ratification of the Appointment of Our Independent Registered Public Accounting Firm."

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**PART IV** 

**Item 15. Exhibits and Financial Statement Schedules.**

&nbsp;&nbsp;&nbsp;&nbsp;Documents filed as part of this annual report include:

1. *[Consolidated Financial Statements.](#i8474629358084e7786308a95e9f157ba_103)* [We have filed the consolidated financial statements listed in the Index to Consolidated Financial Statements, Schedules and Exhibits on page F-1 as part of this annual report on Form 10-K.](#i8474629358084e7786308a95e9f157ba_103)

2. *Financial Statement Schedules and Other.* All financial statement schedules have been omitted because they are not applicable, or not material or the required information is shown in the consolidated financial statements or the notes thereto.

3. *Exhibits.* The exhibits listed below are filed as part of this annual report on Form 10-K.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 2.1\* | <u>[Separation and Distribution Agreement, dated as of January 27, 2017, by and between Varian and (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex21.htm)</u> |
| 3.1\* | <u>[Amended and Restated Certificate of Incorporation, dated January 27, 2017 (as corrected December 11, 2017) (incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K filed December 13, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000168162217000023/exhibit31-10xk.htm)</u> |
| 3.2\* | <u>[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Varex Imaging Corporation, effective as of February 13, 2025 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed February 1](https://www.sec.gov/Archives/edgar/data/1681622/000168162225000018/exhibit3.htm)[4,](https://www.sec.gov/Archives/edgar/data/1681622/000168162225000018/exhibit3.htm)[2025.)](https://www.sec.gov/Archives/edgar/data/1681622/000168162225000018/exhibit3.htm)</u> |
| 3.3\* | <u>[Amended and Restated Bylaws of the Company, as amended February 11, 2021 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed February 16, 2021).](https://www.sec.gov/Archives/edgar/data/0001681622/000168162221000031/exhibit31-amendedandrestat.htm)</u> |
| 4.1 | <u>[Information required by Item 202(a) through (d) and (f) of Regulation S-K for each class of Company securities that is registered under Section 12 of the Exchange Act.](exhibit41-10xk2025.htm)</u> |
| 4.2\* | <u>[Senior Secured Notes Indenture, dated as of September 30, 2020, by and among Varex Imaging Corporation, the Guarantors party thereto and Wells Fargo Bank, National Association, as trustee and collateral agent, including the form of 7.875% Senior Secured Notes due 2027 as Exhibit A (incorporated by reference to Exhibit 4.3 to the Company's Current Annual Report on Form 10-K filed November 30, 2020).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000168162220000116/vrex-20201002.htm)</u> |
| 4.3\* | <u>[First Supplemental Indenture, dated as of December 20, 2024, by and among Varex Imaging Corporation, the Guarantors party thereto and Computershare Trust Company, N.A., in its capacity as successor trustee and successor notes collateral agent (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed December 23, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000168162224000119/vrex-20241220.htm)</u> |
| 10.1\* | <u>[Tax Matters Agreement, dated as of January 27, 2017 by and between Varian and Company (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex102.htm)</u> |
| 10.2\* | <u>[Intellectual Property Matters Agreement, dated as of January 27, 2017, by and between Varian and Company (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex104.htm)</u> |
| 10.3\* | <u>[Trademark License Agreement, dated as of January 27, 2017, by and between Varian and Company (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex105.htm)</u> |
| 10.4\*† | <u>[Varex Imaging Corporation 2017 Omnibus Stock Plan (incorporated by reference to Exhibit 99.1 to the Company's Form S-8, filed January 27, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517021101/d322590dex991.htm)</u> |
| 10.5\*† | <u>[Form of Nonqualified Stock Option Agreement under the 2017 Omnibus Stock Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed February 16, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000114420417009577/v459861_ex10-1.htm)</u> |
| 10.6\*† | <u>[Form of Restricted Stock Unit Award Agreement under the 2017 Omnibus Stock Plan (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed February 16, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000114420417009577/v459861_ex10-2.htm)</u> |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

---

| | |
|:---|:---|
| 10.7\*† | <u>[Varex Imaging Corporation 2017 Employee Stock Purchase Plan, as Amended (incorporated by reference to Appendix A to the proxy statement filed by the Registrant on December 30, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000110465924132504/tm2424275d9_def14a.htm)</u> |
| 10.8\*† | <u>[Varex Imaging Corporation Management Incentive Plan (incorporated by reference to Exhibit 10.9 of the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex109.htm)</u> |
| 10.9\*† | <u>[Form of Change in Control Agreement (incorporated by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K filed November 19, 2021)](https://www.sec.gov/Archives/edgar/data/1681622/000168162222000091/exhibit1011-10xk2022.htm)</u>. |
| 10.10\*† | <u>[Form of Indemnification Agreement (incorporated by reference to Exhibit 10.11 to the Company's Current Report on Form 8-K filed January 30, 2017).](https://www.sec.gov/Archives/edgar/data/1681622/000119312517022649/d146912dex1011.htm)</u> |
| 10.11\*† | <u>[Varex Imaging Corporation 2016 Deferred Compensation Plan (incorporated by reference to Exhibit 10.6 to Amendment No. 2 to Form 10 filed by the Company on December 8, 2016).](https://www.sec.gov/Archives/edgar/data/1681622/000119312516788584/d223180dex106.htm)</u> |
| 10.12\*† | <u>[Varex Imaging Corporation Frozen Deferred Compensation Plan (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to Form 10 filed by the Company on December 8, 2016).](https://www.sec.gov/Archives/edgar/data/1681622/000119312516788584/d223180dex107.htm)</u> |
| 10.13\*† | <u>[Form of Grant Agreement for Deferred Stock Units under the 2017 Omnibus Stock Plan (incorporated by reference to Exhibit 10.18 to the Company's Annual Report on Form 10-K filed December 20, 2019).](https://www.sec.gov/Archives/edgar/data/1681622/000168162219000083/exhibit1018-10xk2019.htm)</u> |
| 10.14\*† | <u>[Form of Nonqualified Stock Option Agreement, Form of Restricted Stock Unit Agreement and Form of Grant Agreement – Deferred Stock Units under the Varex Imaging Corporation 2020 Omnibus Stock Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 14, 2020).](https://www.sec.gov/Archives/edgar/data/1681622/000110465920022081/tm207429d3_ex10-1.htm)</u> |
| 10.15\*† | <u>[Form of Performance Unit Agreement under the 2020 Omnibus Stock Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed November 17, 2023).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1681622/000168162223000077/vrex-20231117.htm)</u> |
| 10.16\*† | <u>[Varex Imaging Corporation 2020 Omnibus Stock Plan, as Amended and Restated (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 9, 2024).](https://www.sec.gov/Archives/edgar/data/1681622/000168162224000014/ex101-2020omnibusstockplan.htm)</u> |
| 10.17\* | <u>[Credit Agreement dated as of March 26, 2024, by and among Varex Imaging Corporation, Varex Imaging West, LLC, Varex Imaging Deutschland AG, the Guarantors party thereto and Zions Bancorporation, N.A. DBA Zions First National bank, as administrative and collateral agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed March 27, 2024).](https://www.sec.gov/Archives/edgar/data/1681622/000168162224000052/exhibit101zions-varexxrevo.htm)</u> |
| 10.18\* | <u>[Amendment No. 1 to Revolving Credit and Guarantee Agreement, dated August 30, 2024, made and entered into by and among Varex Imaging Corporation, Varex Imaging West, LLC, Varex Imaging Deutschland AG, the other Loan Parties party thereto and Zions Bancorporation, N.A. DBA Zions First National Bank, as administrative and collateral agent for the lenders party thereto (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed November 19, 2024).](https://www.sec.gov/Archives/edgar/data/1681622/000168162224000089/exhibit1023-10xk2024.htm)</u> |
| 10.19\* | <u>[Amendment No. 2 to Revolving Credit and Guaranty Agreement among the Company, Varex Imaging West, LLC, Varex Imaging Deutschland AG, the other Loan Parties party thereto and Zions Bancorporation, N.A. DBA Zions First National Bank (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed December 17, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000168162224000104/vrex-20241213.htm)</u> |
| 10.20† | <u>[Executive Transition, Separation and Release Agreement, dated as of September 5, 2025, by and between Varex Imaging Corporation and Kimberley E. Honeysett.](exhibit1020-202510xk.htm)</u> |
| 19.1\* | <u>[Varex Imaging Corporation Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Company's Annual Report on Form 10-K filed November 19, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000168162224000089/vrex-20240927.htm)</u> |
| 21.1 | <u>[List of Subsidiaries as of October 3, 2025](exhibit211-10xk2025.htm)</u> |
| 23.1 | <u>[Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm](exhibit231-10xk2025.htm)</u> |
| 31.1 | <u>[Chief Executive Officer Certification Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act.](exhibit311-10xk2025.htm)</u> |
| 31.2 | <u>[Chief Financial Officer Certification Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act.](exhibit312-10xk2025.htm)</u> |
| 32.1 | <u>[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit321-10xk2025.htm)</u> |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

---

| | |
|:---|:---|
| 32.2 | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit322-10xk2025.htm)</u> |
| 97.1\* | <u>[Varex Imaging Corporation Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the Company's Annual Report on Form 10-K filed November 19, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001681622/000168162224000089/vrex-20240927.htm)</u> |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101). |
| \* | Incorporated herein by reference |
| † | Management contract or compensatory agreement. |

---

**Item 16. Form 10-K Summary**

&nbsp;&nbsp;&nbsp;&nbsp;None

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **VAREX IMAGING CORPORATION** |
| Date: | November 18, 2025 | By: | /s/ Shubham Maheshwari |
|  |  |  | **Shubham Maheshwari** |
|  |  |  | **Chief Financial Officer** |
|  |  |  | ***(Duly Authorized Officer and Principal Financial Officer)*** |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Capacity** | **Date** |
| **/s/ SUNNY S. SANYAL** | President and Chief Executive Officer and Director<br>*(Principal Executive Officer)* | November 18, 2025 |
| Sunny S. Sanyal |  |  |
| **/s/ SHUBHAM MAHESHWARI** | Chief Financial Officer<br>*(Principal Financial and Accounting Officer)* | November 18, 2025 |
| Shubham Maheshwari |  |  |
| **/s/ WALTER M ROSEBROUGH, JR.** | Chair of the Board | November 18, 2025 |
| Walter M Rosebrough, Jr. |  |  |
| **/s/ KATHLEEN L. BARDWELL** | Director | November 18, 2025 |
| Kathleen L. Bardwell |  |  |
| **/s/ JOCELYN D. CHERTOFF** | Director | November 18, 2025 |
| Jocelyn D. Chertoff |  |  |
| **/s/ TIMOTHY E. GUERTIN** | Director | November 18, 2025 |
| Timothy E. Guertin |  |  |
| **/s/ JAY K. KUNKEL** | Director | November 18, 2025 |
| Jay K. Kunkel |  |  |
| **/s/ CHRISTINE A. TSINGOS** | Director | November 18, 2025 |
| Christine A. Tsingos |  |  |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| <u>[Report of Independent Registered Public Accounting Firm (PCAOB ID](#i8474629358084e7786308a95e9f157ba_3526)[No.](#i8474629358084e7786308a95e9f157ba_3526)34[)](#i8474629358084e7786308a95e9f157ba_106)</u> | <u>[F-1](#i8474629358084e7786308a95e9f157ba_3526)</u> |
| <u>[Consolidated Statements of Operations for the fiscal years en](#i8474629358084e7786308a95e9f157ba_16)[ded](#i8474629358084e7786308a95e9f157ba_16)2025[,](#i8474629358084e7786308a95e9f157ba_16)2024[,](#i8474629358084e7786308a95e9f157ba_16)[and](#i8474629358084e7786308a95e9f157ba_16)2023</u> | <u>[F-4](#i8474629358084e7786308a95e9f157ba_16)</u> |
| <u>[Consolidated Statements of Comp](#i8474629358084e7786308a95e9f157ba_19)[rehensive](#i8474629358084e7786308a95e9f157ba_19)(Loss) Income[for th](#i8474629358084e7786308a95e9f157ba_19)[e fiscal ye](#i8474629358084e7786308a95e9f157ba_19)[ars ended](#i8474629358084e7786308a95e9f157ba_19)2025[,](#i8474629358084e7786308a95e9f157ba_19)2024[, and](#i8474629358084e7786308a95e9f157ba_19)2023</u> | <u>[F-5](#i8474629358084e7786308a95e9f157ba_19)</u> |
| <u>[Consolidated Balance Sheets as of the end of fiscal years](#i8474629358084e7786308a95e9f157ba_22)2025[and](#i8474629358084e7786308a95e9f157ba_22)2024</u> | <u>[F-6](#i8474629358084e7786308a95e9f157ba_22)</u> |
| <u>[Consolidated Statements of Stockholders' Equity for the fiscal years](#i8474629358084e7786308a95e9f157ba_1784)2025[,](#i8474629358084e7786308a95e9f157ba_19)2024[, and](#i8474629358084e7786308a95e9f157ba_19)2023</u> | <u>[F-7](#i8474629358084e7786308a95e9f157ba_1784)</u> |
| <u>[Consolidated Statements of Cash Flows for the fiscal years ended](#i8474629358084e7786308a95e9f157ba_31)2025[,](#i8474629358084e7786308a95e9f157ba_19)2024[, and](#i8474629358084e7786308a95e9f157ba_19)2023</u> | <u>[F-8](#i8474629358084e7786308a95e9f157ba_31)</u> |
| <u>[Notes to the Consolidated Financial Statements](#i8474629358084e7786308a95e9f157ba_34)</u> | <u>[F-9](#i8474629358084e7786308a95e9f157ba_34)</u> |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Stockholders and the Board of Directors of Varex Imaging Corporation

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Varex Imaging Corporation and subsidiaries (the "Company") as of October 3, 2025 and September 27, 2024, the related consolidated statements of operations, comprehensive (loss) income, stockholders' equity, and cash flows, for each of the three years in the period ended October 3, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of October 3, 2025 and September 27, 2024, and the results of its operations and its cash flows for each of the three years in the period ended October 3, 2025, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of October 3, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated November 18, 2025, expressed an unqualified opinion on the Company's internal control over financial reporting.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

***Inventories – Valuation of Excess and Obsolete Inventories — Refer to Note 1 to the financial statements***

*Critical Audit Matter Description*

Inventories are valued at the lower of cost or net realizable value. The Company evaluates the carrying value of its inventories taking into consideration such factors as historical sales and anticipated future sales compared to quantities on hand and the prices the Company expects to obtain for products in its various markets. The Company adjusts excess and obsolete inventories to net realizable value, and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues. Estimating the amount of excess and obsolete inventories involves significant judgment and estimates.

We identified the valuation of excess and obsolete inventories as a critical audit matter because of management's significant judgment related to its estimates of anticipated future sales in determining the valuation of excess and obsolete inventories. This required a high degree of auditor judgment and an increased extent of effort.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

*How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to management's estimates of the valuation of excess and obsolete inventories included the following, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the effectiveness of controls over the valuation of excess and obsolete inventories. The controls we tested included those over the calculation and the accuracy and completeness of underlying data used in the calculation, including historical sales and anticipated future sales by product, product quantities on hand, and applicable prices.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We evaluated management's ability to accurately estimate the valuation of excess and obsolete inventories by comparing actual inventory write-downs to management's historical estimates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We performed procedures to evaluate the reasonableness of management's methods, assumptions, and judgments used in developing their estimate of the valuation of excess and obsolete inventories, which included consideration of historical sales, anticipated future sales, and information obtained from production planning and supply chain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the accuracy and completeness of the underlying data used in the Company's calculations of the valuation of excess and obsolete inventories, including historical usage, anticipated future sales, quantities on hand, and pricing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We assessed the reasonableness of the assumptions used in estimating the valuation of excess and obsolete inventories by considering the anticipated future sales information obtained from production planning and supply chain employees, and developing an independent expectation which was then compared to the results of the Company's calculations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the mathematical accuracy of the Company's calculations of excess and obsolete inventories.

***Goodwill – Medical Reporting Unit – Refer to Notes 1 and 12 of the financial statements***

*Critical Audit Matter Description*

The Company evaluates goodwill for impairment at least annually or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The evaluation includes consideration of qualitative factors including industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. As a result of various changes in circumstances, the Company performed a quantitative impairment analysis to determine the fair value of its reporting units during the fiscal quarter ended July 4, 2025. The Company used both an income approach utilizing the discounted cash flow method and a market approach utilizing the public company market multiple method. As a result of the impairment test, the Company determined that the carrying amount of the Medical reporting unit was below its fair value, and the Company recorded a $93.9 million goodwill impairment charge to its Medical reporting unit.

We identified the valuation of the Medical reporting unit performed as of July 4, 2025 as a critical audit matter because of the significant judgments and estimates management made to determine the fair value of the reporting unit. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management's estimates and assumptions related to selection of the discount rate and forecasts of future revenues used in determining the fair value of the Medical reporting unit, including the need to involve our fair value specialists.

*How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to management's estimates and assumptions for selection of the discount rate and forecasts of future revenues in determining the fair value of the Medical reporting unit as of July 4, 2025 included the following, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the effectiveness of controls over management's goodwill impairment evaluation, including those over the determination of the fair value of the Medical reporting unit, such as controls related to management's estimates and assumptions for the selection of the discount rate and forecasts of future revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We evaluated the reasonableness of management's revenue forecast estimates by comparing key assumptions to historical results, current industry and peer trends, and information from sales and marketing personnel of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• With the assistance of fair value specialists, we evaluated the reasonableness of the discount rate by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Testing the source information underlying the determination of the discount rate and testing the mathematical accuracy of the calculation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Developing a range of independent estimates for the discount rate and comparing those to the discount rate selected by management.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We evaluated whether the revenue forecast estimates were consistent with evidence obtained in other areas of the audit.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

/s/ Deloitte & Touche LLP

Salt Lake City, Utah

November 18, 2025

We have served as the Company's auditor since 2021.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**VAREX IMAGING CORPORATION**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions, except per share amounts)** | **2025** | **2024** | **2023** |
| Revenues, net | $844.6 | $811.0 | $893.4 |
| Cost of revenues | 554.1 | 554.1 | 603.1 |
| &nbsp;&nbsp;Gross profit | 290.5 | 256.9 | 290.3 |
| Operating expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 91.1 | 87.0 | 84.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 133.3 | 137.8 | 128.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | 93.9 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 318.3 | 224.8 | 213.2 |
| Operating (loss) income | (27.8) | 32.1 | 77.1 |
| Interest income | 8.5 | 7.3 | 3.7 |
| Interest expense | (35.5) | (30.2) | (29.3) |
| Other expense, net | (4.4) | (4.2) | (20.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest and other expense, net | (31.4) | (27.1) | (45.8) |
| (Loss) income before taxes | (59.2) | 5.0 | 31.3 |
| Income tax expense (benefit) | 10.7 | 53.3 | (16.6) |
| Net (loss) income | (69.9) | (48.3) | 47.9 |
| Less: Net income attributable to noncontrolling interests | 0.4 | 0.5 | 0.5 |
| Net (loss) income attributable to Varex | $(70.3) | $(48.8) | $47.4 |
| **Net (loss) income per common share attributable to Varex** |  |  |  |
| Basic | $(1.70) | $(1.20) | $1.18 |
| Diluted | $(1.70) | $(1.20) | $1.07 |
| **Weighted average common shares outstanding** |  |  |  |
| Basic | 41.4 | 40.8 | 40.3 |
| Diluted | 41.4 | 40.8 | 50.3 |

---

*See accompanying Notes to the Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_7)</u>

**VAREX IMAGING CORPORATION**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME** 

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Net (loss) income | $(69.9) | $(48.3) | $47.9 |
| Other comprehensive loss |  |  |  |
| &nbsp;&nbsp;&nbsp;Unrealized loss on defined benefit obligations |  |  | (1.0) |
| &nbsp;&nbsp;&nbsp;Gain on forward contracts | 0.1 | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;Unrealized (loss) gain on available-for-sale securities | (0.1) | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (2.3) | (1.9) | (0.5) |
| Total comprehensive (loss) income | (72.2) | (50.0) | 46.6 |
| &nbsp;&nbsp;&nbsp;Less: Comprehensive income attributable to noncontrolling interests | 0.4 | 0.5 | 0.5 |
| Comprehensive (loss) income attributable to Varex | $(72.6) | $(50.5) | $46.1 |

---

*See accompanying Notes to the Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_7)</u>

**VAREX IMAGING CORPORATION**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| **(In millions, except share and per share amounts)** | **October 3, 2025** | **September 27, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $145.0 | $168.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 10.1 | 31.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $2.1 million and $1.0 million at October 3, 2025 and September 27, 2024, respectively | 156.6 | 157.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 299.4 | 264.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 30.7 | 26.9 |
| Total current assets | 641.8 | 649.9 |
| Property, plant, and equipment, net | 157.8 | 153.4 |
| Goodwill | 198.4 | 291.0 |
| Intangible assets, net | 14.0 | 16.1 |
| Investments in privately-held companies | 24.5 | 26.8 |
| Deferred tax assets | 2.9 | 1.3 |
| Operating lease assets | 29.4 | 28.3 |
| Other assets | 38.6 | 46.8 |
| **Total assets** | $1107.4 | $1213.6 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $69.9 | $59.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other current liabilities | 98.4 | 78.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liabilities | 4.4 | 4.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current maturities of long-term debt, net | 1.5 | 46.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenues | 13.0 | 7.9 |
| Total current liabilities | 187.2 | 195.9 |
| Long-term debt, net | 366.0 | 397.1 |
| Deferred tax liabilities | 5.5 | 4.0 |
| Operating lease liabilities | 24.0 | 23.0 |
| Other long-term liabilities | 38.1 | 50.4 |
| **Total liabilities** | 620.8 | 670.4 |
| Stockholders' equity: |  |  |
| Preferred stock, $0.01 par value: 20,000,000 shares authorized, none issued |  |  |
| Common stock, $0.01 par value: 150,000,000 shares authorized |  |  |
| &nbsp;&nbsp;&nbsp;Shares issued and outstanding: 41,689,672 and 41,094,179 at October 3, 2025 and September 27, 2024, respectively | 0.4 | 0.4 |
| Additional paid-in capital | 483.3 | 467.2 |
| Accumulated other comprehensive loss | (5.2) | (2.9) |
| (Accumulated deficit) retained earnings | (5.9) | 64.4 |
| Total Varex stockholders' equity | 472.6 | 529.1 |
| Noncontrolling interests | 14.0 | 14.1 |
| **Total stockholders' equity** | 486.6 | 543.2 |
| **Total liabilities and stockholders' equity** | $1107.4 | $1213.6 |

---

*See accompanying Notes to the Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_7)</u>

**VAREX IMAGING CORPORATION**

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-in Capital** | **Accumulated Other Comprehensive income (loss)** | **Retained Earnings (Accumulated Deficit)** | **Total Varex Equity** | **Noncontrolling Interests** | **Total Stockholders' Equity** |
| **(In millions)** | **Shares** | **Amount** | **Additional Paid-in Capital** | **Accumulated Other Comprehensive income (loss)** | **Retained Earnings (Accumulated Deficit)** | **Total Varex Equity** | **Noncontrolling Interests** | **Total Stockholders' Equity** |
| **September 30, 2022** | 40.1 | $0.4 | $469.1 | $0.1 | $59.7 | $529.3 | $13.3 | $542.6 |
| Net income |  |  |  |  | 47.4 | 47.4 | 0.5 | 47.9 |
| Cumulative effect of accounting change |  |  | (34.6) |  | 6.1 | (28.5) |  | (28.5) |
| Exercise of stock options |  |  | 0.2 |  |  | 0.2 |  | 0.2 |
| Common stock issued upon vesting of restricted shares | 0.2 |  |  |  |  |  |  |  |
| Shares withheld on vesting of restricted stock | (0.1) |  | (1.4) |  |  | (1.4) |  | (1.4) |
| Common stock issued under employee stock purchase plan | 0.3 |  | 3.9 |  |  | 3.9 |  | 3.9 |
| Share-based compensation |  |  | 13.5 |  |  | 13.5 |  | 13.5 |
| Realized gain on forward contracts |  |  |  | 0.1 |  | 0.1 |  | 0.1 |
| Unrealized gain on change in fair value of available-for-sale securities |  |  |  | 0.1 |  | 0.1 |  | 0.1 |
| Unrealized loss on defined benefit obligations, net of tax |  |  |  | (1.0) |  | (1.0) |  | (1.0) |
| Foreign currency translation adjustments |  |  |  | (0.5) |  | (0.5) |  | (0.5) |
| Other |  |  | (0.3) |  |  | (0.3) | (0.5) | (0.8) |
| **September 29, 2023** | 40.5 | $0.4 | $450.4 | $(1.2) | $113.2 | $562.8 | $13.3 | $576.1 |
| Net (loss) income |  |  |  |  | (48.8) | (48.8) | 0.5 | (48.3) |
| Common stock issued upon vesting of restricted shares | 0.4 |  |  |  |  |  |  |  |
| Shares withheld on vesting of restricted stock | (0.1) |  | (2.2) |  |  | (2.2) |  | (2.2) |
| Common stock issued under employee stock purchase plan | 0.3 |  | 3.8 |  |  | 3.8 |  | 3.8 |
| Share-based compensation |  |  | 15.2 |  |  | 15.2 |  | 15.2 |
| Realized gain on forward contracts |  |  |  | 0.1 |  | 0.1 |  | 0.1 |
| Unrealized gain on change in fair value of available-for-sale securities |  |  |  | 0.1 |  | 0.1 |  | 0.1 |
| Foreign currency translation adjustments |  |  |  | (1.9) |  | (1.9) |  | (1.9) |
| Business acquisitions |  |  |  |  |  |  | 0.7 | 0.7 |
| Other |  |  |  |  |  |  | (0.4) | (0.4) |
| **September 27, 2024** | 41.1 | $0.4 | $467.2 | $(2.9) | $64.4 | $529.1 | $14.1 | $543.2 |
| Net (loss) income |  |  |  |  | (70.3) | (70.3) | 0.4 | (69.9) |
| Common stock issued upon vesting of restricted shares | 0.4 |  |  |  |  |  |  |  |
| Shares withheld on vesting of restricted stock | (0.1) |  | (1.9) |  |  | (1.9) |  | (1.9) |
| Common stock issued under employee stock purchase plan | 0.3 |  | 3.3 |  |  | 3.3 |  | 3.3 |
| Share-based compensation |  |  | 14.8 |  |  | 14.8 |  | 14.8 |
| Realized gain on forward contracts |  |  |  | 0.1 |  | 0.1 |  | 0.1 |
| Unrealized loss on change in fair value of available-for-sale securities |  |  |  | (0.1) |  | (0.1) |  | (0.1) |
| Foreign currency translation adjustments |  |  |  | (2.3) |  | (2.3) |  | (2.3) |
| Other |  |  | (0.1) |  |  | (0.1) | (0.5) | (0.6) |
| **October 3, 2025** | 41.7 | $0.4 | $483.3 | $(5.2) | $(5.9) | $472.6 | $14.0 | $486.6 |

---

*See accompanying Notes to the Consolidated Financial Statements*

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_7)</u>

**VAREX IMAGING CORPORATION**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |  |
| &nbsp;&nbsp;Net (loss) income | $(69.9) | $(48.3) | $47.9 |
| &nbsp;&nbsp;Adjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 15.0 | 15.3 | 13.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 23.2 | 21.2 | 19.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 4.0 | 9.9 | 13.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | (0.5) | 38.1 | (38.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from equity method investments | 2.7 | 2.0 | 1.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of equity method investment |  |  | 16.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred loan costs | 2.7 | 2.8 | 2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on purchase of business |  | (2.1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | 93.9 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory write-down | 3.8 | 4.9 | 5.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (1.8) | 1.5 | 3.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 0.1 | 6.7 | 9.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | (39.9) | 6.6 | 20.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (3.6) | 3.3 | 7.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 6.2 | (3.2) | (15.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other current and long-term liabilities | 0.1 | (9.1) | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenues | 5.7 | (2.3) | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 41.7 | 47.3 | 108.4 |
| **Cash flows from investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment | (22.9) | (26.9) | (20.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on settlement of cash flow hedge |  |  | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of marketable debt securities | 11.5 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities of marketable debt securities | 50.5 | 58.8 | 28.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of marketable debt securities | (30.6) | (56.6) | (52.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of marketable equity securities |  | (0.2) | (2.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of certificates of deposit |  | (4.2) | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities of certificates of deposit | 3.4 | 1.8 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement of net investment hedge | (0.8) |  | 7.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions of businesses, net of cash acquired |  | 0.9 | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (0.8) | (1.1) | (2.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 10.3 | (27.5) | (44.9) |
| **Cash flows from financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes related to net share settlement of equity awards | (1.9) | (2.2) | (1.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of senior secured notes | 126.9 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments of borrowings | (201.9) | (1.6) | (2.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options |  |  | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs | (1.2) | (2.3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from shares issued under employee stock purchase plan | 3.3 | 3.8 | 3.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (1.1) | (1.0) | (0.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (75.9) | (3.3) | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effects of exchange rate changes on cash and cash equivalents and restricted cash | 0.6 | (0.1) | 0.1 |
| &nbsp;&nbsp;Net (decrease) increase in cash and cash equivalents and restricted cash | (23.3) | 16.4 | 63.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents and restricted cash at beginning of period | 170.4 | 154.0 | 90.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents and restricted cash at end of period | $147.1 | $170.4 | $154.0 |
| Supplemental cash flow information: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $31.3 | $27.6 | $27.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid, net of refunds | 18.6 | 20.2 | 16.7 |
| Supplemental non-cash activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment financed through accounts payable | $5.4 | $1.0 | $2.7 |

---

*See accompanying Notes to the Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_7)</u>

**VAREX IMAGING CORPORATION**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Description of Business***

&nbsp;&nbsp;&nbsp;&nbsp;Varex Imaging Corporation (the "Company" or "Varex") designs, manufactures, sells, and services a broad range of medical products, which include X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, ionization chambers, high voltage connectors, image processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. The Company sells its products to imaging system original equipment manufacturer ("OEM") customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary equipment, as well as to independent service companies and distributors, and directly to end-users for replacement purposes.

&nbsp;&nbsp;&nbsp;&nbsp;The Company also designs, manufactures, sells and services industrial products, which include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, coolers, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex's products into their inspection or irradiation systems and processes. The Company also manufactures and sells its own X-ray imaging systems for industrial applications. The Company conducts an active research and development program to focus on new technologies and applications in both medical and industrial X-ray imaging.

***Basis of Presentation***

&nbsp;&nbsp;&nbsp;&nbsp;The accompanying Consolidated Financial Statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and in accordance with accounting principles generally accepted in the United States ("GAAP"). The Company has consolidated all its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated in consolidation.

***Revision of Prior Period Financial Statements***

&nbsp;&nbsp;&nbsp;&nbsp;During the third quarter of 2025, the Company identified an accounting error related to its deferred tax assets and liabilities and income tax expense calculations in prior periods. The Company has revised its prior period Consolidated Statements of Operations, Consolidated Statements of Comprehensive (Loss) Income, Consolidated Balance Sheets, Consolidated Statements of Stockholders' Equity, and Consolidated Statements of Cash Flows to correct this error. The Company evaluated the effect of the error on the previously issued Consolidated Financial Statements and determined that the related impacts were not material, individually or in aggregate. However, correcting the cumulative effect of the errors as out-of-period adjustments would be material for the current year. As such the Company has corrected these errors in the Consolidated Financial Statements for all prior periods presented herein.

&nbsp;&nbsp;&nbsp;&nbsp;The following tables provide a reconciliation of the revisions for the previously reported Consolidated Statements of Operations, Consolidated Statements of Comprehensive (Loss) Income, Consolidated Statements of Stockholders' Equity, and Consolidated Statements of Cash Flows as of the fiscal years ended September 27, 2024 and September 29, 2023 and the revisions for the previously reported Consolidated Balance Sheets as of the fiscal year ended September 27, 2024.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
| **(In millions, except per share amounts)** | **As Previously Reported** | **Revision** | **As Revised** | **As Previously Reported** | **Revision** | **As Revised** |
| Income tax expense (benefit) | $52.2 | $1.1 | $53.3 | $(17.4) | $0.8 | $(16.6) |
| Net (loss) income | (47.2) | (1.1) | (48.3) | 48.7 | (0.8) | 47.9 |
| Net (loss) income attributable to Varex | (47.7) | (1.1) | (48.8) | 48.2 | (0.8) | 47.4 |
| **Net (loss) income per common share attributable to Varex** |  |  |  |  |  |  |
| Basic | $(1.17) | $(0.03) | $(1.20) | $1.20 | $(0.02) | $1.18 |
| Diluted | $(1.17) | $(0.03) | $(1.20) | $1.08 | $(0.01) | $1.07 |

---

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
| **(In millions)** | **As Previously Reported** | **Revision** | **As Revised** | **As Previously Reported** | **Revision** | **As Revised** |
| Net (loss) income | $(47.2) | $(1.1) | $(48.3) | $48.7 | $(0.8) | $47.9 |
| Total comprehensive (loss) income | (48.9) | (1.1) | (50.0) | 47.4 | (0.8) | 46.6 |
| Comprehensive (loss) income attributable to Varex | (49.4) | (1.1) | (50.5) | 46.9 | (0.8) | 46.1 |

---

**CONSOLIDATED BALANCE SHEETS**

---

| | | | |
|:---|:---|:---|:---|
| | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** |
| **(In millions)** | **As Previously Reported** | **Revision** | **As Revised** |
| Deferred tax assets | $4.7 | $(3.4) | $1.3 |
| **Total assets** | 1217.0 | (3.4) | 1213.6 |
| Deferred tax liabilities | 1.4 | 2.6 | 4.0 |
| **Total liabilities** | 667.8 | 2.6 | 670.4 |
| Retained earnings | 70.4 | (6.0) | 64.4 |
| Total Varex stockholders' equity | 535.1 | (6.0) | 529.1 |
| **Total stockholders' equity** | 549.2 | (6.0) | 543.2 |
| **Total liabilities and stockholders' equity** | 1217.0 | (3.4) | 1213.6 |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

---

| | | | |
|:---|:---|:---|:---|
| **(In millions)** | **Retained Earnings** | **Total Varex Equity** | **Total Stockholders' Equity** |
| **As Previously Reported** | | | |
| For the Year Ended September 29, 2023 |  |  |  |
| &nbsp;&nbsp;Balance at September 30, 2022 | $63.8 | $533.4 | $546.7 |
| &nbsp;&nbsp;Net income | 48.2 | 48.2 | 48.7 |
| &nbsp;&nbsp;Balance at September 29, 2023 | $118.1 | $567.7 | $581.0 |
| **Revision** |  |  |  |
| For the Year Ended September 29, 2023 |  |  |  |
| &nbsp;&nbsp;Balance at September 30, 2022 | $(4.1) | $(4.1) | $(4.1) |
| &nbsp;&nbsp;Net loss | (0.8) | (0.8) | (0.8) |
| &nbsp;&nbsp;Balance at September 29, 2023 | $(4.9) | $(4.9) | $(4.9) |
| **As Revised** |  |  |  |
| For the Year Ended September 29, 2023 |  |  |  |
| &nbsp;&nbsp;Balance at September 30, 2022 | $59.7 | $529.3 | $542.6 |
| &nbsp;&nbsp;Net income | 47.4 | 47.4 | 47.9 |
| &nbsp;&nbsp;Balance at September 29, 2023 | $113.2 | $562.8 | $576.1 |
| **(In millions)** | **Retained Earnings** | **Total Varex Equity** | **Total Stockholders' Equity** |
| **As Previously Reported** |  |  |  |
| For the Year Ended September 27, 2024 |  |  |  |
| &nbsp;&nbsp;Balance at September 29, 2023 | $118.1 | $567.7 | $581.0 |
| &nbsp;&nbsp;Net loss | (47.7) | (47.7) | (47.2) |
| &nbsp;&nbsp;Balance at September 27, 2024 | $70.4 | $535.1 | $549.2 |
| **Revision** |  |  |  |
| For the Year Ended September 27, 2024 |  |  |  |
| &nbsp;&nbsp;Balance at September 29, 2023 | $(4.9) | $(4.9) | $(4.9) |
| &nbsp;&nbsp;Net loss | (1.1) | (1.1) | (1.1) |
| &nbsp;&nbsp;Balance at September 27, 2024 | $(6.0) | $(6.0) | $(6.0) |
| **As Revised** |  |  |  |
| For the Year Ended September 27, 2024 |  |  |  |
| &nbsp;&nbsp;Balance at September 29, 2023 | $113.2 | $562.8 | $576.1 |
| &nbsp;&nbsp;Net loss | (48.8) | (48.8) | (48.3) |
| &nbsp;&nbsp;Balance at September 27, 2024 | $64.4 | $529.1 | $543.2 |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
|  | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** |
| **(In millions)** | **As Previously Reported** | **Revision** | **As Revised** | **As Previously Reported** | **Revision** | **As Revised** |
| Cash flows from operating activities: |  |  |  |  |  |  |
| &nbsp;&nbsp;Net (loss) income | $(47.2) | $(1.1) | $(48.3) | $48.7 | $(0.8) | $47.9 |
| &nbsp;&nbsp;Deferred taxes | 37.0 | 1.1 | 38.1 | (39.5) | 0.8 | (38.7) |

---

&nbsp;&nbsp;&nbsp;&nbsp;These revisions had no impact on gross profit, operating expenses, or operating income in any of the fiscal periods.

***Segment Reporting***

&nbsp;&nbsp;&nbsp;&nbsp;The Company has two reportable operating segments; (i) Medical and (ii) Industrial. See Note 13, *Segment Information,* included in this report, for further information on the Company's segments.

***Fiscal Year***

&nbsp;&nbsp;&nbsp;&nbsp;The fiscal years of the Company as reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2025 was the 53-week period that ended October 3, 2025, fiscal year 2024 was the 52-week period that ended September 27, 2024, and fiscal year 2023 was the 52-week period that ended September 29, 2023.

***Variable Interest Entities***

&nbsp;&nbsp;&nbsp;&nbsp;For entities in which the Company has variable interests, the Company focuses on identifying which entity has the power to direct the activities that most significantly impact the variable interest entity's economic performance and which entity has the obligation to absorb losses or the right to receive residual returns from the variable interest entity. If the Company is the primary beneficiary of a variable interest entity, the assets, liabilities, and results of operations of the variable interest entity will be included in the Company's consolidated financial statements. As of October 3, 2025, the Company had variable interests in two entities, neither of which were consolidated by the Company.

***Use of Estimates***

&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.

***Cash and Cash Equivalents***

&nbsp;&nbsp;&nbsp;&nbsp;The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.

***Restricted Cash***

&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Consolidated Balance Sheets. Cash and cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **September 27, 2024** | **September 27, 2024** |
| **(In millions)** | **Beginning of Period** | **End of Period** | **Beginning of Period** | **End of Period** |
| Cash and cash equivalents | $168.7 | $145.0 | $152.6 | $168.7 |
| Restricted cash | 1.7 | 2.1 | 1.4 | 1.7 |
| Total as presented in the Consolidated Statements of Cash Flows | $170.4 | $147.1 | $154.0 | $170.4 |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Fair Value***

&nbsp;&nbsp;&nbsp;&nbsp;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;Level 1 — Quoted prices in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or, other inputs that are observable or can be corroborated by observable market data.

&nbsp;&nbsp;&nbsp;&nbsp;Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

***Derivative Instruments and Hedging Activities***

&nbsp;&nbsp;&nbsp;&nbsp;The Company records all derivatives on the Consolidated Balance Sheets at fair value as of the reporting date. For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss and reclassified from Accumulated other comprehensive loss ("OCI") into earnings when the hedged transaction affects earnings. For derivatives that are designated and qualify as net investment hedges, the gain or loss on the derivative is reported as a component of other comprehensive income or loss until the hedged item is sold. The portion of the change in fair value of the Company's net investment hedges (or cross currency swaps) related to the cross-currency basis spread is an excluded component in the assessment of the effectiveness of these net investment hedges (or cross currency swaps). A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case, a quantitative assessment of hedge effectiveness is performed.

***Concentration of Risk***

&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases, and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. When these suppliers are unable to meet the Company's supply needs, the Company's production is negatively impacted.

&nbsp;&nbsp;&nbsp;&nbsp;Credit is extended to customers based on an evaluation of the customer's financial condition, and collateral is not required. In certain circumstances, a customer may be required to prepay all or a portion of the contract price prior to transfer of control. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** | **2023** |
| Canon Medical Systems Corporation | 18.0% | 17.6% | 16.5% |

---

&nbsp;&nbsp;&nbsp;&nbsp;Canon Medical Systems Corporation accounted for 14.0% and 9.5% of the Company's accounts receivable as of October 3, 2025 and September 27, 2024, respectively.

***Inventories, net***

&nbsp;&nbsp;&nbsp;&nbsp;Inventory is valued at the lower of cost or net realizable value. Costs include materials, labor, external service, and manufacturing overhead and is computed on a first-in-first-out basis. The Company evaluates the carrying value of its inventories taking into consideration such factors as historical and anticipated future sales compared to quantities on hand and the prices the Company expects to obtain for products. The Company adjusts excess and obsolete inventories to net realizable value and write-downs of excess and obsolete inventories are recorded as a component of cost of revenues.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's inventories, net:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Raw materials and parts | $228.1 | $214.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Work-in-process | 31.3 | 16.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finished goods | 40.0 | 34.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $299.4 | $264.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded inventory write-downs of $3.8 million, $4.9 million, and $5.6 million in fiscal years ended 2025, 2024, and 2023, respectively.

***Property, Plant and Equipment, net***

&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment are stated at cost, net of accumulated depreciation. Major improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or remaining lease term. Land is not subject to depreciation, but land improvements are depreciated over fifteen years. Land leasehold rights and leasehold improvements are depreciated over the lesser of their estimated useful lives or remaining lease terms. Buildings are depreciated up to thirty years. Machinery and equipment are depreciated over a range from three to seven years. Assets subject to lease are depreciated over the lesser of their estimated useful lives or remaining lease terms. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted, and an impairment assessment may be performed on the recoverability of the carrying amounts. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts.

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's property, plant, and equipment, net:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| Land | $8.6 | $8.6 |
| Buildings and leasehold improvements | 166.3 | 165.5 |
| Machinery and equipment | 217.0 | 206.5 |
| Construction in progress | 36.9 | 25.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross property, plant, and equipment | $428.8 | $405.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Accumulated depreciation and amortization | (271.0) | (252.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total property, plant, and equipment, net | $157.8 | $153.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded depreciation expense of $23.2 million, $21.2 million, and $19.5 million in fiscal years 2025, 2024 and 2023, respectively.

***Equity Method Investments***

&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control of, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. During fiscal year 2023, the Company recorded a before-tax impairment charge totaling $16.4 million, which is included in other expense, net in the Company's Consolidated Statements of Operations. There was no impairment recorded during fiscal years 2025 and 2024.

***Marketable Securities***

&nbsp;&nbsp;&nbsp;&nbsp;The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

*Marketable Debt Securities*

&nbsp;&nbsp;&nbsp;&nbsp;The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, marketable securities, and other assets within the Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss and are recognized in the Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during fiscal years 2025 and 2024.

*Marketable Equity Securities*

&nbsp;&nbsp;&nbsp;&nbsp;Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of other expense, net in the Company's Consolidated Statements of Operations. See Note 4, *Fair Value*, for further details.

***Goodwill and Intangible Assets***

&nbsp;&nbsp;&nbsp;&nbsp;Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. Purchased intangible assets are carried at cost, net of accumulated amortization, and are included in intangible assets, net in the Company's Consolidated Balance Sheets. Intangible assets with finite lives are amortized over their estimated useful lives of primarily two to seven years using the straight-line method.

***Impairment of Long-lived Assets, Intangible Assets, and Goodwill***

&nbsp;&nbsp;&nbsp;&nbsp;The Company reviews long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company assesses these assets for impairment based on their estimated undiscounted future cash flows. If the carrying value of the assets exceeds the estimated future undiscounted cash flows, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.

&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates goodwill for impairment at least annually at the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The evaluation includes consideration of qualitative factors including industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. If the Company determines that a quantitative analysis is necessary, the Company performs a step one analysis, which consists of a comparison of the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. In fiscal years 2024 and 2023 the Company performed the annual goodwill qualitative impairment test for our two reporting units and determined that, at those dates, it was not more likely than not that the fair values of the reporting units were less than their carrying amount and accordingly recorded no impairment.

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2025, changes in facts and circumstances related to a sustained decrease in the Company's stock price, a decrease in its market capitalization, and downward revisions in its longer term forecast received during the quarter, which included the impact of tariffs and the China Ministry of Commerce ("MOFCOM") initiating two investigations related to medical products imported into China (the "MOFCOM Investigations"), which were temporarily suspended in May 2025 and August 2025 and indefinitely suspended in November 2025, resulted in the Company determining that an indicator of possible impairment existed within its reporting units. Accordingly, in connection with the preparation of its financial statements for the three months ended July 4, 2025, the Company performed a quantitative impairment analysis to determine the fair values of those reporting units, using both an income approach utilizing the discounted cash flow method and a market approach utilizing the public company market multiple method. Based on the output of the analysis, the Company determined that the carrying of its Medical reporting unit exceeded its fair value. Accordingly, the Company recorded $93.9 million of impairment charge to its Medical reporting unit within impairment of goodwill in the Consolidated Statements of Operations. See Note 5 *Goodwill and Intangible Assets,* for further details.

***Loss Contingencies***

&nbsp;&nbsp;&nbsp;&nbsp;From time to time, the Company is involved in legal proceedings, claims, and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable, the nature of the contingency and the fact that an estimate cannot be made is disclosed.

***Supplier Finance Programs***

&nbsp;&nbsp;&nbsp;&nbsp;The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company's responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary.

&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the change in the direct supplier financing obligation:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| Confirmed obligations outstanding at the beginning of the period | $2.6 | $4.2 |
| &nbsp;&nbsp;&nbsp;Invoices confirmed during the period | 27.9 | 31.3 |
| &nbsp;&nbsp;&nbsp;Confirmed invoices paid during the period | (27.6) | (32.9) |
| Confirmed obligations outstanding at the end of the period | $2.9 | $2.6 |

---

***Environmental Obligations***

&nbsp;&nbsp;&nbsp;&nbsp;The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of October 3, 2025 and September 27, 2024, the Company's estimated environmental liability for these sites was $3.2 million and $3.9 million, net of expected insurance proceeds, respectively.

***Product Warranty***

&nbsp;&nbsp;&nbsp;&nbsp;The Company warrants most of its products for a specific period of time, usually 12 to 27 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.

&nbsp;&nbsp;&nbsp;&nbsp;The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.

&nbsp;&nbsp;&nbsp;&nbsp;The following table reflects the changes in the Company's accrued product warranty:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| Accrued product warranty, at beginning of period | $10.8 | $7.7 |
| &nbsp;&nbsp;&nbsp;New accruals charged to cost of revenues | 13.0 | 21.0 |
| &nbsp;&nbsp;&nbsp;Product warranty expenditures | (15.3) | (17.9) |
| Accrued product warranty, at end of period | $8.5 | $10.8 |

---

***Leases***

&nbsp;&nbsp;&nbsp;&nbsp;The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.

***Revenue Recognition***

&nbsp;&nbsp;&nbsp;&nbsp;The Company's revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.

&nbsp;&nbsp;&nbsp;&nbsp;The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.

&nbsp;&nbsp;&nbsp;&nbsp;The Company determines revenue recognition through the following steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Identification of the contract, or contracts, with a customer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Identification of the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Determination of the transaction price

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Allocation of the transaction price to the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Recognition of revenue when, or as, a performance obligation is satisfied

*Contracts and Performance Obligations*

&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.

*Transaction Price and Allocation to Performance Obligations*

&nbsp;&nbsp;&nbsp;&nbsp;Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company's judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company's anticipated performance and all information (historical, current, and forecasted) that is reasonably available.

&nbsp;&nbsp;&nbsp;&nbsp;The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.

&nbsp;&nbsp;&nbsp;&nbsp;If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

*Recognition of Revenue*

&nbsp;&nbsp;&nbsp;&nbsp;Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.

&nbsp;&nbsp;&nbsp;&nbsp;Product revenue is generally recognized when the customer obtains control of the Company's product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.

&nbsp;&nbsp;&nbsp;&nbsp;Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.

*Disaggregation of Revenue*

&nbsp;&nbsp;&nbsp;&nbsp;Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 13, *Segment Information*, for the disaggregation of the Company's revenue based on reportable operating segments and Note 2, *Revenue*, for the disaggregation of revenue by geographic region and country.

*Contract Balances*

&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Consolidated Balance Sheets. The Company does not have any material contract assets.

&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.

&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Consolidated Balance Sheets.

*Costs to Obtain or Fulfill a Customer Contract*

&nbsp;&nbsp;&nbsp;&nbsp;The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.

***Allowance for Credit Losses***

&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates the creditworthiness of customers prior to authorizing shipment for all major sale transactions. On a quarterly basis, the Company considers historical trends, current information and any reasonable and supportable forecasts to determine if an amount should be included in the allowance for credit losses. The Company had an allowance for credit losses of $2.1 million and $1.0 million as of October 3, 2025 and September 27, 2024, respectively.

***Share-Based Compensation Expense***

&nbsp;&nbsp;&nbsp;&nbsp;The Company has an equity-based incentive plan that provides for the grant of nonqualified stock options, restricted stock units, and performance stock units to directors, officers, and other employees. The Company also permits employees to purchase shares under the Varex employee stock purchase plan.

&nbsp;&nbsp;&nbsp;&nbsp;The Company values stock options granted and the option component of the shares of common stock purchased under the equity-based incentive plans and stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. Share-based compensation expense for restricted stock units is measured using the fair value of the Company's stock on the date of grant and is amortized over the award's respective service period. The Black-Scholes option-pricing model requires the input of certain assumptions, and changes in the assumptions can materially affect the fair value estimates of share-based payment awards.

&nbsp;&nbsp;&nbsp;&nbsp;The Company measures and recognizes expense for all share-based payment awards based on their fair values. Share-based compensation expense recognized in the Consolidated Statements of Operations includes compensation expense for the share-based payment awards based on the grant date fair value estimated in accordance with the guidance on share-based compensation. The

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

Company records forfeitures as they occur. The Company attributes the value of share-based compensation to expense using the straight-line method. The Company considers only the direct tax impacts of share-based compensation awards when calculating the amount of tax windfalls or shortfalls.

&nbsp;&nbsp;&nbsp;&nbsp;Vesting of certain performance stock units is linked to the achievement of performance goals based on Adjusted EBITDA margin. Share-based compensation expense for these performance stock units are recognized over the performance period based on the probability of achieving the performance targets. Certain performance stock units include a market condition based on our relative total shareholder return over the performance period compared to a predetermined peer group. The fair value of these awards is determined using a Monte Carlo simulation as of the date of the grant and share-based compensation expense will not be adjusted should the target awards vary from actual awards. For additional information, see Note 11, *Employee Stock Plans*, included in this report.

***Software Development Costs***

&nbsp;&nbsp;&nbsp;&nbsp;Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.

***Research and Development***

&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. These costs primarily include employees' compensation, consulting fees, and material costs.

***Taxes on Income***

&nbsp;&nbsp;&nbsp;&nbsp;Current income tax expense or benefit is the amount of income taxes expected to be payable or receivable for the current year. Deferred income tax liabilities or assets are established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. Future changes in tax regulation can have a material impact, including tax rate changes or the realization of deferred tax assets. In addition, we provide reserves for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance for accounting for income taxes. A portion of the U.S. general business tax credits for research outside of the financial statement line for research and development ("R&D") have a small degree of uncertainty. A reasonable reserve is maintained on the uncertain portion until either the Internal Revenue Service chooses to audit or the statute of limitation expires. A reserve for R&D is typical for companies that calculate and utilize this general business credit. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.

&nbsp;&nbsp;&nbsp;&nbsp;We regularly evaluate the realizability of our deferred tax assets based on the weight of all available evidence, both positive and negative, including the history of recent earnings and expected future taxable income on a jurisdictional basis and our ability to generate sufficient taxable income in the future to realize the net deferred tax assets.

&nbsp;&nbsp;&nbsp;&nbsp;The 2017 Tax Cuts and Jobs Act ("TCJA") included a provision requiring research and development expenditures to be capitalized for tax years beginning after December 31, 2021, which was effective for the Company starting in fiscal year 2023. With the 2025 One Big Beautiful Bill Act ("OBBBA"), this provision will be repealed starting in fiscal year 2026. As a result of this repeal, U.S. taxable income and cash taxes are expected to be lower over the next several years.

***Foreign Currency Remeasurement and Translation***

&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the U.S. Dollar predominately as the functional currency of its foreign operations. Gains and losses from remeasurement of foreign currency balances into U.S. Dollars are included in the Consolidated Statements of Operations in other expense, net. For the foreign subsidiaries where the local currency is the functional currency, translation adjustments of foreign currency financial statements into U.S. Dollars are recorded to a separate component of accumulated other comprehensive loss.

***Recently Adopted Accounting Pronouncements***

&nbsp;&nbsp;&nbsp;&nbsp;In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within the segment measure of profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023, and interim reporting periods in fiscal

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

years beginning after December 31, 2024. The Company adopted this guidance beginning with this annual report and this guidance will be applied to interim periods starting in fiscal year 2026 on a retrospective basis. Refer to Note 13, *Segment Information,* for our segment reporting disclosures.

***Recent Accounting Standards or Updates Not Yet Effective***

&nbsp;&nbsp;&nbsp;&nbsp;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This standard responds to investor input by requiring public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in the notes to the financial statements. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, but early adoption is permitted. The Company is currently evaluating the impact of this standard on our disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires public companies to annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). ASU 2023-09 will be effective for the annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-09 and does not expect it to have a material effect on its consolidated financial statements.

**2. REVENUE**

***Disaggregation of Revenue***

&nbsp;&nbsp;&nbsp;&nbsp;Revenue is disaggregated from contracts by geographic region, country, and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.

&nbsp;&nbsp;&nbsp;&nbsp;The Company operates various manufacturing and marketing operations outside the United States. The Company's products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.

&nbsp;&nbsp;&nbsp;&nbsp;The following table disaggregates the Company's revenue by geographic region:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Americas | $276.5 | $266.5 | $281.8 |
| EMEA | 284.8 | 280.3 | 290.7 |
| APAC | 283.3 | 264.2 | 320.9 |
| &nbsp;&nbsp;Total revenues, net | $844.6 | $811.0 | $893.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table disaggregates the Company's revenue by country:

---

| | | | |
|:---|:---|:---|:---|
|  | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| &nbsp;&nbsp;United States | $254.9 | $257.7 | $275.1 |
| &nbsp;&nbsp;Japan | 143.5 | 118.1 | 156.6 |
| &nbsp;&nbsp;China | 128.3 | 118.0 | 146.8 |
| &nbsp;&nbsp;Other<sup>(1)</sup> | 317.9 | 317.2 | 314.9 |
| &nbsp;&nbsp;Total revenues, net | $844.6 | $811.0 | $893.4 |

---

<sup>(1)</sup> No individual country included in the Other category generated more than 10% of total revenues, net.

&nbsp;&nbsp;&nbsp;&nbsp;Refer to Note 13, *Segment Information,* for the disaggregation of the Company's revenue based on reportable operating segments.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Right of Return Assets and Refund Liabilities***

&nbsp;&nbsp;&nbsp;&nbsp;Right of return assets are included within the prepaid expenses and other current assets, and other assets in the Consolidated Balance Sheets. Refund liabilities are included within the accrued liabilities and other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The following tables summarize the changes in the right of return assets and refund liabilities for the fiscal years ended October 3, 2025 and September 27, 2024:

---

| | |
|:---|:---|
| **(In millions)** | **Right of Return Assets** |
| Balance at September 29, 2023 | $26.0 |
| &nbsp;&nbsp;&nbsp;Costs recovered from product returns during the period | (7.2) |
| &nbsp;&nbsp;&nbsp;Right of return assets from shipments of products subject to return during the period | 5.6 |
| &nbsp;&nbsp;&nbsp;Adjustment for actual vs. reserved product returns | 0.8 |
| Balance at September 27, 2024 | $25.2 |
| &nbsp;&nbsp;&nbsp;Costs recovered from product returns during the period | (6.7) |
| &nbsp;&nbsp;&nbsp;Right of return assets from shipments of products subject to return during the period | 6.4 |
| Balance at October 3, 2025 | $24.9 |

---

---

| | |
|:---|:---|
| **(In millions)** | **Refund Liabilities** |
| Balance at September 29, 2023 | $28.9 |
| &nbsp;&nbsp;&nbsp;Release of refund liability included in beginning of year refund liability | (8.0) |
| &nbsp;&nbsp;&nbsp;Additions to refund liabilities | 6.2 |
| &nbsp;&nbsp;&nbsp;Adjustment for actual vs. reserved product returns | 0.9 |
| Balance at September 27, 2024 | $28.0 |
| &nbsp;&nbsp;&nbsp;Release of refund liability included in beginning of year refund liability | (7.5) |
| &nbsp;&nbsp;&nbsp;Additions to refund liabilities | 7.1 |
| &nbsp;&nbsp;&nbsp;Adjustment for actual vs. reserved product returns | 0.1 |
| Balance at October 3, 2025 | $27.7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2025, the Company recognized revenue of $7.9 million related to deferred revenue which existed at September 27, 2024. During fiscal year 2024, the Company recognized revenue of $9.9 million related to deferred revenue which existed at September 29, 2023.

***Remaining Performance Obligations***

&nbsp;&nbsp;&nbsp;&nbsp;Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized, which are primarily related to contracts where control will be transferred to customers over the next 12 months. See Note 1, *Summary of Significant Accounting Policies,* for details on the nature of the remaining performance obligations within these contracts and how they will be resolved.

**3. RELATED-PARTY TRANSACTIONS**

***Investment in Privately-Held Companies***

&nbsp;&nbsp;&nbsp;&nbsp;The Company has a 40% ownership interest in dpiX Holding Company LLC ("dpiX Holding"), a holding company that has a 100% ownership interest in dpiX LLC ("dpiX"), a supplier of amorphous silicon-based thin film transistor arrays for flat panels used in the Company's digital image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.

&nbsp;&nbsp;&nbsp;&nbsp;The investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated. In fiscal years 2025, 2024, and 2023, the Company recorded a loss on the equity investment in dpiX Holding of $2.3 million, $1.0 million, and $0.2 million, respectively. The loss on the equity investment in dpiX Holding is included in other expense, net in the Consolidated Statements of Operations. The carrying value of the equity investment in dpiX Holding was $22.5 million and $24.8 million at October 3, 2025 and September 27, 2024, respectively.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2023, the Company recorded an impairment of its investment in dpiX Holding of $16.4 million. See Note 1, *Summary of Significant Accounting Policies,* for details on the nature of the impairment. There were no impairments recorded during fiscal year 2025 or 2024.

&nbsp;&nbsp;&nbsp;&nbsp;In fiscal years 2025, 2024 and 2023, the Company purchased glass transistor arrays from dpiX totaling $19.8 million, $18.0 million, and $18.7 million, respectively. These purchases of glass transistor arrays are included as a component of inventories, net on the Consolidated Balance Sheets or cost of revenues in the Consolidated Statements of Operations.

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025 and September 27, 2024, the Company had accounts payable to dpiX totaling $1.9 million and $3.0 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides it with the right to 50% of dpiX's total manufacturing capacity. In addition, the Company is required to pay for 50% of dpiX's fixed costs, as determined at the beginning of each calendar year. In January 2025, the Company's fixed cost commitment was determined and approved by the dpiX board of directors to be $13.7 million for calendar year 2025. As of October 3, 2025, the Company estimated it has fixed cost commitments of $3.4 million related to the amended agreement with dpiX through the remainder of the calendar year 2025. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).

&nbsp;&nbsp;&nbsp;&nbsp;The Company has determined that dpiX Holding is a variable interest entity because the at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX's economic performance. The Company does not have majority voting rights and no power to unilaterally direct the activities of dpiX Holding, and therefore, is not the primary beneficiary of dpiX Holding. The Company's exposure to loss as a result of its involvement with dpiX Holding is limited to the carrying value of the Company's investment of $22.5 million and fixed cost commitments.

&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, the Company (through one of its wholly-owned subsidiaries) and CETTEEN GmbH ("CETTEEN"), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging GmbH & Co. KG ("VEC"), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method of accounting. The Company has determined that VEC is a variable interest entity.

&nbsp;&nbsp;&nbsp;&nbsp;In fiscal years 2025, 2024, and 2023, the Company recorded a loss on the equity investment in VEC of $0.0 million, $0.1 million, and $0.4 million respectively. The Company's investment in VEC was $2.0 million and $2.0 million as of October 3, 2025 and September 27, 2024, respectively. In fiscal years 2025 and 2024, the Company had loans and other receivables from VEC of $0.8 million and $0.7 million, respectively, which are recorded in prepaid expenses and other current assets in the Consolidated Balance Sheets.

**4. FAIR VALUE**

***Assets and Liabilities Measured at Fair Value on a Recurring Basis***

&nbsp;&nbsp;&nbsp;&nbsp;The fair values of certain of the Company's financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable, net and accounts payable, approximate their fair values due to their short maturities. The fair values of the Company's Senior Secured Notes, as defined in Note 6, *Borrowings* and measured using Level 1 inputs, and as of October 3, 2025 and September 27, 2024 was $375.8 million and $247.6 million respectively. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value at October 3, 2025** | **Fair Value at October 3, 2025** | **Fair Value at October 3, 2025** | **Fair Value at October 3, 2025** |
| **(In millions)** | **Quoted Prices in Active Markets**<br>**(Level 1)** | **Significant Other**<br>**Observable Inputs**<br>**(Level 2)** | **Significant Unobservable Inputs**<br>**(Level 3)** | **Total** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Commercial paper | $— | $2.0 | $— | $2.0 |
| &nbsp;&nbsp;&nbsp;Corporate notes/bonds |  | 4.0 |  | 4.0 |
| &nbsp;&nbsp;&nbsp;Government agencies |  | 2.0 |  | 2.0 |
| &nbsp;&nbsp;&nbsp;U.S. treasury bills |  | 15.8 |  | 15.8 |
| &nbsp;&nbsp;Deferred compensation plan<sup>(1)</sup> | 8.4 |  |  | 8.4 |
| &nbsp;&nbsp;&nbsp;Marketable equity securities | 3.6 |  |  | 3.6 |
| Total assets measured at fair value | $12.0 | $23.8 | $— | $35.8 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Derivative liabilities | $— | $10.4 | $— | $10.4 |
| Total liabilities measured at fair value | $— | $10.4 | $— | $10.4 |

---

<sup>(1)</sup> The assets held under the Company's deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value at September 27, 2024** | **Fair Value at September 27, 2024** | **Fair Value at September 27, 2024** | **Fair Value at September 27, 2024** |
| **(In millions)** | **Quoted Prices in Active Markets**<br>**(Level 1)** | **Significant Other**<br>**Observable Inputs**<br>**(Level 2)** | **Significant Unobservable Inputs**<br>**(Level 3)** | **Total** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Money market funds | $— | $24.4 | $— | $24.4 |
| &nbsp;&nbsp;&nbsp;Corporate notes/bonds |  | 16.5 |  | 16.5 |
| &nbsp;&nbsp;&nbsp;Government agencies |  | 18.3 |  | 18.3 |
| &nbsp;&nbsp;&nbsp;U.S. treasury bills |  | 6.1 |  | 6.1 |
| &nbsp;&nbsp;&nbsp;Certificates of deposit |  | 0.9 |  | 0.9 |
| &nbsp;&nbsp;&nbsp;Derivative assets |  | 1.0 |  | 1.0 |
| &nbsp;&nbsp;Deferred compensation plan<sup>(1)</sup> | 7.5 |  |  | 7.5 |
| &nbsp;&nbsp;&nbsp;Marketable equity securities | 2.6 |  |  | 2.6 |
| Total assets measured at fair value | $10.1 | $67.2 | $— | $77.3 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivative liabilities | $— | $8.6 | $— | $8.6 |
| Total liabilities measured at fair value | $— | $8.6 | $— | $8.6 |

---

<sup>(1)</sup> The assets held under the Company's deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.

***Nonrecurring Fair Value Measurements***

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2025, the Company assessed its goodwill for impairment and concluded that the carrying value of the Medical reporting unit was greater than its fair value. The nonrecurring fair value measurements used by the Company to determine the impairment of the Medical reporting unit goodwill was calculated by equal weighting of the income approach based on estimated discounted future cash flows and the market approach based on comparable publicly traded companies in similar lines of businesses. Under the income approach, fair value is determined based on a discounted cash flow technique that uses estimates of cash flows discounted to present value using rates commensurate with the risks associated with those cash flows. Under the market approach, a market-based value is derived by relating multiples of revenue for a group of comparable public companies to the same measure for

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

each reporting unit to estimate fair value. This valuation resulted in a Level 3 nonrecurring fair value measurement. See Note 5, *Goodwill and Intangible Assets*, for further information on the nature of the impairment.

***Marketable Debt Securities***

&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, marketable securities, and other assets balances on the Consolidated Balance Sheets.

---

| | | | |
|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** |
| **(In millions)** | **Amortized Costs** | **Unrealized Losses** | **Fair Value** |
| Commercial paper | $2.0 | $— | $2.0 |
| Corporate notes/bonds | 4.1 | (0.1) | 4.0 |
| U.S. treasury bills | 15.8 |  | 15.8 |
| Government agencies | 2.0 |  | 2.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable debt securities | $23.9 | $(0.1) | $23.8 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** |
| **(In millions)** | **Amortized Costs** | **Unrealized Gains** | **Fair Value** |
| Corporate notes/bonds | $16.4 | $0.1 | $16.5 |
| U.S. treasury bills | 6.1 |  | 6.1 |
| Government agencies | 18.3 |  | 18.3 |
| Certificates of deposit | 0.9 |  | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable debt securities | $41.7 | $0.1 | $41.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The contractual maturities of marketable debt securities as of October 3, 2025, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** |
| **(In millions)** | **Amortized Costs** | **Fair Value** |
| Contractual maturities: |  |  |
| &nbsp;&nbsp;&nbsp;Due within one year | $23.9 | $23.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable debt securities | $23.9 | $23.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;During the fiscal year ended October 3, 2025, there were no gross realized gains or losses from the sale of certain marketable debt securities that were reclassified out of accumulated other comprehensive loss.

&nbsp;&nbsp;&nbsp;&nbsp;The following tables summarize the balance sheet locations for marketable debt securities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** |
| **(In millions)** | **Commercial Paper** | **Corporate Notes/Bonds** | **Government Agencies** | **Treasury Bills** | **Total** |
| Cash and cash equivalents | $— | $— | $— | $13.7 | $13.7 |
| Marketable securities | 2.0 | 4.0 | 2.0 | 2.1 | 10.1 |
| Total marketable debt securities | $2.0 | $4.0 | $2.0 | $15.8 | $23.8 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** |
| **(In millions)** | **Corporate Notes/Bonds** | **Government Agencies** | **Treasury Bills** | **Certificates of Deposit** | **Total** |
| Cash and cash equivalents | $— | $— | $1 | $— | $1 |
| Marketable securities | 10.5 | 16.3 | 4.1 | 0.9 | 31.8 |
| Other assets | 6.0 | 2.0 | 1.0 |  | 9.0 |
| Total marketable debt securities | $16.5 | $18.3 | $6.1 | $0.9 | $41.8 |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**5. GOODWILL AND INTANGIBLE ASSETS**

&nbsp;&nbsp;&nbsp;&nbsp;The following table reflects goodwill by reportable operating segment:

---

| | | | |
|:---|:---|:---|:---|
| **(In millions)** | **Medical** | **Industrial** | **Total** |
| Balance at September 27, 2024 | $173.0 | $118.0 | $291.0 |
| Impairment of goodwill | (93.9) |  | (93.9) |
| Foreign currency translation adjustments | 0.7 | 0.6 | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at October 3, 2025 | $79.8 | $118.6 | $198.4 |
|  | **Medical** | **Industrial** | **Total** |
| Balance at October 3, 2025 |  |  |  |
| Goodwill | $173.7 | $118.6 | $292.3 |
| Accumulated impairment losses | (93.9) |  | (93.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total goodwill | $79.8 | $118.6 | $198.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company performs its annual goodwill impairment test as of the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Refer to Note 1, *Summary of Significant Accounting Policies,* for further details concerning our annual goodwill impairment evaluation. During the three months ended July 4, 2025, the Company identified triggering events in its Industrial and Medical reporting units due to a sustained decline in its market capitalization, a sustained decline in its stock price, and downward revisions in its longer-term forecast received during the quarter, which included the impact of tariffs and MOFCOM Investigations announcements.

&nbsp;&nbsp;&nbsp;&nbsp;As a result, in connection with the preparation of its financial statements for the three months ended July 4, 2025, the Company performed a quantitative impairment analysis for goodwill related to its Medical and Industrial reporting units. The fair value of the reporting units were determined using both an income approach utilizing the discounted cash flow method and market approach utilizing the public company market multiple method. Based on this analysis, the Company determined that the carrying amount of the Medical reporting unit exceeded fair value, and recorded a goodwill impairment charge of $93.9 million to its Medical reporting unit within impairment of goodwill in the Consolidated Statements of Operations. Additionally, based on the output of the analysis, the Company determined that the fair value of the Industrial reporting unit exceeded its carrying amount. Accordingly, no impairment charge was recorded relating to its Industrial reporting unit.

&nbsp;&nbsp;&nbsp;&nbsp;The goodwill within the Medical reporting unit remains susceptible to future impairment charges. Any significant adverse change in the Company's near- or long-term projections or macroeconomic conditions would result in future impairment charges for the Medical reporting unit.&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;The following table reflects the gross carrying amount and accumulated amortization of the Company's finite-lived intangible assets included in intangible assets, net in the Consolidated Balance Sheets:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** | **September 27, 2024** | **September 27, 2024** | **September 27, 2024** |
| **(In millions)** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
| Acquired existing technology | $74.9 | $(65.5) | $9.4 | $73.8 | $(63.5) | $10.3 |
| Patents, licenses and other | 6.2 | (6.2) |  | 12.6 | (12.6) |  |
| Customer contracts and supplier relationship | 52.3 | (47.7) | 4.6 | 52.8 | (47.0) | 5.8 |
| &nbsp;&nbsp;Total intangible assets | $133.4 | $(119.4) | $14.0 | $139.2 | $(123.1) | $16.1 |

---

&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense for intangible assets was $4.0 million, $9.9 million, and $13.7 million in fiscal years 2025, 2024, and 2023, respectively.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, the estimated future amortization expense of intangible assets with finite lives is as follows:

---

| | |
|:---|:---|
| **(In millions)** | |
| &nbsp;&nbsp;**Fiscal Years:** | |
| &nbsp;&nbsp;&nbsp;2026 | $4.1 |
| &nbsp;&nbsp;&nbsp;2027 | 3.8 |
| &nbsp;&nbsp;&nbsp;2028 | 3.7 |
| &nbsp;&nbsp;&nbsp;2029 | 1.9 |
| &nbsp;&nbsp;&nbsp;2030 | 0.2 |
| &nbsp;&nbsp;&nbsp;Thereafter | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $14.0 |

---

**6. BORROWINGS**

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's short-term and long-term debt:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **September 27, 2024** | | |
| **(In millions, except for percentages)** | **Amount** | **Amount** | **Contractual Interest Rate** | **Effective Interest Rate** |
| **Current maturities of long-term debt:** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible Senior Unsecured Notes | $— | $45.0 | 4.0% | 4.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other debt | 1.5 | 1.5 |  |  |
| **Total current maturities of long-term debt** | $1.5 | $46.5 |  |  |
| **Non-current maturities of long-term debt:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible Senior Unsecured Notes<sup>(1)</sup> | $— | $155.0 | 4.0% | 4.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior Secured Notes | 368.0 | 243.0 | 7.9% | 8.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other debt | 0.4 | 2.1 |  |  |
| **Total non-current maturities of long-term debt** | $368.4 | $400.1 |  |  |
| **Unamortized issuance costs and debt discounts:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs - Convertible Notes | $— | $(1.0) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unamortized issuance costs, net of debt premium - Senior Secured Notes | (2.4) | (2.2) |  |  |
| **Total unamortized issuance costs and debt discounts** | (2.4) | (3.2) |  |  |
| **Total debt outstanding, net** | $367.5 | $443.4 |  |  |

---

<sup>(1)</sup> This amount has been excluded from current liabilities as it is supported by the Revolving Credit Facility and restricted cash from the proceeds of the Senior Secured Notes Add On (as defined below), which are expected to remain outstanding for an uninterrupted period extending beyond one year from the balance sheet date.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;Future principal payments of long-term debt outstanding as of October 3, 2025 are as follows:

---

| | |
|:---|:---|
| **(In millions)** | |
| **Fiscal Years:** | |
| &nbsp;&nbsp;2026 | $1.5 |
| &nbsp;&nbsp;2027 | 368.4 |
| &nbsp;&nbsp;2028 |  |
| &nbsp;&nbsp;2029 |  |
| &nbsp;&nbsp;2030 |  |
| &nbsp;&nbsp;Thereafter |  |
| Total debt outstanding | $369.9 |
| &nbsp;&nbsp;Less: current maturities of long-term debt | (1.5) |
| Non-current portion of long-term debt | $368.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's interest expense:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Contractual interest coupon and other | $32.7 | $26.8 | $26.7 |
| Amortization of debt issuance costs | 2.8 | 3.4 | 2.6 |
| Total interest expense | $35.5 | $30.2 | $29.3 |

---

***Senior Secured Revolving Credit Facility***

&nbsp;&nbsp;&nbsp;&nbsp;On March 26, 2024, the Company entered into a senior secured revolving credit agreement (the "Credit Agreement") providing for a senior secured revolving credit facility of up to $155.0 million (the "Revolving Credit Facility"). Simultaneous with its entry into the Revolving Credit Facility, the Company terminated its $100.0 million asset-based loan revolving credit facility (the "ABL Facility"), dated as of September 30, 2020. As of October 3, 2025, the Revolving Credit Facility remains undrawn.

&nbsp;&nbsp;&nbsp;&nbsp;The maximum availability under the Revolving Credit Facility is $155.0 million, which is available to the Company for revolving loans in U.S. dollars and for the issuance of letters of credit. As of October 3, 2025, the amount available under the Revolving Credit Facility was $154.8 million. The Company may make and repay borrowings from time to time until the maturity of the Revolving Credit Facility. Borrowings under the Revolving Credit Facility will mature, and lending commitments thereunder will terminate, on September 26, 2027. The interest rate for Revolving Credit Facility borrowings is the Secured Overnight Financing Rate ("SOFR") (subject to a floor of 0.00%) plus a margin of 2.00% to 2.75%, depending on the consolidated total net leverage ratio of the Company (as defined in the Credit Agreement). Alternatively, the Company has the option of selecting a base rate equal to the highest of (a) the prime rate, (b) the Federal Funds Rate plus 0.50% and (c) the one-month SOFR (subject to a floor of 0.00%) plus a margin of 1.00%. A Base Rate Loan also has an additional margin of 1.00% to 1.75%. depending on the consolidated total net leverage ratio of the Company at that time. An unused commitment fee of 0.375% per annum was payable from March 26, 2024 until June 28, 2024, and thereafter an unused commitment fee of between 0.30% to 0.40% per annum is payable quarterly on the actual daily unused portion of the Revolving Credit Facility, depending on the consolidated total net leverage ratio of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs, including unamortized deferred costs for continuing lenders under the previously existing ABL Facility, of $2.3 million were capitalized and are included within other assets on the Consolidated Balance Sheets. These costs will be amortized over the term of the new agreement and will be recorded within interest expense in the Consolidated Statements of Operations.

&nbsp;&nbsp;&nbsp;&nbsp;The Credit Agreement contains customary covenants restricting the Company's activities, as well as those of its subsidiaries, including limitations on the ability to sell assets, engage in mergers, or other fundamental changes, enter into capital leases or certain leases not in the ordinary course of business, enter into transactions involving related parties or derivatives, incur or prepay indebtedness, grant liens or negative pledges on its assets, make loans or other investments, pay dividends or repurchase stock or other securities, guarantee third-party obligations, engage in sale leasebacks, and make changes in its corporate structure, though there are certain exceptions and carveouts related to these restrictions. One such covenant involves maintaining compensating cash balances. The Company must maintain with the Cash Management Banks (as defined in the Credit Agreement) one or more accounts and/or Bank Products (as defined in the Credit Agreement) at least 80% of its U.S. cash availability. The compensating balances may be

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

withdrawn but the availability of the Revolving Credit Facility is dependent upon maintenance of such compensating balances. In addition, the Credit Agreement includes financial covenants related to the Company's consolidated total net leverage ratio and its consolidated fixed charge coverage ratio.

&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligations under the Revolving Credit Facility are guaranteed by the Company and a number of Company subsidiaries. These guarantees are secured on a first lien basis by specified assets, including inventory, accounts receivable, cash, intercompany accounts and loans, and certain real property. In addition, the Revolving Credit Facility is secured by second liens on certain assets securing the Company's 7.875% Senior Secured Notes due 2027. An intercreditor agreement governs how the collateral securing the respective debt obligations will be treated among the secured parties.

***Equipment Credit Agreement***

&nbsp;&nbsp;&nbsp;&nbsp;On April 26, 2024, the Company entered into a secured delayed draw term loan credit agreement (the "Equipment Credit Agreement"), providing for a secured equipment credit facility of up to $20.0 million (the "Equipment Credit Facility"). On December 20, 2024, the Company terminated the Equipment Credit Agreement and recognized $0.1 million of the remaining unamortized issuance costs in interest expense in the Consolidated Statements of Operations. There was no principal balance outstanding under the Equipment Credit Facility when it was terminated.

***Convertible Senior Unsecured Notes***

&nbsp;&nbsp;&nbsp;&nbsp;On June 9, 2020, Varex issued $200.0 million in aggregate principal amount of 4.00% Convertible Senior Unsecured Notes due 2025 ("Convertible Notes"). The net proceeds from the issuance of the Convertible Notes, after deducting transaction fees and offering expense payable by the Company, were approximately $193.1 million. The Convertible Notes bore interest at the annual rate of 4.00%, payable semiannually on June 1 and December 1 of each year. On June 1, 2025, the Convertible Notes matured and were settled using $200.0 million in cash.

***Call Spread***

&nbsp;&nbsp;&nbsp;&nbsp;On June 4, 2020 and June 5, 2020, Varex entered into privately negotiated warrant transactions (collectively, the "Warrant Transactions"), whereby the Company sold warrants at a higher strike price relating to the same number of shares of Varex common stock that initially underlie the Convertible Notes, subject to customary anti-dilution adjustments. The initial strike price of the warrants is $24.975 per share (subject to adjustment under the terms of the Warrant Transactions), which was 50% above the last reported sale price of Varex common stock on June 4, 2020. The Warrant Transactions could have a dilutive effect to the Company's stockholders to the extent that the market price per share of Varex common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants. The number of shares underlying the Warrant Transactions is 9.6 million. The number of warrants outstanding as of October 3, 2025 was 9.6 million. The warrants expire after a 90 day trading period (as described in the warrant agreements) that begins on September 2, 2025.

***Senior Secured Notes***

&nbsp;&nbsp;&nbsp;&nbsp;Varex issued $300.0 million aggregate principal amount of 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes") pursuant to an indenture dated September 30, 2020. Interest payments are paid semiannually on April 15 and October 15 of each year, beginning on April 15, 2021. The Senior Secured Notes will mature on October 15, 2027, unless earlier redeemed or repurchased by Varex. On July 15, 2021, we redeemed $30.0 million, and on March 18, 2022, we redeemed $27.0 million of the Senior Secured Notes.

&nbsp;&nbsp;&nbsp;&nbsp;On December 20, 2024, the Company issued an additional $125.0 million of Senior Secured Notes (the "Senior Secured Notes Add On") pursuant to the Base Indenture, as supplemented by a supplemental indenture, dated December 20, 2024. The net proceeds from the Senior Secured Notes Add On after initial purchasers' premium, commissions, estimated fees, accrued interest in arrears, and expenses of $1.1 million, were approximately $123.9 million. The Company used the proceeds from the offering to repay a portion of the Convertible Notes on their maturity date of June 1, 2025. As of October 3, 2025, the aggregate principal amount of the outstanding Senior Secured Notes was $368.0 million.

&nbsp;&nbsp;&nbsp;&nbsp;The Senior Secured Notes are secured by a first priority lien on substantially all of the assets of Varex and the assets and capital stock of its subsidiary guarantors (subject to exceptions), except for assets for which a first priority security interest is pledged for the Revolving Credit Facility, in which the Senior Secured Notes have a second lien security interest. The Senior Secured Notes include negative covenants, subject to certain exceptions, restricting or limiting Varex's ability and the ability of its restricted subsidiaries to, among other things, incur liens on collateral; sell certain assets; incur additional indebtedness; pay dividends; issue preferred shares; consolidate, merge, or sell all or substantially all of its assets; and enter into certain transactions with their affiliates.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**7. NET (LOSS) INCOME PER SHARE**

&nbsp;&nbsp;&nbsp;&nbsp;Basic net (loss) income per common share is computed by dividing the net (loss) income for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) income per common share reflects the effects of potentially dilutive securities, which is computed by dividing the sum of net (loss) income and any adjustments to net income by the sum of the weighted average number of common shares outstanding and dilutive common shares.

&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions, except per share amounts)** | **2025** | **2024** | **2023** |
| **Net (loss) income per share - basic** |  |  |  |
| Net (loss) income attributable to Varex | $(70.3) | $(48.8) | $47.4 |
| Basic weighted average shares outstanding | 41.4 | 40.8 | 40.3 |
| &nbsp;&nbsp;Basic net (loss) income per share attributable to Varex | $(1.70) | $(1.20) | $1.18 |
| **Net (loss) income per share - diluted** |  |  |  |
| Net (loss) income attributable to Varex | $(70.3) | $(48.8) | $47.4 |
| Interest expense on Convertible Notes, net of tax |  |  | 6.2 |
| &nbsp;&nbsp;Diluted net (loss) income | $(70.3) | $(48.8) | $53.6 |
| Basic weighted average shares outstanding | 41.4 | 40.8 | 40.3 |
| &nbsp;&nbsp;Dilutive effect of Convertible Notes |  |  | 9.6 |
| &nbsp;&nbsp;Dilutive effect of share-based awards and other |  |  | 0.4 |
| Diluted weighted average shares outstanding | 41.4 | 40.8 | 50.3 |
| &nbsp;&nbsp;Diluted net (loss) income per share attributable to Varex | $(1.70) | $(1.20) | $1.07 |
| **Anti-dilutive share summary** |  |  |  |
| Share-based awards and other | 3.4 | 3.3 | 2.7 |
| Convertible notes |  | 9.6 |  |
| Warrants | 9.6 | 9.6 | 9.6 |
| &nbsp;&nbsp;Total anti-dilutive shares | 13.0 | 22.5 | 12.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying stock options, unvested stock awards, purchase rights granted under the employee stock purchase plan, warrants, and Convertible Notes using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net (loss) income per share attributable to Varex when their effect is dilutive.

**8. LEASES**

&nbsp;&nbsp;&nbsp;&nbsp;The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of less than one year to approximately ninety-three years, some of which may include options to extend the leases for up to five years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.

&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company's incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The following table presents supplemental balance sheet information related to the Company's operating and finance leases:

---

| | | | |
|:---|:---|:---|:---|
| **(In millions)** | **Balance Sheet Location** | **October 3, 2025** | **September 27, 2024** |
| **Assets** | | | |
| Operating lease right-of-use assets | *Operating lease assets* | $29.4 | $28.3 |
| Finance lease right-of-use assets | *Property, plant, and equipment, net* | 5.7 | 6.6 |
| **Liabilities** |  |  |  |
| Operating lease liabilities (current) | *Current operating lease liabilities* | 4.4 | 4.0 |
| Finance lease liabilities (current) | *Accrued liabilities and other current liabilities* | 0.4 | 0.4 |
| Operating lease liabilities (non-current) | *Operating lease liabilities* | 24.0 | 23.0 |
| Finance lease liabilities (non-current) | *Other long-term liabilities* | 5.6 | 5.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **September 27, 2024** |
| Operating lease weighted average remaining lease term (in years) | 7.7 | 7.9 |
| Operating lease weighted average discount rate | 7.2% | 8.0% |
| Finance lease weighted average remaining lease term (in years) | 13.2 | 13.9 |
| Finance lease weighted average discount rate | 6.1% | 6.1% |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information related to the Company's operating and finance leases:

---

| | | | |
|:---|:---|:---|:---|
| **(In millions)** | **2025** | **2024** | **2023** |
| Total operating lease costs<sup>(1)</sup> | $6.2 | $6.3 | $5.8 |
| &nbsp;&nbsp;Amortization of right-of-use assets | $1.0 | $0.3 | $0.2 |
| &nbsp;&nbsp;Interest on lease liabilities | 0.4 |  |  |
| Total finance lease costs | $1.4 | $0.3 | $0.2 |
| Operating cash flows from operating leases | $6.1 | $5.9 | $7.8 |
| Operating cash flows from finance leases | 0.4 |  |  |
| Financing cash flows from finance leases | 0.6 | 0.5 | 0.3 |
| &nbsp;&nbsp;**Total cash paid for amounts included in the measurement of lease liabilities** | $7.1 | $6.4 | $8.1 |
| Noncash operating right-of-use assets obtained in exchange for new lease liabilities | $8.1 | $5.4 | $10.6 |
| Noncash finance right-of-use assets obtained in exchange for new lease liabilities | 0.2 | 6.5 | 0.2 |
| &nbsp;&nbsp;**Total right-of-use assets obtained in exchange for new lease liabilities** | $8.3 | $11.9 | $10.8 |

---

<sup>(1)</sup> Includes variable and short-term lease expense, which were immaterial for fiscal years 2025, 2024, and 2023.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:

---

| | | |
|:---|:---|:---|
| **(In millions)** | | |
| **Fiscal years:** |<br>**Operating Leases** |<br>**Finance Leases** |
| 2026 | $6.2 | $0.7 |
| 2027 | 5.5 | 0.7 |
| 2028 | 4.5 | 0.6 |
| 2029 | 3.7 | 0.6 |
| 2030 | 3.6 | 0.6 |
| Thereafter | 14.0 | 5.5 |
| **Total future lease payments** | $37.5 | $8.7 |
| &nbsp;&nbsp;Less: imputed interest | (9.1) | (2.7) |
| **Present value of lease liabilities** | $28.4 | $6.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, the Company had not entered into any material leases that have not yet commenced.

**9. FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES**

&nbsp;&nbsp;&nbsp;&nbsp;As part of the Company's overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.

&nbsp;&nbsp;&nbsp;&nbsp;The Company records all derivatives on the Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case the Company would test for effectiveness on a more frequent basis. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period income. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.

&nbsp;&nbsp;&nbsp;&nbsp;Credit risk related to derivative transactions reflect the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company's exposure to the counterparty's credit risk is generally limited to the amounts, if any, by which the counterparty's obligations to the Company exceed the Company's obligations to the counterparty. The Company's policy is to enter into contracts only with financial institutions that meet certain minimum credit ratings to help mitigate counterparty credit risk.

***Derivatives Designated as Hedging Instruments - Net Investment Hedges***

&nbsp;&nbsp;&nbsp;&nbsp;The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive loss along with the foreign currency translation adjustments on those investments. During fiscal year 2023, the Company terminated all three of its previously outstanding cross currency swap contracts which resulted in cash received upon settlement of $7.3 million. The gain on the cross currency swap contracts was recorded in accumulated other comprehensive loss where it will remain until such time that substantial liquidation of the international operations should occur. Concurrent with the termination of the previous cross currency swap contracts, the Company entered into two new cross currency swap contracts which have been designated as net investment hedges.

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, the Company had the following outstanding derivatives designated as net investment hedging instruments:

---

| | | |
|:---|:---|:---|
| **(In millions, except number of instruments)** | **Number of Instruments** | **Notional Value** |
| Cross currency swap contracts | 2 | $51.8 |

---

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying Consolidated Statements of Operations where the results are recorded for net investment hedges:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Amount of Loss Recognized in OCI on Derivatives<br>Fiscal Year Ended** | **Amount of Loss Recognized in OCI on Derivatives<br>Fiscal Year Ended** | **Amount of Loss Recognized in OCI on Derivatives<br>Fiscal Year Ended** | **Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)** | **Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) <br>Fiscal Year Ended** | **Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) <br>Fiscal Year Ended** | **Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) <br>Fiscal Year Ended** |
| **(In millions)** | **2025** | **2024** | **2023** | **Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)** | **2025** | **2024** | **2023** |
| Cross currency swap contracts | $(2.7) | $(3.9) | $(4.4) | Interest expense | $0.8 | $0.9 | $0.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Consolidated Balance Sheets where the instruments are recorded:

---

| | | | |
|:---|:---|:---|:---|
| | | **Derivative Assets and Liabilities** | **Derivative Assets and Liabilities** |
| **(In millions)**<br>**Derivatives Designated as Net Investment Hedges** |<br>**Balance Sheet Location** | **October 3, 2025** | **September 27, 2024** |
| Cross currency swap contracts | Prepaid expenses and other current assets | $— | $1.0 |
| Cross currency swap contracts | Accrued liabilities and other current liabilities | 10.4 |  |
| Cross currency swap contracts | Other long-term liabilities | $— | $8.6 |

---

***Derivatives not Designated as Hedging Instruments***

&nbsp;&nbsp;&nbsp;&nbsp;During the second quarter of fiscal year 2025, the Company elected to partially dedesignate $6.9 million of the cross currency swap contracts that ceased to meet the effectiveness criteria and hedge accounting was discontinued. At the time of dedesignation, the total amount recorded for the dedesignated portion as a cumulative fair value basis adjustment on the cross currency swap was a loss of $0.4 million. The loss on the cross currency swap dedesignation is recorded in accumulated other comprehensive loss where it will remain until such time that substantial liquidation of the international operations should occur. The dedesignated cross currency swap contract is considered an economic hedge of the Company's investments in wholly-owned international operations. As such, changes in the fair value of the dedesignated cross currency swap after the date of dedesignation have been reported in other expense, net in the Consolidated Statements of Operations. During the third quarter of fiscal year 2025, the Company unwound the dedesignated portion of its outstanding cross currency swap contract which resulted in cash paid upon settlement of $0.8 million. The Company recognized $0.1 million of loss on the unwinding of the dedesignated portion, which was reported in other expense, net in the Consolidated Statements of Operations.

***Balance Sheet Hedges***

&nbsp;&nbsp;&nbsp;&nbsp;The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency-denominated monetary assets and liabilities, primarily cash, lease contracts, third-party accounts receivable and payable, and intercompany accounts receivable and payable. These forward contracts are generally entered into at the end of one fiscal period and expire by the end of the next fiscal period. These forward contracts are not designated for hedge accounting treatment; therefore, the change in fair value of these derivatives is recorded as a component of other expense, net in the Consolidated Statements of Operations and offsets the change in fair value of the foreign currency-denominated assets and liabilities, which are also recorded as a component of other expense, net. The Company has not and does not intend to use derivative financial instruments for speculative or trading purposes.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the notional amounts of outstanding foreign currency contracts as of October 3, 2025:

---

| | | |
|:---|:---|:---|
| | **Notional Value of Derivatives not Designated as Hedging Instruments:** | **Notional Value of Derivatives not Designated as Hedging Instruments:** |
| **(In millions of equivalent USD)** | **Buy Contracts** | **Sell Contracts** |
| Australian Dollar | $— | $2.9 |
| Chinese Renminbi |  | 15.6 |
| Euro |  | 27.8 |
| Japanese Yen | 7.3 |  |
| Mexican Peso |  | 1.3 |
| Philippine Peso | 16.3 |  |
| Swiss Franc | 2.4 |  |
| &nbsp;&nbsp;Total notional value | $26.0 | $47.6 |

---

**10. NONCONTROLLING INTERESTS**

&nbsp;&nbsp;&nbsp;&nbsp;In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in its Consolidated Balance Sheets and recorded the noncontrolling interests. The noncontrolling interest related to the partner's 25% interest is included in noncontrolling interests in the equity section of the Company's Consolidated Balance Sheets. Income representing the noncontrolling partner's share of income from operations is included in the Company's Consolidated Statements of Operations.

&nbsp;&nbsp;&nbsp;&nbsp;In April 2015, the Company acquired 73.5% of the then outstanding shares of MeVis Medical, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the "DPLTA") with MeVis Medical. In fiscal years 2017 and 2018, the Company purchased an additional 0.2% of outstanding shares such that the Company now owns 73.7% of the outstanding shares of common stock of MeVis Medical. Under the DPLTA, MeVis Medical subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis Medical, an annual recurring net compensation of €0.95 per MeVis Medical share. At October 3, 2025, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.

&nbsp;&nbsp;&nbsp;&nbsp;During the first quarter of fiscal year 2024, the Company acquired a controlling interest in MeVis Breastcare, in which the Company now holds an 87.1% ownership interest. In connection with this acquisition, the Company recorded an associated noncontrolling interest of $0.7 million.

&nbsp;&nbsp;&nbsp;&nbsp;The changes in noncontrolling interests were as follows:

---

| | | |
|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** |
| Noncontrolling interests, at beginning of period | $14.1 | $13.3 |
| &nbsp;&nbsp;Net income attributable to noncontrolling interests | 0.4 | 0.5 |
| &nbsp;&nbsp;Business acquisitions |  | 0.7 |
| &nbsp;&nbsp;Other | (0.5) | (0.4) |
| Noncontrolling interests, at end of period | $14.0 | $14.1 |

---

**11. EMPLOYEE STOCK PLANS**

***Employee Stock Plans***

&nbsp;&nbsp;&nbsp;&nbsp;Certain of the Company's employees participate in the Varex Imaging Corporation 2020 Omnibus Stock Plan, as Amended and Restated (the "2020 Stock Plan"), the 2017 Omnibus Stock Plan (the "2017 Stock Plan"), and the Varex Imaging Corporation 2017 Employee Stock Purchase Plan (the "2017 ESPP") which allow the grants of stock options, restricted stock units and performance shares among other types of awards to eligible employees.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, Varex stockholders approved the 2017 ESPP, which provides eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start and end of a six-month purchase period. During fiscal year 2025, the Company's Board of Directors approved an increase in the number of shares available for issuance under the 2017 ESPP of 0.9 million shares. As of October 3, 2025 the 2017 ESPP provides for the purchase of up to 2.7 million shares of Varex common stock.

***Share-Based Compensation Expense***

&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company's direct employees.

&nbsp;&nbsp;&nbsp;&nbsp;The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Cost of revenues | $2.0 | $1.8 | $1.7 |
| Research and development | 3.2 | 3.4 | 3.3 |
| Selling, general, and administrative  | 9.8 | 10.1 | 8.5 |
| &nbsp;&nbsp;&nbsp;Total share-based compensation expense | $15.0 | $15.3 | $13.5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The unrecognized share-based compensation cost as of October 3, 2025 was $20.3 million, and is expected to be recognized over a weighted average period of 2.1 years. As of October 3, 2025, there were approximately 4.5 million and 0.8 million shares of common stock available for future issuances under the 2020 Stock Plan and the 2017 ESPP, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of ESPP grants. The Company calculated the fair value of option grants and the option component of ESPP grants on the respective dates of grant using the following weighted average assumptions:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Employee Stock Option Plan** | **Employee Stock Option Plan** | **Employee Stock Option Plan** | **Employee Stock Purchase Plans** | **Employee Stock Purchase Plans** | **Employee Stock Purchase Plans** |
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Expected term (in years) |  | 6.1 | 6.9 | 0.5 | 0.5 | 0.5 |
| Risk-free interest rate | —% | 3.8% | 3.6% | 4.4% | 5.2% | 4.8% |
| Expected volatility | —% | 45.7% | 43.9% | 57.3% | 34.2% | 34.8% |
| Expected dividend | —% | —% | —% | —% | —% | —% |
| Weighted average fair value at grant date | $— | $5.85 | $9.75 | $3.79 | $3.97 | $4.96 |

---

&nbsp;&nbsp;&nbsp;&nbsp;Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.

***Risk-Free Interest Rate***

&nbsp;&nbsp;&nbsp;&nbsp;The interest rates used are based on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.

***Expected Term***

&nbsp;&nbsp;&nbsp;&nbsp;Options granted generally vest over a period of 48 months and expire 7 to 10 years from the date of grant. Employee stock purchase plan offering periods are typically 6 months and provide eligible employees with an opportunity to purchase shares of Varex common stock at 85% of the lower of its fair market value at the start or end of a six-month purchase period. The Company has elected to use the simplified method in calculating the expected term of its options due to a lack of sufficient historical information.

***Expected Dividend Yield***

&nbsp;&nbsp;&nbsp;&nbsp;The dividend rate used is zero as the Company has never paid any cash dividends on its common stock and does not anticipate doing so in the foreseeable future. The Company is also restricted from paying dividends on common stock under its debt facilities.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

***Expected Volatility***

&nbsp;&nbsp;&nbsp;&nbsp;Authoritative accounting guidance on stock-based compensation indicates that companies should consider volatility over a period generally commensurate with the expected or contractual term of the stock option. The expected volatility is based on the historical volatility of the Company's common stock.

***Stock Option Activity***

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the activity for stock options under Varex's employee incentive plans for the Company's employees:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In thousands, except per share amounts and the remaining term)** | **Options** | **Price Range** | **Weighted Average Exercise Price** | **Weighted Average Remaining Term (in years)** | **Aggregate Intrinsic Value**<sup>(1)</sup> |
| Outstanding at September 27, 2024 | 2097 | $13.61 - $37.60 | $26.79 | 5.5 | $— |
| &nbsp;&nbsp;&nbsp;Canceled, expired or forfeited | (267) | $22.13 - $37.60 | 34.84 |  |  |
| Outstanding at October 3, 2025 | 1830 | $13.61 - $31.42 | $25.61 | 5.1 | $— |
| Exercisable at October 3, 2025 | 1675 | $13.61 - $31.42 | $25.89 | 4.9 | $— |

---

<sup>(1)</sup> The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $11.94 as of October 3, 2025, the last trading date of the Company's respective fiscal years, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.

&nbsp;&nbsp;&nbsp;&nbsp;The grant-date fair value of options granted during fiscal years 2025, 2024, and 2023 was $0.0 million, $0.1 million and $4.0 million, respectively. The total intrinsic value of the options exercised during the years ended October 3, 2025, September 27, 2024, and September 29, 2023 was $0.0 million, $0.0 million and $0.1 million, respectively.

***Restricted Stock Units, Performance Stock Units, Restricted Stock Awards and Deferred Stock Units***

&nbsp;&nbsp;&nbsp;&nbsp;The Company issues performance stock units ("PSUs") to certain officers and key employees in connection with our long-term incentive program. Each PSU represents the right to receive one share of our common stock, provided that the applicable performance and vesting conditions are satisfied. The fair value of PSUs are linked to the achievement of financial performance metrics or a market condition based on our relative total shareholder return over the performance period compared to a predetermined peer group.

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards and deferred stock units under the 2020 Stock Plan:

---

| | | |
|:---|:---|:---|
| **(In thousands, except per share amounts)** | **Number of Shares** | **Weighted Average Grant-Date Fair Value** |
| Outstanding at September 27, 2024 | 1670 | $20.74 |
| &nbsp;&nbsp;&nbsp;Granted | 776 | 14.95 |
| &nbsp;&nbsp;&nbsp;Vested | (407) | 21.30 |
| &nbsp;&nbsp;&nbsp;Canceled or expired | (93) | 20.40 |
| Outstanding at October 3, 2025 | 1946 | $18.35 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The total grant-date fair value of shares granted was $11.6 million, $17.2 million, and $11.3 million for fiscal years 2025, 2024, and 2023, respectively. Shares outstanding at October 3, 2025, September 27, 2024, and September 29, 2023 had an estimated market value of $23.2 million, $20.0 million, and $24.0 million, respectively.

**12. TAXES ON INCOME (LOSS)**

&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense or benefit is based on reported income or loss before income taxes. Deferred income taxes reflect the effect of temporary differences between asset and liability amounts that are recognized for financial reporting purposes and the amounts that are recognized for income tax purposes. These deferred taxes are measured by applying currently enacted tax laws. Valuation allowances are recognized to reduce deferred tax assets to the amount that is more likely than not to be realized.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The income tax expense (benefit) was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Current income tax expense: |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $4.6 | $9.7 | $9.8 |
| &nbsp;&nbsp;&nbsp;State and local | 0.5 | 0.6 | 0.3 |
| &nbsp;&nbsp;&nbsp;Foreign | 6.3 | 4.6 | 12.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current | $11.4 | $14.9 | $22.7 |
| Deferred income tax (benefit) expense: |  |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $— | $38.5 | $(37.9) |
| &nbsp;&nbsp;&nbsp;State and local | (0.2) | (1.1) | (0.2) |
| &nbsp;&nbsp;&nbsp;Foreign | (0.5) | 1.0 | (1.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred | (0.7) | 38.4 | (39.3) |
| Income tax expense (benefit) | $10.7 | $53.3 | $(16.6) |

---

&nbsp;&nbsp;&nbsp;&nbsp;The (loss) income before taxes are generated from the following geographic areas:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| United States | $(25.8) | $(15.1) | $(6.2) |
| Foreign | (33.4) | 20.1 | 37.5 |
| &nbsp;&nbsp;&nbsp;(Loss) income before taxes | $(59.2) | $5.0 | $31.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The effective tax rate differs from the U.S. federal statutory tax rate as a result of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** | **2023** |
| Federal statutory income tax rate | 21.0% | 21.0% | 21.0% |
| State and local taxes, net of federal tax benefit | (0.4) | (7.5) | 0.3 |
| Impairment of goodwill | (33.3) |  |  |
| Statutory rate change impact on prior year deferreds |  | (0.3) |  |
| Return to provision | 1.3 | (30.9) | (4.7) |
| Research and development credit | 5.0 | (41.9) | (8.4) |
| Foreign rate difference | (3.0) | (1.6) | 6.3 |
| Share-based compensation | (2.7) | 43.6 | 3.8 |
| Change in valuation allowance | (7.1) | 1101.1 | (65.7) |
| U.S. tax reform - international provisions | 2.1 | (32.0) | (9.2) |
| Other | (1.0) | 14.5 | 3.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effective tax rate | (18.1)% | 1066.0% | (53.0)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2025, the Company's effective tax rate varied from the U.S. federal statutory rate of 21% primarily due to the goodwill impairment that took place in the third quarter of fiscal year 2025, the unfavorable impact of U.S. deferred tax attributes and losses in certain foreign jurisdictions for which a valuation allowance is provided, as well as profit in foreign jurisdictions with statutory tax rates greater than 21%. These unfavorable items were partially offset by the favorable impact of U.S. tax reform regarding international provision, R&D credits, and return to provision adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;The Organization for Economic Cooperation and Development enacted model rules for Pillar Two, which became effective for the Company in fiscal year 2025. However, on June 28, 2025, the G7 released a joint statement that it had reached an understanding with the United States for a side-by-side system based on certain accepted principles, including that U.S.-parented groups, such as ours, would be exempted from certain provisions of Pillar Two. As a result, there remains a great deal of uncertainty

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

as to the final Pillar Two model rules applicable to our Company and its subsidiaries. The Company has estimated its fiscal year 2025 Pillar Two tax expense, and has included these amounts in the calculation of the fiscal year 2025 tax provision.

&nbsp;&nbsp;&nbsp;&nbsp;On July 4, 2025, the OBBBA was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions, including the option to claim 100% accelerated depreciation deductions and qualified property, with retrospective application beginning January 20, 2025. The legislation has multiple effective dates, with the 100% accelerated depreciation deduction starting to be effective during the fiscal year ended October 3, 2025, and others implemented through future years.

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2024, the Company's effective tax rate varied from the U.S. federal statutory rate of 21% primarily due to the unfavorable impact of U.S. deferred tax attributes and losses in certain foreign jurisdictions for which a valuation allowance is provided, as well as profit in foreign jurisdictions with statutory tax rates greater than 21%. These unfavorable items were partially offset by the favorable impact of U.S. tax reform regarding international provision, R&D credits, and return to provision adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2023, the Company's effective tax rate varied from the U.S. federal statutory rate of 21% primarily due to the favorable impact of the release of the U.S. valuation allowance, U.S. tax reform regarding international provisions, R&D credits, and return to provision adjustments. These favorable items were partially offset by the unfavorable impact of profit in foreign jurisdictions with statutory tax rates greater than 21%.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The significant components of deferred tax assets and liabilities are as follows:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| **Deferred tax assets:** | | |
| &nbsp;&nbsp;&nbsp;Inventory adjustments | $4.4 | $4.7 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 6.8 | 6.3 |
| &nbsp;&nbsp;&nbsp;Product warranty | 1.6 | 2.0 |
| &nbsp;&nbsp;&nbsp;Unrealized exchange gain | 3.7 | 3.0 |
| &nbsp;&nbsp;&nbsp;Deferred compensation | 2.0 | 1.7 |
| &nbsp;&nbsp;&nbsp;Net operating loss carryforwards | 18.6 | 18.9 |
| &nbsp;&nbsp;&nbsp;Accrued vacation | 0.6 | 0.6 |
| &nbsp;&nbsp;&nbsp;Accrued incentives | 0.9 | 0.3 |
| &nbsp;&nbsp;&nbsp;Credit carryforwards | 4.2 | 3.6 |
| &nbsp;&nbsp;&nbsp;Deferred financing fees | 0.1 | 2.5 |
| &nbsp;&nbsp;&nbsp;Interest expense limitation | 1.1 |  |
| &nbsp;&nbsp;&nbsp;Capitalized interest | 1.0 | 1.1 |
| &nbsp;&nbsp;&nbsp;Lease liabilities | 6.4 | 7.5 |
| &nbsp;&nbsp;&nbsp;Investments in privately held companies | 4.2 | 4.0 |
| &nbsp;&nbsp;&nbsp;Royalty advance | 1.5 | 6.6 |
| &nbsp;&nbsp;&nbsp;Research and experimentation capitalization | 37.8 | 30.8 |
| &nbsp;&nbsp;&nbsp;Other DTA | 5.2 | 3.9 |
|  | $100.1 | $97.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Valuation allowance | (79.4) | (74.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total deferred tax assets** | $20.7 | $22.8 |
| **Deferred tax liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Acquired intangibles | $(3.4) | $(3.9) |
| &nbsp;&nbsp;&nbsp;Property, plant and equipment | (5.7) | (7.1) |
| &nbsp;&nbsp;&nbsp;Goodwill amortization |  | (6.0) |
| &nbsp;&nbsp;&nbsp;Operating lease assets | (6.1) | (7.3) |
| &nbsp;&nbsp;&nbsp;Other DTL | (8.1) | (1.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total deferred tax liabilities** | (23.3) | (25.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net deferred tax liabilities** | $(2.6) | $(2.7) |
| **Reported As:** |  |  |
| &nbsp;&nbsp;&nbsp;Deferred tax assets | $20.7 | $22.8 |
| &nbsp;&nbsp;&nbsp;Deferred tax liabilities | (23.3) | (25.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net deferred tax liabilities** | $(2.6) | $(2.7) |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company is maintaining its reinvestment assertion with respect to foreign earnings for the year ended October 3, 2025, which is that all earnings prior to fiscal year 2018 are permanently reinvested for all countries, and that all earnings for Varex Imaging Sweden and Oy Varex Imaging Finland, are also indefinitely reinvested in those countries, but post fiscal year 2017 earnings in all other countries are not permanently reinvested. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. state income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend.

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025, the Company had foreign net operating loss carryforwards ("NOL") of approximately $89.6 million carried forward indefinitely.

&nbsp;&nbsp;&nbsp;&nbsp;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. Also, net operating loss carryforwards in jurisdictions with current losses provide uncertainty for realization. As of October 3, 2025,

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

based on the Company's assessment of the realizability of net deferred tax assets, it reached the conclusion that it was more likely than not that one of its Indian subsidiaries' deferred tax assets are not realizable. As a result, a valuation allowance was placed against the subsidiaries' Indian deferred tax assets. The Company also maintains full valuation allowances against the net deferred tax assets in Sweden, the United Kingdom, the United States, and Saudi Arabia, due to recent historical losses and/or the uncertainty of future taxable income to realize those net operating losses. The valuation allowance increased by $4.7 million during fiscal year 2025 and increased by $56.0 million during fiscal year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;The changes in the Company's valuation allowance for deferred tax assets were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Valuation allowance balance–beginning of fiscal year | $74.7 | $18.7 | $32.2 |
| &nbsp;&nbsp;&nbsp;Other increases | 4.7 | 56.0 |  |
| &nbsp;&nbsp;&nbsp;Other decreases |  |  | (13.5) |
| Valuation allowance balance—end of fiscal year | $79.4 | $74.7 | $18.7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for uncertainty in income taxes following a two-step approach for recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that, based on the technical merits, the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.

&nbsp;&nbsp;&nbsp;&nbsp;The changes in the Company's unrecognized tax benefits were as follows:

---

| | | |
|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** |
| Unrecognized tax benefits balance–beginning of fiscal year | $1.6 | $1.4 |
| &nbsp;&nbsp;&nbsp;Additions based on tax positions related to the current year | 0.2 | 0.2 |
| &nbsp;&nbsp;&nbsp;Reductions resulting from the expiration of the applicable statute of limitations | (0.5) |  |
| Unrecognized tax benefits balance—end of fiscal year | $1.3 | $1.6 |

---

&nbsp;&nbsp;&nbsp;&nbsp;As of October 3, 2025 and September 27, 2024, the total amount of gross unrecognized tax benefits was $1.3 million and $1.6 million, respectively, all of which would affect the effective tax rate if recognized.

&nbsp;&nbsp;&nbsp;&nbsp;The Company includes interest and penalties related to income taxes within income tax expense (benefit) on the Consolidated Statements of Operations. Interest and penalties of $0.1 million, $0.2 million, and $0.2 million were included for the fiscal periods ended October 3, 2025, September 27, 2024, and September 29, 2023, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;The Company files U.S. federal and state income tax returns and non-U.S. income tax returns in various jurisdictions. All of these returns are subject to examination by their respective taxing jurisdictions from the date of filing through each applicable statute of limitation period. Other periods for entities acquired are still open and subject to examination. Generally, periods prior to 2015 are no longer subject to examination.

**13. SEGMENT INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;The Company has two reportable operating segments: Medical and Industrial, which aligns with how its CEO, who is the Company's Chief Operating Decision Maker ("CODM") reviews the Company's performance. The segments align the Company's products and service offerings with customer use in medical and industrial markets and are consistent with how the Company's CEO evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross profit. The operating and reportable segment structure provides alignment between business strategies and operating results.

***Description of Segments***

&nbsp;&nbsp;&nbsp;&nbsp;The Medical segment designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, automatic exposure control devices, generators, and heat exchangers.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses.

&nbsp;&nbsp;&nbsp;&nbsp;The Industrial segment designs, develops, manufactures, sells and services X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other vertical markets, as well as X-ray imaging systems for industrial applications. The Company's industrial products include Linatron® X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers. In addition, the Company licenses proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to industrial customers.

&nbsp;&nbsp;&nbsp;&nbsp;Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company's operations to similar operations of other companies may not be meaningful.

&nbsp;&nbsp;&nbsp;&nbsp;Information related to the Company's segments is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Revenues, net |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical | $592.6 | $581.7 | $673.3 |
| &nbsp;&nbsp;&nbsp;Industrial | 252.0 | 229.3 | 220.1 |
| Total revenues | 844.6 | 811.0 | 893.4 |
| Cost of revenues |  |  |  |
| &nbsp;&nbsp;Medical | 392.5 | 405.0 | 467.8 |
| &nbsp;&nbsp;Industrial | 161.6 | 149.1 | 135.3 |
| Total cost of revenues | 554.1 | 554.1 | 603.1 |
| Gross profit |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical | 200.1 | 176.7 | 205.5 |
| &nbsp;&nbsp;&nbsp;Industrial | 90.4 | 80.2 | 84.8 |
| Total gross profit | 290.5 | 256.9 | 290.3 |
| Total operating expenses | 318.3 | 224.8 | 213.2 |
| Interest and other expense, net | (31.4) | (27.1) | (45.8) |
| (Loss) income before taxes | (59.2) | 5.0 | 31.3 |
| Income tax expense (benefit) | 10.7 | 53.3 | (16.6) |
| Net (loss) income | (69.9) | (48.3) | 47.9 |
| Less: Net income attributable to noncontrolling interests | 0.4 | 0.5 | 0.5 |
| Net (loss) income attributable to Varex | $(70.3) | $(48.8) | $47.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The Company does not disclose total assets by segment as this information is not provided to the CODM.

***Geographic Information***&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's long-lived assets by geographic region:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| &nbsp;&nbsp;Americas | $102.7 | $109.2 |
| &nbsp;&nbsp;EMEA | 40.9 | 27.6 |
| &nbsp;&nbsp;APAC | 14.2 | 16.6 |
| Total property, plant, and equipment, net | $157.8 | $153.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;See Note 2, *Revenue,* for disaggregation of revenue by geographic region and country.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**14. OTHER FINANCIAL INFORMATION**&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's accrued liabilities and other current liabilities:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| Accrued compensation and benefits | $43.4 | $30.0 |
| Product warranty | 8.5 | 10.8 |
| Taxes payable | 5.3 | 8.1 |
| Refund liability | 7.7 | 7.5 |
| Derivative liability | 10.4 |  |
| Accrued interest | 13.5 | 11.7 |
| Other | 9.6 | 10.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total accrued liabilities and other current liabilities | $98.4 | $78.6 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's other long-term liabilities:

---

| | | |
|:---|:---|:---|
| **(In millions)** | **October 3, 2025** | **September 27, 2024** |
| Long-term income tax payable | $2.3 | $4.0 |
| Environmental liabilities | 2.4 | 3.0 |
| Defined benefit obligation liability | 6.2 | 5.9 |
| Long-term refund liability | 20.0 | 20.5 |
| Derivative liability |  | 8.6 |
| Long-term other | 7.2 | 8.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other long-term liabilities | $38.1 | $50.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the Company's other expense, net:

---

| | | | |
|:---|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** | **Fiscal Years** |
| **(In millions)** | **2025** | **2024** | **2023** |
| Loss from equity method investments | $(2.3) | $(1.0) | $(1.4) |
| Gain on purchase of business |  | 2.1 |  |
| Impairment of equity method investment |  |  | (16.4) |
| Realized losses on foreign currencies, net | (3.0) | (2.3) | (1.0) |
| Other | 0.9 | (3.0) | (1.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense, net | $(4.4) | $(4.2) | $(20.2) |

---

**15. BUSINESS COMBINATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;As of September 29, 2023, the Company, through two of its consolidated subsidiaries, Varex Imaging Deutschland AG and MeVis Medical Solutions AG ("MeVis Medical"), held a combined ownership interest in MeVis BreastCare GmbH and MeVis BreastCare Gmbh & Co KG (referred to in combination as "MeVis Breastcare") of 37.6%. Because the Company had the ability to exercise significant influence in, but not control, over MeVis Breastcare, it was historically accounted for as an equity method investment.

&nbsp;&nbsp;&nbsp;&nbsp;During the first quarter of fiscal year 2024, the Company increased its ownership in MeVis Breastcare to 87.1% for a purchase price of $0.9 million, resulting in the Company now holding a controlling interest in MeVis Breastcare. The purchase of this additional ownership interest was accounted for as a business combination achieved in stages, or step acquisition. As a result, the previously held equity interest was remeasured to its acquisition-date fair value, with a gain of $0.9 million recognized in other expense, net in the Consolidated Statements of Operations. The assets and liabilities of MeVis Breastcare were then recorded on the Company's balance sheet at their fair values in accordance with ASC 805, and a gain on bargain purchase of $1.2 million was recorded during the first quarter of fiscal year 2024 in other expense, net in the Consolidated Statements of Operations. Because the purchase price did not give consideration to the other assets of the business, the fair value of the ownership interest acquired exceeded the price paid to the third party partial owner and this resulted in a gain on bargain purchase.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare:

---

| | |
|:---|:---|
| | **USD<br>(in millions)** |
| **Consideration paid** | |
| Cash | $0.9 |
| Fair value of total consideration transferred | 0.9 |
| **Remeasurement of previous equity interest** |  |
| Carrying value of previous equity interest before acquisition | 1.1 |
| Fair value of previous equity interest at acquisition date | 2.0 |
| Remeasurement gain recorded on previous equity interest | 0.9 |
| **Total of consideration paid and fair value of previous equity interest** | $2.9 |
| **Recognized amounts of identifiable assets acquired and liabilities assumed** |  |
| Cash and cash equivalents | $1.8 |
| Accounts receivable, net | 1.2 |
| Intangible assets, net | 2.6 |
| Accounts payable | (0.1) |
| Accrued liabilities and other current liabilities | (0.6) |
| Other long-term liabilities | (0.1) |
| Total identifiable net assets | 4.8 |
| Noncontrolling interest in MeVis Breastcare | (0.7) |
| Bargain purchase gain | (1.2) |
| **Total** | $2.9 |

---

**16. COMMITMENTS AND CONTINGENCIES**

***Lease Commitments***

&nbsp;&nbsp;&nbsp;&nbsp;See Note 8, *Leases,* for additional information about the Company's lease commitments.

***Other Commitments***

&nbsp;&nbsp;&nbsp;&nbsp;See Note 3, *Related-Party Transactions,* for additional information about the Company's commitments to dpiX.

&nbsp;&nbsp;&nbsp;&nbsp;See Note 10, *Noncontrolling Interests,* for additional information about the Company's commitment to the noncontrolling shareholders of MeVis.

&nbsp;&nbsp;&nbsp;&nbsp;The Company has an environmental liability of approximately $3.2 million as of October 3, 2025. See Note 1, *Summary of Significant Accounting Policies,* for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;The Company enters into purchase agreements with its suppliers in the ordinary course of its business for the purchase of goods and services. Some of these purchase agreements are non-cancellable and thus contractually obligate the Company to future cash payments. The Company has non-cancellable supplier purchase obligations of approximately $3.0 million as of October 3, 2025.

***Contingencies***

&nbsp;&nbsp;&nbsp;&nbsp;The Company did not have any material contingent liabilities as of October 3, 2025 and September 27, 2024. Legal expenses are expensed as incurred.

------

<u>[**Table of Contents**](#i8474629358084e7786308a95e9f157ba_1835)</u>

**17. EMPLOYEE BENEFIT PLANS**

&nbsp;&nbsp;&nbsp;&nbsp;Varex's 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan's related trust intended to be tax exempt under Section 501(a) of the Code and intended for all full-time employees in the United States. This plan allows employees to contribute a portion of their pretax salary up to the maximum dollar limitation prescribed by the Internal Revenue Service. The Company made matching contributions to the plan totaling $4.4 million, $4.6 million, and $4.9 million in fiscal years 2025, 2024, and 2023, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;The Company also maintains defined benefit plans for certain employees located outside the United States. The net pension liability is included in other long-term liabilities on the Company's Consolidated Balance Sheets and totaled $6.2 million and $5.9 million as of October 3, 2025 and September 27, 2024, respectively. The Company's net periodic benefit costs for the Company's defined benefit plans were not material for fiscal years 2025, 2024, and 2023.

**18. ACCUMULATED OTHER COMPREHENSIVE LOSS**

&nbsp;&nbsp;&nbsp;&nbsp;The following tables present the changes in the accumulated balances for each component of accumulated other comprehensive loss:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(In millions)** | **Gain on Forward Contracts** | **Unrealized Loss on Defined Benefit Obligations** | **CTA, Including Impact of Net Investment Hedge** | **Unrealized (Loss) Gain on Available-For-Sale Securities** | **Accumulated Other Comprehensive Loss** |
| Balance at September 29, 2023 | $(0.5) | $(0.4) | $(0.3) | $— | $(1.2) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications |  |  | (3.9) | 0.1 | (3.8) |
| &nbsp;&nbsp;Adjustments reclassified out of accumulated other comprehensive loss | 0.1 |  |  |  | 0.1 |
| &nbsp;&nbsp;Foreign currency translation adjustment |  |  | 2.0 |  | 2.0 |
| Balance at September 27, 2024 | $(0.4) | $(0.4) | $(2.2) | $0.1 | $(2.9) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications |  | 0.1 | (2.7) | (0.1) | (2.7) |
| &nbsp;&nbsp;Adjustments reclassified out of accumulated other comprehensive loss | 0.1 |  |  |  | 0.1 |
| &nbsp;&nbsp;Income tax impact |  | (0.1) |  |  | (0.1) |
| &nbsp;&nbsp;Foreign currency translation adjustment |  |  | 0.4 |  | 0.4 |
| Balance at October 3, 2025 | $(0.3) | $(0.4) | $(4.5) | $— | $(5.2) |

---

**19. SUBSEQUENT EVENTS**

&nbsp;&nbsp;&nbsp;&nbsp;On October 14, 2025, the Company purchased certain equipment, inventory, and other assets to be used in the Company's operations. The Company anticipates accounting for the transaction as an asset acquisition in accordance with U.S. GAAP. The purchase price for the asset acquisition was $3.6 million.

## Exhibit 4.1

**Exhibit 4.1**

**DESCRIPTION OF VAREX'S CAPITAL STOCK**

*The following is a summary of the material terms of Varex's capital stock contained in Varex's amended and restated certificate of incorporation and bylaws and the in the Delaware General Corporation Law ("DGCL"). The summaries and descriptions below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, bylaws or the DGCL.*

**General**

Varex's authorized capital stock consists of 150 million shares of common stock, par value $0.01 per share, and 20 million shares of preferred stock, par value $0.01 per share, all of which shares of preferred stock are undesignated. Varex's board of directors may establish the rights and preferences of the preferred stock from time to time.

**Common Stock**

Each holder of Varex common stock is entitled to one vote for each share on all matters to be voted upon by the common stockholders, and there are no cumulative voting rights. Subject to any preferential rights of any outstanding preferred stock, holders of Varex common stock are entitled to receive ratably the dividends, if any, declared from time to time by Varex's board of directors out of funds legally available for that purpose. If there is a liquidation, dissolution or winding up of Varex, holders of its common stock would be entitled to ratable distribution of its assets remaining after the payment in full of liabilities and any preferential rights of any then-outstanding preferred stock.

Holders of Varex common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of Varex common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of Varex common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that Varex may designate and issue in the future.

**Preferred Stock**

Varex's board of directors is authorized, subject to limitations prescribed by the DGCL and by Varex's amended and restated certificate of incorporation, to issue up to 20 million shares of preferred stock in one or more series without further action by the holders of its common stock. Varex's board of directors have the discretion, subject to limitations prescribed by the DGCL and by Varex's amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.

**Anti-Takeover Effects of Various Provisions of Delaware Law and Varex's Certificate of Incorporation and Bylaws**

Provisions of the DGCL and Varex's amended and restated certificate of incorporation and bylaws could make it more difficult to acquire Varex by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and takeover bids that Varex's board of directors may consider inadequate and to encourage persons seeking to acquire control of Varex to first negotiate with Varex's board of directors. Varex believes that the benefits of increased protection of its ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure it outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms.

***Delaware Anti-Takeover Statute****.* Varex is subject to Section 203 of the DGCL, an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a "business

------

combination" with an "interested stockholder" for a period of three years following the time the person became an interested stockholder, unless (i) prior to such time, the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) the voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender or vote stock held by the plan); or (iii) on or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock of such corporation not owned by the interested stockholder. Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation's voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by Varex's board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by Varex's stockholders.

***Classified Board****.* Varex's amended and restated certificate of incorporation and bylaws provide that its board of directors was initially divided into three classes, two of which are comprised of two directors and one of which is comprised of three directors. In connection with the spin-off of Varex from Varian, directors of each class were initially elected for staggered three-year terms. In accordance with Varex's certificate of incorporation, (i) commencing with the class of directors standing for election at the Company's 2020 annual meeting, directors will stand for election for a two-year term; (ii) commencing with the class of directors standing for election at the Company's 2021 annual meeting, directors will stand for election for a one-year term; and (iii) commencing with the Company's 2022 annual meeting, and at each annual meeting thereafter, all directors will stand for election for a one-year term. Until the board is declassified, it would take at least two elections of directors for any individual or group to gain control of Varex's board of directors. Accordingly, these provisions could discourage a third party from initiating a proxy contest, making a tender offer or otherwise attempting to gain control of Varex.

At any meeting of stockholders for the election of directors at which a quorum is present, the election will be determined by a majority of the votes cast by the stockholders entitled to vote in the election, with directors not receiving a majority of the votes cast required to tender their resignations for consideration by the board, except that in the case of a contested election, the election will be determined by a plurality of the votes cast by the stockholders entitled to vote in the election.

***Removal of Directors****.* For so long as the Varex board of directors is classified, Varex's amended and restated certificate of incorporation provides that its stockholders may remove its directors only for cause, by an affirmative vote of holders of at least a majority of Varex's voting stock then-outstanding. Following the 2022 annual meeting, Varex's stockholders may remove its directors with or without cause by an affirmative vote of at least a majority of Varex's voting stock then-outstanding.

***Amendments to Certificate of Incorporation****.* Varex's amended and restated certificate of incorporation provide that the affirmative vote of the holders of at least 66 2/3% of its voting stock then-outstanding is required to amend certain provisions relating to the term and removal of its directors, the filling of its board vacancies, the calling of special meetings of stockholders, stockholder action by written consent, the elimination of liability of directors to the extent permitted by Delaware law and indemnification of directors and officers. The provisions of the amended and restated certificate of incorporation relating to the 66 2/3% voting threshold will be of no force and effect effective as of the completion of the 2021 annual meeting of stockholders and the amended and restated certificate of incorporation may thereafter be amended by the affirmative vote of the holders of at least a majority of the outstanding voting stock then-outstanding.

***Amendments to Bylaws****.* Varex's amended and restated bylaws provide that they may be amended by Varex's board of directors or by the affirmative vote of holders of a majority of Varex's voting stock then-outstanding.

***Size of Board and Vacancies****.* Varex's amended and restated bylaws provide that the number of directors on its board of directors will be fixed exclusively by its board of directors, except that the minimum number of

------

directors will be three. Any vacancies created in its board of directors resulting from any increase in the authorized number of directors or the death, resignation, retirement, disqualification, removal from office or other cause will be filled by a majority of the board of directors then in office, even if less than a quorum is present, or by a sole remaining director. Any director appointed to fill a vacancy on Varex's board of directors will be appointed for a term expiring at the next election of the class for which such director has been appointed, and until his or her successor has been elected and qualified.

***Special Stockholder Meetings****.* Varex's amended and restated certificate of incorporation provides that only the board of directors, pursuant to a resolution adopted by the majority of the whole board, or the chairman of the board of directors may call special meetings of Varex stockholders. The majority of the board of directors must concur with the calling of the meeting by the chairman. Stockholders may not call special stockholder meetings.

***Stockholder Action by Written Consent****.* Varex's amended and restated certificate of incorporation expressly eliminates the right of its stockholders to act by written consent effective as of the distribution. Stockholder action must take place at the annual or a special meeting of Varex stockholders.

***Requirements for Advance Notification of Stockholder Nominations and Proposals****.* Varex's certificate of incorporation mandates that stockholder nominations for the election of directors will be given in accordance with the bylaws. The amended and restated bylaws will establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors as well as minimum qualification requirements for stockholders making the proposals or nominations. Additionally, the bylaws require that candidates for election as director disclose their qualifications and make certain representations.

***No Cumulative Voting****.* The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors unless the company's certificate of incorporation provides otherwise. Varex's amended and restated certificate of incorporation do not provide for cumulative voting.

***Undesignated Preferred Stock****.* The authority of Varex's board of directors to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control of Varex's company through a merger, tender offer, proxy contest or otherwise by making such attempts more difficult or more costly. Varex's board of directors may be able to issue preferred stock with voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of common stock.

**Limitations on Liability, Indemnification of Officers and Directors and Insurance**

The DGCL authorizes corporations to limit or eliminate the personal liability of directors and officers to corporations and their stockholders for monetary damages for breaches of directors' and officers' fiduciary duties as directors and officers, and Varex's amended and restated certificate of incorporation includes such exculpation provisions. Varex's amended and restated certificate of incorporation and bylaws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of Varex, or for serving at Varex's request as a director or officer or another position at another corporation or enterprise, as the case may be. Varex's amended and restated certificate of incorporation and bylaws also provide that Varex must indemnify and advance reasonable expenses to its directors and officers, subject to its receipt of an undertaking from the indemnified party as may be required under the DGCL. Varex's amended and restated certificate of incorporation will expressly authorize Varex to carry directors' and officers' insurance to protect Varex, its directors, officers and certain employees for some liabilities.

The limitation of liability and indemnification provisions in Varex's amended and restated certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against Varex's directors and officers, even though such an action, if successful, might otherwise benefit Varex and its stockholders. However, these provisions do not limit or eliminate Varex's rights, or those of any stockholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director's duty of care. The provisions do not alter the liability of directors under the federal securities laws.

**Exclusive Forum**

------

Varex's amended and restated certificate of incorporation provide that unless the board of directors otherwise determines, the state courts located within the State of Delaware or, if no state court located in the State of Delaware has jurisdiction, the federal court for the District of Delaware, will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of Varex, any action asserting a claim of breach of a fiduciary duty owed by any director or officer of Varex to Varex or Varex's stockholders, any action asserting a claim against Varex or any director or officer of Varex arising pursuant to any provision of the DGCL or Varex's amended and restated certificate of incorporation or bylaws, or any action asserting a claim against Varex or any director or officer of Varex governed by the internal affairs doctrine.

**Authorized but Unissued Shares**

Varex's authorized but unissued shares of common stock and preferred stock may be issued without stockholder approval. Varex may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of Varex by means of a proxy contest, tender offer, merger or otherwise.

## Exhibit 10.20

**Exhibit 10.20**

**<u>EXECUTIVE TRANSITION, SEPARATION AND RELEASE AGREEMENT</u>**

This Executive Transition, Separation and Release Agreement ("Agreement") is made and entered into between Kimberley Honeysett ("Employee'') and Varex Imaging Corporation ("Varex" or the "Company") (collectively the "Parties," and one of the Parties a "Party").

**<u>RECITALS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.WHEREAS, Employee is employed by Varex as Chief Legal Officer, General Counsel and Corporate Secretary ("CLO");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.WHEREAS, Employee will continue to be employed and work in her current capacity until October 3, 2025 (the "Transition Date"), and then as a non-executive employee or advisor until December 12, 2027 (the "Separation Date") (the period between the Transition Date and the Separation Date being the "Continued Service Period");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.WHEREAS, the Parties wish to enter into this Agreement to outline the terms and conditions of Employee's employment during the Continued Service Period; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.WHEREAS, Employee and Varex wish to fully and finally settle all issues, differences, and claims, whether potential or actual, between Employee and Varex, including, but not limited to, any claims that might arise out of Employee's employment with Varex or the end of Employee's employment with Varex.

**<u>AGREEMENT</u>**

NOW THEREFORE, in consideration of the recitals stated above and the mutual promises made below and in the exhibits attached hereto, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.<u>RECITALS.</u>** The Parties acknowledge that the "RECITALS" clauses preceding this Section 1 are true and correct and hereby incorporated herein by this reference as material parts and definitions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.<u>CONTINUED SERVICE PERIOD AND OTHER EMPLOYMENT.</u>** At the time of the Transition Date, Employee shall step down and be relieved of all responsibilities and duties as CLO and undertake a coordinated effort to most effectively transition out of and/or tender resignations as to any and all officer or director roles with Varex or its affiliates. During the Continued Service Period, Employee will report to Varex's Chief Executive Officer and will perform all reasonably requested services in a professional manner. In addition, while considered an employee, Employee agrees to act in the best interests of Varex and in accordance with the Varex Code of Conduct, Global Anti-Corruption Policy, and the U.S. Employee Handbook, and to assist Varex with reasonable requests for assistance including responding to questions, providing information, transitioning out of affiliate officer and direct positions at Varex's request, and cooperatively transitioning her duties and on-going projects to others at Varex. Notwithstanding the foregoing, during the Continued Service Period, Varex may, in its own discretion, relieve Employee of all duties and during the Continued Service Period Employee may work remotely and be available for in person meetings as reasonably necessary and upon reasonable notice. The requested services from Employee during the Continued Service Period

------

will not include her providing legal advice to Varex and she will not be contacting nor expected to contact customers, vendors, investors or other stakeholders of Varex. The required services from Employee during the Continued Service Period is expected to not exceed one hundred hours per year, except where additional time may be needed for certain projects or input or participation in litigation matters. To the extent additional time is requested by Varex, Employee will be reimbursed for time at an hourly rate to be separately agreed, plus expenses incurred. Employee is permitted to obtain or secure other employment during this period, recognizing that Employee has confidentiality, ethical and other obligations to Varex that continue after employment. At such time as other employment is secured, Employee's employment with Varex shall be transitioned to a consultant arrangement without any break in service for the remainder of the Continued Service Period. If at that time Employee is eligible for benefits with a new Employer, then Employee shall obtain such benefits and benefits shall conclude with Varex as of the date that Employee is eligible for benefits with her new employer such that she will not experience any break in coverage. If Employee does not secure new employment and benefits, then benefits shall continue through Varex or through COBRA reimbursed benefits through the Separation Date and any applicable tail period. Prior to accepting new employment, Employee agrees to notify Varex of such potential employment and both parties agree to discuss potential conflicts of interest, competitive services concerns, confidential information, and related issues. As appropriate after the Transition Date, and before any different employment is secured by Employee, Varex reserves the right to limit access to all Varex systems, confidential and proprietary information, and company data. Employee also agrees to inform any such future employer of her obligations under this Agreement and Varex is also permitted to share such obligations if necessary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.<u>CONSIDERATION.</u>** In exchange for Employee executing and not revoking or rescinding this Agreement, as described in Section 17, and provided that Employee's service has not terminated prior to the Separation Date and Employee executes by December 1, 2027 at the time of the Separation Date, the second release attached hereto as Exhibit A and described below in Section 5 (the "Second Release"), Varex agrees to provide the following consideration:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Continued Service Period and Compensation.</u> Despite no independent requirement outside of this Agreement to maintain Employee's employment through the Separation Date, Varex shall provide Employee with the Continued Service Period and the following compensation. Employee will continue to be paid at her current annual salary of $424,000.00 through the Transition Date, through the regular payroll process. Following that, during the Continued Service Period and through the Separation Date (approximately 26.5 months), Employee will be paid salary continuation in the total amount of $424,000.00 over the first 12 months of the Continued Service Period, followed by payment of an aggregate of $100,000.00 during the remainder of the Continued Service Period, for a combined total of $524,000.00, all of which is subject to all applicable and proper wage withholdings, paid on a bi-weekly basis through the Company's normal payroll process.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Management Incentive Plan Participation.</u> In addition to the foregoing, after the Effective Date of this Agreement and subject to performance conditions and board discretion applicable to all eligible employees, Varex will (i) pay to Employee the Management Incentive Plan ("MIP") bonus amounts earned for FY25 following board approval of FY25 MIP

------

per normal MIP approval process; and (ii) pay to Employee the MIP bonus amount earned, if any, for FY26 calculated based upon company's FY26 MIP attainment as approved by Varex's board of directors or committee thereof per normal MIP approval process, using employee's FY25 rate of salary, and Employee's individual MIP achievement score averaged over the prior three years, but in no event shall the bonus amount paid be less than 50% of the target amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Benefits and Vesting.</u> In addition to the foregoing, (i) During the period between the Effective Date and the Transition Date, Employee will be eligible for all benefits for which she is currently eligible, including health insurance (provided however that such participation shall be on taxable basis to the extent necessary to avoid adverse tax consequences to Employee or other participants under the plan, as determined by Varex after consultation with Employee), participation in the Deferred Compensation Plan and the MIP as previously approved by the Varex Compensation and Management Development Committee. (ii) During the Continued Service Period (or through the time Employee secures other employment with benefit eligibility), the Employee will also continue to be eligible for financial planning reimbursement and all other benefits for which she is currently eligible and for which other non-executive employees are eligible, including healthcare benefits through Varex (which for FY26 will include participation in the MDVIP program). If, however, the contemplated transition results in a loss of health benefits coverage such that Employee becomes eligible for coverage under the Consolidated Omnibus Budget Reconciliation Act ("COBRA"), Varex will pay the premiums for COBRA benefit continuation coverage directly to the insurance carrier and will reimburse Employee for the costs of similar health insurance coverage between any potential end of COBRA coverage through the Separation Date or through the such time as Employee secures other employment with benefit eligibility. Varex's obligations to cover healthcare benefits shall end when or if Employee becomes eligible for healthcare benefits and insurance coverage through any other employer and the termination of Employee's Varex healthcare benefits shall be effective as of the date she receives healthcare benefits from the new employer such that there is no break in coverage. (iii) During the Continued Service Period or through such time as the Employee secures other employment, Varex will continue to reimburse Employee for bar and professional association dues and reasonable expenses associated with continuing education and will reimburse her for financial planning assistance for fiscal years 2025 and 2026 up to the annual benefit amount that she was eligible for prior to the Transition Date. (iv) Varex will provide Employee with up to one year of outplacement services, with such amounts paid directly to the service provider. (v) It is understood that Employee will not be eligible to receive any further equity grants and after the Transition Date, and during the Continued Service Period will not be subject to the Company's equity holding requirements or trading window restrictions applicable to officers of the Company (it being understood that Employee will be subject to general insider trading rules and other restrictions applicable to standard employees and consultants, and that that Employee will generally not be provided access to material, non-public information during the Continued Service Period). (vi) Employee recognizes that because Varex is providing the Continued Service Period, Employee shall be eligible for continued vesting in equity awards granted prior to the Transition Period until the Separation Date (with settlement of any equity awards to be made in all cases on the regularly scheduled vesting/settlement dates of the applicable award), provided she complies with this Agreement and executes the Second Release at the time of the Separation Date and by December 1, 2027.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Change in Control Agreement, D&O Coverage, and Indemnification.</u> After the Transition Date, Employee's Change in Control Agreement with Varex shall expire, but Varex agrees that with respect to any change in control between the Transition Date and the Separation Date, Varex shall either fulfill the obligations herein or provide commensurate consideration as if Employee completed her obligations through the Separation Date. Employee shall be covered by Varex's Directors and Officers insurance policy through the Transition Date and for as long as she remains an officer or director of any affiliated entity. After the Transition Date and upon removal as an officer and director from all affiliated entities, Employee will not be covered for subsequent actions by the Directors and Officers insurance policy but will be covered and indemnified in the same manner as any employee or consultant for services performed within the course and scope of such employment and/or consultancy. Varex agrees that the Indemnification Agreement dated as of January 20, 2017 shall survive the termination of Employee's employment and remain in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Taxes.</u> Tax and other applicable withholdings will be applied to the payments described in this Section 3 as required by law, including, if necessary, payments made for the continuation of health insurance coverage. However, within all legal limits and requirements, Varex will attempt to pay for continued health care coverage in a manner that does not require such payments to be taxed as income to Employee. Each payment under this Agreement will be treated as a separate payment for purposes of Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"). In the event that any payment or benefit hereunder (i) constitutes nonqualified deferred compensation subject to (and not exempt from) Section 409A, (ii) is determined to be payable upon Employee's separation from service (within the meaning of Section 409A) and (iii) Employee is deemed at the time of such separation to be a "specified" employee under Section 409A, then such payment or benefit shall not be made or commence until the earliest of (x) the expiration of the six (6)-month period measured from the date of Employee's separation from service; or (y) the date of Employee death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee under Section 409A in the absence of such deferral. Upon the expiration of the applicable deferral period, any compensation or benefits which would have otherwise been paid during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or her beneficiary in one lump sum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Release.</u> Varex agrees to provide a release to Employee as stated below in section 7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>No Obligation.</u> Employee acknowledges this consideration, payments, and promises as good, sufficient and valuable consideration for the promises, releases, and waivers contained in this Agreement and the Second Release. Except as otherwise noted herein and the obligations under this Agreement, Employee agrees that she is not otherwise entitled to this consideration and that this consideration is accepted as the full and final resolution of all matters related to her employment, including the separation of such employment, with Varex. Except as provided herein, Employee represents that she has been paid all wages, benefits and compensation due to Employee as of the Effective Date. Employee agrees that if she does not execute the Second Release by December 1, 2027 (subject to the two-day notice of breach and

------

opportunity to cure provided in section 4, below) at the time of the Separation Date, then employment will end on December 4, 2027, Employee shall not vest in any further equity grants, and Varex will be entitled to repayment by Employee of all consideration already provided by Varex pursuant to this agreement, except for $1,000, in addition to any other legal remedies available to Varex.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.<u>TERMINATION.</u>** This Agreement, and Varex's obligations thereunder, may be terminated by Varex at any time for Cause. For purposes of this Section, "Cause" means (i) Employee's material breach of provisions and obligations in this Agreement, (ii) after the date hereof, any other form of "misconduct" or unethical or illegal conduct (as further described in the Company's U.S. Corrective Action Procedure), or (iii) Employee's failure to execute the Second Release on or by December 1, 2027. Materiality shall be determined in Varex's reasonable discretion. Varex will provide to Employee written notice of the conduct or actions it views as constituting "Cause" prior to any such termination for Cause. Employee shall have 30 days (or in the case of (iii), two days) to respond to Varex, in writing, and cure the conduct or actions if possible. Should Employee fail to cure the breach then the Agreement and Employee's employment will be terminated for Cause (and in the case of (iii) the termination will take effect on December 4, 2027). Upon such termination, Varex will cease providing any further consideration, compensation or benefits to Employee set forth in this Agreement, and will be entitled to repayment by Employee of consideration already provided by Varex pursuant to this agreement, except for $1,000, in addition to any other legal remedies available to Varex. Should Varex materially breach the provisions of this Agreement, Employee will provide to Varex written notice of the same and allow Varex 30 days to respond, in writing, and cure the conduct or actions if possible. Should Varex fail to cure the breach, the consideration obligations in Section 3(a) and 3(b) above shall become due in full, and Varex shall continue the health benefits coverages provided in Section 3(c) through the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.<u>RELEASE.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)**General Release.** Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to her by Varex. In addition to the release set forth in the Agreement, Employee acknowledges that Employee must sign the Second Release by December 1, 2027 (subject to the two-day notice of breach and opportunity to cure provided in section 4, above) and not revoke or rescind such signature at the time of the Separation Date, in order to obtain the consideration outlined above in Section 3. **Varex shall provide a signature copy of the Second Release to Employee between November 1, 2027 and November 23, 2027.** Employee, for herself and her respective family members, attorneys, heirs, executors, administrators, successors and assigns, fully, finally and forever releases and discharges Varex, all parent, subsidiary and/or affiliated companies, as well as its and their successors, assigns, officers, owners, directors, agents, representatives, attorneys and employees (all of whom are referred to throughout this Agreement as "Varex" or the "Company"), of and from, and agrees not to sue concerning, any and all claims, demands, actions, causes of action, suits, damages, obligations, liabilities, losses and expenses, of any and every nature whatsoever, whether in law or equity, relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that she may possess arising from any omissions, acts or facts occurring through the effective date of this Agreement and relating in any way to

------

Employee's employment with Varex. Specifically included in this waiver and release are, among other things, any and all claims based on, arising out of, or related to Employee's employment or other relationship with Varex; any claims for physical or emotional injuries; claims for violation of federal, state or local laws that prohibit harassment, discrimination, or retaliation on the basis of race, national origin, religion, gender, age, marital status, bankruptcy status, disability, perceived disability, ancestry, sexual orientation, family and medical leave, or any other form of harassment, discrimination, or retaliation or related causes of action; statutory or common law claims of any kind, including but not limited to those arising under:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. &nbsp;&nbsp;&nbsp;&nbsp;Title VII of the Civil Rights Act of 1964, as amended; the Rehabilitation Act of 1973, 42 U.S.C. Section 1981, as amended; the Fair Labor Standards Act; the Americans with Disabilities Act, as amended; the Fair Credit Reporting Act; the Pregnancy Discrimination Act; the Age Discrimination in Employment Act, as amended; the Uniformed Services Employment and Reemployment Rights Act; the Immigration Reform and Control Act; the National Labor Relations Act; the Equal Pay Act; the Family and Medical Leave Act; the Lilly Ledbetter Fair Pay Act; the Worker Adjustment Retaining & Notification Act; the Employee Retirement Income Security Act; the Older Workers Benefit Protection Act; the Occupational Safety and Health Act; the Families First Coronavirus Response Act; the Coronavirus Aid, Relief and Economic Security Act; the Utah Antidiscrimination Act; the Utah Payment of Wages Act; the Utah Genetic Testing Privacy Act; the Internet Employment Privacy Act; the Utah Employment Selection Procedures law; the Utah Labor Code; the California Family Rights Act (Cal. Govt. Code § 12945.2 *et. seq.*); the California Fair Employment and Housing Act (Cal. Govt. Code § 12900 *et. seq.*); the California Healthy Workplaces, Healthy Families Act (Cal. Labor Code § 245 *et. seq.*); the California Kin Care Law (Cal. Labor Code § 233 *et. seq.*); any other Utah or California statutes, codes and regulations; any federal, state or local human rights or labor laws; and any and all similar federal, state or local employment related laws or regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. &nbsp;&nbsp;&nbsp;&nbsp;Any statutory provision regarding harassment/retaliation/discrimination, including retaliation prohibited by Labor Code §§ 1102.5, 232.5, and 132(a), the Occupational Safety and Health Act, as amended, the Utah Occupational Safety and Health Act, the Sarbanes-Oxley Act of 2002 and all claims under the Utah law and the California Government Code;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. &nbsp;&nbsp;&nbsp;&nbsp;Contract, tort, and property rights, breach of contract, breach of implied-in-fact contract, breach of the implied covenant of good faith and fair dealing, tortious interference with contract or current or prospective economic advantage, fraud, deceit, invasion of privacy, unfair competition, misrepresentation, defamation, wrongful termination, tortious infliction of emotional distress (whether intentional or negligent), breach of fiduciary duty, violation of public policy, or any other common law claim of any kind whatsoever;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. &nbsp;&nbsp;&nbsp;&nbsp;Any claim for damages or declaratory or injunctive relief of any kind;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. &nbsp;&nbsp;&nbsp;&nbsp;Any common law claims whatsoever, claims for equity, stock options or any other benefits; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. &nbsp;&nbsp;&nbsp;&nbsp;Any amounts allegedly due as wages, benefits, sick or COVID pay, penalties, interest or damages and all claims under the Utah Labor Code, Utah Payment of Wages Act, and California Labor Code and Wage Order as a result of an employment relationship with any of the Released Parties.

Nothing in this Agreement is intended to waive claims for: (i) workers' compensation, (ii) unemployment insurance benefits, (iii) Consolidated Omnibus Budget Reconciliation Act ("COBRA") benefits, (iv) vested rights under any pension, 401(k) or ERISA-covered employee benefit plans provided by Varex as applicable on the date Employee signs this Agreement, (v) those matters which cannot be released by private agreement, or (vi) claims made pursuant to the Indemnification Agreement dated as of January 20, 2017.

Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. Notwithstanding the foregoing, this release by Employee does not include any claim that the law does not allow to be waived or any claim that may arise after the Effective Date. This release does not extend to any obligations incurred under this Agreement. Employee also agrees not to participate in any class, collective, representative, or group action that may include any of the claims released above, and will affirmatively opt out of any such class, collective, representative or group action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &nbsp;&nbsp;&nbsp;&nbsp;<u>ADEA Release.</u> Employee specifically agrees and acknowledges:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.That her waiver of rights under this Agreement includes a release of all claims relating to her age and is knowing and voluntary as required under the Age Discrimination in Employment Act, 29 U.S.C. § 621 *et. seq.* ("ADEA'') and the Older Workers Benefit Protection Act ("OWPA").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.That she understands the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.That they are hereby advised in writing to consult with an attorney prior to executing this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv.That the Company has given her a period of up to twenty-one (21) days within which to consider this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v.That her waiver under this Agreement is in exchange for consideration that they are not otherwise entitled to;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi.Any changes or amendments to this Agreement, whether material or immaterial, will not restart the 21-day consideration period described above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vii. That, following her execution of this Agreement, she has seven (7) days in which to revoke her agreement to this Agreement by notifying Varex at

------

the address provided in Paragraph 18, and that, if she chooses not to so revoke, the Agreement shall then become effective and enforceable and the payment listed above shall then be made to her in accordance with the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;viii. This Agreement does not release ADEA and OWPA claims occurring after the date of signing.

In the event Employee signs this Agreement and returns it to the Company in less than the twenty-one (21) day period identified above, Employee hereby acknowledges that she has freely and voluntarily chosen to waive the time period allotted for considering this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. &nbsp;&nbsp;&nbsp;&nbsp;<u>NO OTHER CLAIMS; PROTECTED ACTIVITY.</u>** Employee represents that she has not filed, nor has she assigned to others the right to file, nor are there currently pending from her, any complaints or lawsuits against Varex with any court, and that she will not file, or assign to others the right to file, or make any further claims against Varex at any time for actions taken up to and including the date Employee executes this Agreement. Additionally, Employee acknowledges that, other than the consideration provided for in this Agreement, she has been properly paid all wages, salary, bonus, severance benefits, vacation pay, and expenses (except for any expenses incurred by Employee that she will complete any reimbursement request within 30 days of the Transition Date). Employee also acknowledges that, as of the date she has signed this Agreement, she has not suffered any on the job injury for which she has not already filed a claim. However, nothing in this Agreement prevents Employee from filing a charge or complaint with or from participating in an investigation or proceeding conducted by the Equal Employment Opportunity Commission, the Securities and Exchange Commission, the National Labor Relations Board, the Occupational Safety and Health Commission or any other federal, state or local agency charged with the enforcement of any laws, including providing documents or other information, although by signing this Agreement, Employee is waiving her right to recover any individual relief (including back pay, front pay, reinstatement or other legal or equitable relief) in any charge, complaint, or lawsuit or other proceeding brought by her or on her behalf by any third party, except for any right Employee may have to receive a payment from a government agency (and not the Company) for information provided to the government agency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. &nbsp;&nbsp;&nbsp;&nbsp;<u>VAREX'S RELEASE OF EMPLOYEE.</u>** As additional consideration for the promises and releases made by Employee in this Agreement, Varex releases all claims against Employee and agrees to sign the Second Release, which shall also include Varex's release of all claims against Employee. Specifically, Varex, for itself and its officers, directors, agents, successors, and assigns, as well as on behalf of its affiliated entities, and their officers, directors, agents, successors, and assigns, fully, finally and forever releases and discharges Employee, and her agents, successors, and assigns, of and from, and agrees not to sue concerning, any and all claims, demands, actions, causes of action, suits, damages, obligations, liabilities, losses and expenses, of any and every nature whatsoever, whether in law or equity, relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that it or they may possess arising from any omissions, acts or facts occurring through the effective date of this Agreement and relating in any way to Employee's employment with Varex. This release is limited to conduct within the course and scope of Employee's employment or duties and expressly excludes any fraudulent or malicious conduct on the part of Employee.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. &nbsp;&nbsp;&nbsp;&nbsp;<u>PROPRIETARY INFORMATION.</u>** Employee acknowledges and affirms that on or about the first day of her employment with Varex, she signed and will comply with the Proprietary Information and Inventions Agreement ("PIIA") with the Company. Also, in exchange for the consideration provided above, Employee acknowledges that in her position with Varex, she obtained confidential business and proprietary information regarding Varex. Employee agrees that she will remain bound by the terms of the Proprietary Information and Inventions Agreement. Employee agrees that she has not made and will not make any confidential business and proprietary information known to any member of the public. In addition, Employee agrees that she will return to Varex all confidential and proprietary information and all other Company property, as well as all copies or excerpts of any property, files or documents obtained as a result of her employment with Varex, upon request by Varex. This paragraph is not intended to preclude Employee from testifying truthfully in any court of law or being fully and candidly involved in an investigation or proceedings before a governmental agency, although Employee agrees that she will testify as to Varex matters only if served with a lawfully executed subpoena.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. &nbsp;&nbsp;&nbsp;&nbsp;<u>NON-DISPARAGEMENT; NON-SOLICITATION; NON-COMPETITION.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*Non-Disparagement.* Employee agrees that she has not and will not make statements to customers and suppliers of Varex or to other members of the public that are in any way disparaging or negative towards Varex, Varex's products or services, or Varex's representatives or employees. Varex as an entity agrees not to make itself, and to instruct its executive employees to not make, any disparaging or negative statements to the public about Employee. With respect to employment references, Varex will respond to reference requests from potential employers regarding Employee by providing information stating the dates of employment and the position held by Employee. To facilitate such response, Employee agrees to direct potential employers to contact the Company's Human Resources Department. Varex shall provide to Employee a reference letter, signed by Varex's Chief Executive Officer and reasonably acceptable to Employee for Employee to use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Non-Solicitation of Varex Employees.* During the Continued Service Period and for one year after the Separation Date, Employee will not, directly or indirectly, solicit, recruit or hire any employee or contractor of Varex or any of its subsidiaries or other affiliates to work for Employee or any third party other than Varex or engage in any activity that would cause any employee or contractor to violate any agreement with Varex or any of its subsidiaries or other affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*Non-Solicitation of Varex Customers and Suppliers.* During the Continued Service Period and for one year after the Separation Date, Employee will not directly, and will not direct anyone else to, solicit, entice or induce any Customer or Supplier (as defined below) of Varex or any of its subsidiaries or other affiliates to become a Customer or Supplier of any other person or entity engaged in any competitive activity, or to cease doing business with Varex, and Employee will not assist any person or entity in taking any such action. For purposes of this Agreement, (x) a "Customer" of Varex means any person, corporation, partnership, trust, division, business unit, department or agency which, as of the beginning of the Continued Service Period or within one (1) year prior thereto, shall be or shall have been a customer,

------

distributor or agent of Varex or any of its subsidiaries or other affiliates or shall be or shall have been contacted by Varex or any of its subsidiaries or other affiliates for the purpose of soliciting it to become a customer, distributor or agent of Varex, and (y) a "Supplier" of Varex means any person, corporation, partnership, trust, division, business unit, department or agency which, as of the beginning of the Continued Service Period or within (1) year prior thereto, shall be or shall have been a supplier, vendor, manufacturer or developer for any product or significant component, design or software used in any product or service of Varex or any of its subsidiaries or other affiliates and the circumstances are such that solicitation of that supplier on behalf of a competitor is likely to cause harm to Varex. The post Separation Date restriction applies only to customers or suppliers about whom Employee received specific confidential information during her employment or with whom Employee had direct personal contact during her employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)*Non-Competition.* During the time Employee remains an employee of Varex during the Continued Service Period and until she secures other employment, Employee shall comply with the non-competition provision outlined in the PIIA. Employee also acknowledges that she has ethical obligations as a lawyer that may require her to not provide legal services to certain persons. Employee will comply with those ethical obligations. The parties also acknowledged that Employee is governed by Rule 5.6 of the Utah Rules of Professional Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Varex and Employee agree that her compliance with the provisions of this Section 9 shall constitute compliance with sections 2.a. and 2.b. of the Clawback Agreements and other similar provisions of policies or agreements executed by Employee in connection with her receipt of equity awards (stock options, restricted stock units, performance stock units, etc.)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. &nbsp;&nbsp;&nbsp;&nbsp;<u>NON-ADMISSION OF LIABILITY OR WRONGFUL CONDUCT.</u>** Neither this Agreement nor the Second Release shall be construed as an admission by Varex of any liability or acts of wrongdoing or discrimination, nor shall it be considered to be evidence of such liability, wrongdoing or discrimination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. &nbsp;&nbsp;&nbsp;&nbsp;<u>COOPERATION.</u>** Employee agrees to reasonably cooperate with Varex regarding any pending or subsequently filed litigation, claims or other dispute items involving Varex that relate to matters within the knowledge or responsibility of Employee during her employment with Varex. Without limiting the foregoing, Employee agrees (i) to meet with Varex representatives, its counsel or other designees at mutually convenient times and places with respect to any items within the scope of this provision; (ii) to provide truthful testimony regarding same to any court, agency or other adjudicatory body; and (iii) to provide Varex with notice of contact by any adverse party or such adverse party's representative except as may be required by law. Varex will reimburse Employee for all reasonable expenses (and her time at the rate as outlined in Section 2 above) in connection with the cooperation described in this paragraph.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. &nbsp;&nbsp;&nbsp;&nbsp;<u>CONFIDENTIALITY.</u>** The nature and terms of this Agreement and the Second Release are strictly confidential and they have not been and shall not be disclosed by Employee at any time to any person other than her lawyer, her accountant, a governmental agency or her immediate family without the prior written consent of an officer of Varex, except as necessary in any legal proceedings directly related to the provisions and terms of this Agreement or the

------

Second Release, to prepare and file income tax forms or pursuant to court order after reasonable notice to Varex. Should Employee share information about or within this Agreement or the Second Release with her immediate family, she agrees that she will ensure that they agree to the confidentiality language in this paragraph. However, nothing in this Agreement prevents employee or the Company from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct either party has reason to believe is unlawful. In the event Varex makes this Agreement public, then Employee would not be bound to this provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. &nbsp;&nbsp;&nbsp;&nbsp;<u>GOVERNING LAW.</u>** This Agreement shall be interpreted under the laws of the State of Utah.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. &nbsp;&nbsp;&nbsp;&nbsp;<u>SEVERABILITY AND MODIFICATION.</u>** The provisions of this Agreement are severable, and if any part of this Agreement except Section 5, 6, or 7 is found by a court of law to be unenforceable, the remainder of the Agreement will continue to be valid and effective and any provision found to be unenforceable shall be modified to be enforceable to the fullest extent permitted by law that is most consistent with the terms of this Agreement. If Section 5, 6, or 7 is found to be unenforceable, the parties agree to seek a determination by the court as to the rights of the parties, including whether Employee is entitled to retain the consideration paid to her under the Agreement. To the extent that any provision of this Agreement is found or becomes invalid by law, the provision shall be modified by any court of competent jurisdiction to be valid and enforceable to the greatest extent permitted by law that is most consistent with the intentions of the parties as evidence by the original provision in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. &nbsp;&nbsp;&nbsp;&nbsp;<u>SOLE AND ENTIRE AGREEMENT.</u>** This Agreement sets forth the entire agreement between the parties, except for the obligations contained in the Proprietary Information and Inventions Agreement (as modified herein) and the Indemnification Agreement dated as of January 20, 2017. Any other prior agreements between or directly involving the parties to the Agreement are superseded by the terms of this Agreement and thus are rendered null and void. Any amendment to this Agreement must be in writing, signed by the parties hereto, and stating the intent of the parties to amend this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. &nbsp;&nbsp;&nbsp;&nbsp;<u>NO OTHER PROMISES.</u>** Employee affirms that the only consideration for her signing this Agreement is that set forth herein, that no other promise or agreement of any kind has been made to or with her by any person or entity to cause her to execute this document, and that she fully understands the meaning and intent of this Agreement, including but not limited to, its final and binding effect. In addition, Employee affirms that, other than the consideration in this Agreement, she will not be entitled to any Company-sponsored benefit, plan or property unless such benefit, plan or property is a vested benefit or required by law. Any amendment to this Agreement must be in writing, signed by the parties hereto, and stating the intent of the parties to amend this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17. &nbsp;&nbsp;&nbsp;&nbsp;<u>TIME TO CONSIDER AND SEEK LEGAL ADVICE; EFFECTIVE DATE.</u>** Varex advises Employee to consult with an attorney in regard to this Agreement, including whether to sign this Agreement. Varex agrees that it will reimburse Employee up to $7,500.00 for her reasonable attorney's fees in connection with such consultation. Employee acknowledges that she has been given twenty-one (21) days from the time that she receives this Agreement to

------

consider whether to sign it, although she may choose to sign it earlier. Employee agrees that if she chooses to sign this Agreement before the end of this twenty-one (21) day period, it is because she freely chose to do so after carefully considering its terms. Additionally, Employee shall have seven (7) days from the date she signs this Agreement to change her mind and revoke or rescind the Agreement. Such revocation must be in writing and delivered to the Company's Chief Human Resources Officer by mail at the Company's headquarters and by email to karen.aranki@vareximaging.com.

If Employee exercises her right to revoke or rescind the release of claims under the ADEA, Varex may, at its option, either nullify this Agreement in its entirety, or keep it in effect in all respects other than as to that portion of the release of claims that Employee has revoked. Employee agrees and understands that if Varex chooses to nullify the Agreement in its entirety, Varex will have no obligations or benefits under this Agreement.

If Employee does not revoke or rescind this Agreement within seven (7) days of her signing, this Agreement will become final and binding on the day following such seven (7) day period (the "Effective" date of the Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18. &nbsp;&nbsp;&nbsp;&nbsp;<u>LEGALLY BINDING AGREEMENT.</u>** &nbsp;&nbsp;&nbsp;&nbsp;Employee understands and acknowledges (1) that she has read and understands this Agreement; (2) that by signing this Agreement, she acknowledges that she is voluntarily entering into the Agreement and is thereafter barred from instituting claims against Varex in the manner and to the extent set forth in Section 5 and Section 6 above, except for claims she may assert under the indemnification provisions hereof and under the Indemnification Agreement dated as of January 20, 2017; and (3) that this Agreement is final and binding, subject to Employee's right to revoke as stated above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19. &nbsp;&nbsp;&nbsp;&nbsp;<u>ATTORNEYS' FEES.</u>** Should an action be brought to enforce the terms of this agreement, the prevailing party shall be entitled to recover reasonable attorneys' fees and costs incurred in prosecuting the action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20. &nbsp;&nbsp;&nbsp;&nbsp;<u>VOLUNTARY EXECUTION OF AGREEMENT.</u>** This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the Parties hereto, with the full intent of releasing all claims. The Parties acknowledge that they have read this Agreement, have been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of their own choice or that they have voluntarily declined to seek such counsel, understand the terms and consequences of this Agreement and of the releases it contains, and are fully aware of the legal and binding effect of this Agreement.

------

---

| | |
|:---|:---|
| Date: September 5, 2025 | **/s/ Kimberly Honeysett** |
|  | **Kimberly Honeysett** |
|  | **For: Varex Imaging Corporation** |
| Date: September 5, 2025 | By: **/s/ SUNNY S. SANYAL** |
|  | Its: CEO |
|  | Name: Sunny Sanyal |

---

------

<u>Exhibit A "Second Release": Release of Claims at Separation Date</u> 

As part of the consideration provided by Employee under the Executive Transition and Separation Agreement and Release, Employee was allowed to remain employed through December 12, 2027 (the "Separation Date" and the time from the Transition Date to the Separation Date being the "Continued Service Period") and Employee continued vesting and receiving other related benefits and consideration. Employee also agreed, that in order to obtain all of the benefits and consideration provided under the Executive Transition and Separation Agreement and Release, that Employee would execute this updated release of claims at or by December 1, 2027 connected to the Separation Date (the "Second Release"), and Employee agreed not to revoke or rescind her signature. **Varex has provided a signature copy of the Second Release to Employee between November 1, 2027 and November 23, 2027.** Employee expressly agree that she has received valuable and sufficient consideration in exchange for this further exchange of releases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.<u>SECOND RELEASE.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)</u>**General Release.** Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to her by Varex. Employee, for herself and her respective family members, attorneys, heirs, executors, administrators, successors and assigns, fully, finally and forever releases and discharges Varex, all parent, subsidiary and/or affiliated companies, as well as its and their successors, assigns, officers, owners, directors, agents, representatives, attorneys and employees (all of whom are referred to throughout this Agreement as "Varex" or the "Company"), of and from, and agrees not to sue concerning, any and all claims, demands, actions, causes of action, suits, damages, obligations, liabilities, losses and expenses, of any and every nature whatsoever, whether in law or equity, relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that she may possess arising from any omissions, acts or facts occurring through the effective date of this Agreement and relating in any way to Employee's employment with Varex. Specifically included in this waiver and release are, among other things, any and all claims based on, arising out of, or related to Employee's employment or other relationship with Varex; any claims for physical or emotional injuries; claims for violation of federal, state or local laws that prohibit harassment, discrimination, or retaliation on the basis of race, national origin, religion, gender, age, marital status, bankruptcy status, disability, perceived disability, ancestry, sexual orientation, family and medical leave, or any other form of harassment, discrimination, or retaliation or related causes of action; statutory or common law claims of any kind, including but not limited to those arising under:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &nbsp;&nbsp;&nbsp;&nbsp;Title VII of the Civil Rights Act of 1964, as amended; the Rehabilitation Act of 1973, 42 U.S.C. Section 1981, as amended; the Fair Labor Standards Act; the Americans with Disabilities Act, as amended; the Fair Credit Reporting Act; the Pregnancy Discrimination Act; the Age Discrimination in Employment Act, as amended; the Uniformed Services Employment and Reemployment Rights Act; the Immigration Reform and Control Act; the National Labor Relations Act; the Equal Pay Act; the Family and Medical Leave Act; the Lilly Ledbetter Fair Pay Act; the Worker Adjustment Retaining & Notification Act; the Employee Retirement Income

------

Security Act; the Older Workers Benefit Protection Act; the Occupational Safety and Health Act; the Families First Coronavirus Response Act; the Coronavirus Aid, Relief and Economic Security Act; the Utah Antidiscrimination Act; the Utah Payment of Wages Act; the Utah Genetic Testing Privacy Act; the Internet Employment Privacy Act; the Utah Employment Selection Procedures law; the Utah Labor Code; the California Family Rights Act (Cal. Govt. Code § 12945.2 *et. seq.*); the California Fair Employment and Housing Act (Cal. Govt. Code § 12900 *et. seq.*); the California Healthy Workplaces, Healthy Families Act (Cal. Labor Code § 245 *et. seq.*); the California Kin Care Law (Cal. Labor Code § 233 *et. seq.*); any other Utah or California statutes, codes and regulations; any federal, state or local human rights or labor laws; and any and all similar federal, state or local employment related laws or regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) &nbsp;&nbsp;&nbsp;&nbsp;Any statutory provision regarding harassment/retaliation/discrimination, including retaliation prohibited by Labor Code §§ 1102.5, 232.5, and l32(a), the Occupational Safety and Health Act, as amended, the Utah Occupational Safety and Health Act, the Sarbanes-Oxley Act of 2002 and all claims under the Utah law and the California Government Code;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Contract, tort, and property rights, breach of contract, breach of implied-in-fact contract, breach of the implied covenant of good faith and fair dealing, tortious interference with contract or current or prospective economic advantage, fraud, deceit, invasion of privacy, unfair competition, misrepresentation, defamation, wrongful termination, tortious infliction of emotional distress (whether intentional or negligent), breach of fiduciary duty, violation of public policy, or any other common law claim of any kind whatsoever;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any claim for damages or declaratory or injunctive relief of any kind;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Any common law claims whatsoever, claims for equity, stock options or any other benefits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Any amounts allegedly due as wages, benefits, sick or COVID pay, penalties, interest or damages and all claims under the Utah Labor Code, Utah Payment of Wages Act, and California Labor Code and Wage Order as a result of an employment relationship with any of the Released Parties.

Nothing in this Second Release is intended to waive claims for: (i) workers' compensation, (ii) unemployment insurance benefits, (iii) Consolidated Omnibus Budget Reconciliation Act ("COBRA") benefits, (iv) vested rights under any pension, 401 (k) or ERISA-covered employee benefit plans provided by Varex as applicable on the date Employee signs this Agreement, or (v) those matters which cannot be released by private agreement.

Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. Notwithstanding the foregoing, this release by Employee does not include any claim that the law does not allow to be waived or any claim that may arise after the Effective Date. This release does not extend to any obligations incurred under this Second Release. Employee also agrees not to participate in any class, collective, representative, or group action that may include any of the claims released above, and will affirmatively opt out of any such class, collective, representative or group action.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &nbsp;&nbsp;&nbsp;&nbsp;**ADEA Release.** Employee specifically agrees and acknowledges:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp; That her waiver of rights under this Agreement includes a release of all claims relating to her age and is knowing and voluntary as required under the Age Discrimination in Employment Act, 29 U.S.C. § 621 *et. seq.* ("ADEA'') and the Older Workers Benefit Protection Act ("OWPA").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp; That she understands the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) &nbsp;&nbsp;&nbsp;&nbsp;That they are hereby advised in writing to consult with an attorney prior to executing this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) &nbsp;&nbsp;&nbsp;&nbsp;That the Company has given her a period of up to twenty-one (21) days within which to consider this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) &nbsp;&nbsp;&nbsp;&nbsp;That her waiver under this Agreement is m exchange for consideration that they are not otherwise entitled to;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;&nbsp;&nbsp; Any changes or amendments to this Agreement, whether material or immaterial, will not restart the 21-day consideration period described above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) &nbsp;&nbsp;&nbsp;&nbsp;That, following her execution of this Agreement, she has seven (7) days in which to revoke her agreement to this Agreement by notifying Varex at the address provided in Paragraph 18, and that, if she chooses not to so revoke, the Agreement shall then become effective and enforceable and the payment listed above shall then be made to her in accordance with the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) &nbsp;&nbsp;&nbsp;&nbsp;This Agreement does not release ADEA and OWPA claims occurring after the date of signing.

In the event Employee signs this Second Release and returns it to the Company in less than the twenty-one (21) day period identified above, Employee hereby acknowledges that she has freely and voluntarily chosen to waive the time period allotted for considering this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>LEGALLY BINDING AGREEMENT.</u>** &nbsp;&nbsp;&nbsp;&nbsp;Employee understands and acknowledges (1) that she has read and understands this Agreement; (2) that by signing this Agreement, she acknowledges that they are voluntarily entering into the Agreement and is thereafter barred from instituting claims against Varex in the manner and to the extent set forth in Section 5 and Section 6 above; and (3) that this Agreement is final and binding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>VOLUNTARY EXECUTION OF AGREEMENT.</u>** This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the Parties hereto, with the full intent of releasing all claims. The Parties acknowledge that they have read this Agreement, have been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of their own choice or that they have voluntarily declined to seek such counsel, understand the terms and consequences of this Agreement and of the releases it contains, and are fully aware of the legal and binding effect of this Agreement.

------

Date: , 2027. <br> Employee

## Exhibit 21.1

**Exhibit 21.1**

**VAREX IMAGING CORPORATION**

**LIST OF SUBSIDIARIES**

**as of October 3, 2025**

---

| | |
|:---|:---|
| **<u>Name</u>** | **<u>Jurisdiction of Incorporation</u>** |
| Direct Conversion Ltd | United Kingdom |
| Irradiation Systems, LLC | Nevada, USA |
| MeVis Medical Solutions AG (73.7%) | Germany |
| MeVis Breastcare GmbH (86.1%) | Germany |
| MeVis Breastcare GmbH & Co. KG (86.1%) | Germany |
| Oy Varex Imaging Finland Ltd. | Finland |
| Varex Imagens Brasil, Ltda. | Brazil |
| Varex Imaging Americas Corporation | Illinois, USA |
| Varex Imaging Arabia, LLC (75%) | Saudi Arabia |
| Varex Imaging Deutschland AG | Germany |
| Varex Imaging Equipment (China) Co., Ltd. | China |
| Varex Imaging France SARL | France |
| Varex Imaging Group Nederland B.V. | Netherlands |
| Varex Imaging Holdings, Inc. | Delaware, USA |
| Varex Imaging India Private Limited | India |
| Varex Imaging International AG | Switzerland |
| Varex Imaging International Holdings B.V. | Netherlands |
| Varex Imaging Investments B.V. | Netherlands |
| Varex Imaging Italia Srl | Italy |
| Varex Imaging Japan, K.K. | Japan |
| Varex Imaging Manufacturing India Private Limited | India |
| Varex Imaging Mexico, S. de R.L. de C.V. | Mexico |
| Varex Imaging Nederland B.V. | Netherlands |
| Varex Imaging Philippines, Inc. | Philippines |
| Varex Imaging Spain S.L. | Spain |
| Varex Imaging Sweden AB | Sweden |
| Varex Imaging Technologies (Beijing) Co. Ltd. | China |
| Varex Imaging UK Limited | United Kingdom |
| Varex Imaging West Holdings, Inc. | Delaware, USA |
| Varex Imaging West, LLC | Delaware, USA |
| Virtual Media Integration, LLC | Delaware, USA |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-277143, 333-215770, 333-236487, 333-262686, and 333-285538 on Form S-8 of our reports dated November 18, 2025, relating to the financial statements of Varex Imaging Corporation and the effectiveness of Varex Imaging Corporation's internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended October 3, 2025.

/s/ Deloitte & Touche LLP

Salt Lake City, Utah

November 18, 2025

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)**

**AS ADOPTED PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Sunny S. Sanyal, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report on Form 10-K of Varex Imaging Corporation (the "registrant");

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;&nbsp;&nbsp;&nbsp;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | November 18, 2025 | By: | /s/ Sunny S. Sanyal |
|  |  |  | **Sunny S. Sanyal** |
|  |  |  | **President, Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)**

**AS ADOPTED PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Shubham Maheshwari certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report on Form 10-K of Varex Imaging Corporation (the "registrant");

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;&nbsp;&nbsp;&nbsp;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | November 18, 2025 | By: | /s/ Shubham Maheshwari |
|  |  |  | **Shubham Maheshwari** |
|  |  |  | **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the accompanying Annual Report of Varex Imaging Corporation (the "Company"), on Form 10-K for the fiscal year ended October 3, 2025 (the "Report"), I, Sunny S. Sanyal, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | November 18, 2025 | By: | /s/ Sunny S. Sanyal |
|  |  |  | **Sunny S. Sanyal** |
|  |  |  | **President, Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the accompanying Annual Report of Varex Imaging Corporation (the "Company"), on Form 10-K for the fiscal year ended October 3, 2025 (the "Report"), I, Shubham Maheshwari, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | November 18, 2025 | By: | /s/ Shubham Maheshwari |
|  |  |  | **Shubham Maheshwari** |
|  |  |  | **Chief Financial Officer** |

---

<br>